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Summary
Death receptor 3 (DR3) is a death domain-containing type I transmembrane protein. It can 
bring about a wide range of responses from apoptosis to proliferation through association with 
intracellular signaling molecules. The only accepted ligand for DR3 is TNF-like protein 1A 
(TL1A). An important role for DR3 in inflammatory disease states is emerging with links being 
made with inflammatory bowel disease (IBD), Rheumatoid Arthritis, atherosclerosis, allergic 
lung inflammation and in renal inflammation. The project undertaken in this thesis investigated 
the role of DR3 in a murine model for rheumatoid arthritis, namely antigen-induced arthritis 
(AIA), using mice genetically deficient in DR3. A further aim of this project was to generate 
reagents for use in DR3 research through the employment of DR3 gene cloning strategies.
DR3 deficient animals displayed a high degree of protection from mAIA in terms of resolution 
of joint swelling and the pathological degenerative alterations occurring within the joint. At day 
21 post-arthritis induction, a time-point when maximal structural damage would likely be 
observed, DR37 animals showed a significant reduction in all histopathological parameters 
including a complete absence of bone erosion. This effect was shown to be DR3 specific 
through the administration of TL1A to control animals. Mice receiving increasing 
concentrations of TL1A showed a dose-dependent increase in synovial hyperplasia and bone 
erosion. DR3 deficient mice also displayed protection from cartilage depletion following 
induction of AIA. In an attempt to dissect a mechanism for this reduced disease severity, an 
analysis of osteoclast numbers and F4/80+ osteoclast precursor cell numbers within the joints 
was undertaken. DR3 sufficient mice displayed significantly more osteoclasts at sites of focal 
bone erosion which could not be attributed to differences in F4/80+ precursor cell numbers.
The results presented here identify a potentially novel target for the treatment of human 
inflammatory joint disease.
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1. Introduction 
1.1 The Tumour Necrosis Factor (TNF) Superfamily
The discovery of the TNF superfamily was made following the identification of the 
proteins TNF and Lymphotoxin (LT). TNF was originally named in 1975 when it was 
described as a factor capable of bringing about the necrosis of tumours (Carswell et 
al.f 1975). LT was first described in 1968 also as a tumour necrosing factor (Williams 
and Granger, 1968). When the sequences and structures of these proteins were 
later determined in 1985, it became apparent that they displayed homology and 
were capable of binding the same cell surface receptors (Aggarwal et al., 1985). 
Thus the beginnings of a receptor/ligand superfamily started to emerge. The TNF 
superfamily now comprises at least 29 receptors and 19 ligands (Aggarwal et al., 
2003) which interact to bring about a variety of cellular effects. Table 1.1 provides a 
list of receptors and ligands belonging to the TNF superfamily, patterns of cellular 
expression and some of the general biological functions they are associated with.
1.1.1 General Structure of Receptors and Ligands
TNF receptors (TNFRs) are characterised by the presence of a cysteine-rich region in 
their extracellular domain (MacEwan, 2002). Apart from the receptors 
osteoprotegerin (OPG) and decoy receptor 3 (DcR3) which are produced as 
secreted proteins, TNF receptors are type I trans-membrane proteins (Bossen et al., 
2006). A small subset of these receptors displays an additional region of homology 
within the cytoplasmic tail which is known as the death domain. At least 8 family 
members containing the death domain have been identified and these are
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indicated in table 1.1. The death domain confers the ability to bring about 
programmed cell death or apoptosis (Orlinick and Chao, 1998).
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Receptor Cellular Expression Death Domain? Ligand Cellular Expression General Roles
TNFR1 Generally ubiquitous expression Yes TNFa/lTa Immune c ells Host defence/inflammation/septic shock
TNFR2 Immune cells/endothelial cells No TNEa/LTa Immune c ells Host defence
IT0R NK ce!ls/T cells No LTa/0 Immune c ells Host defence/organogenesis
FAS Generally ubiquitous expression Yes FASL Splenocytes/thymocytes Host defence/immune cell homeostasis
CD40 Immune cells No CD40L T cells/B cells Immune cell homeostasis
RANK Osteoclasts No RANKL T cells/osteoblasts Osteodastogenesis
OPG Osteoclasts/endothelial cells No RANKL T cells/osteoblasts Decoy receptor
DR3 T cells/B cells/endothelial cells Yes TL1A Endothelial cells/T cells/macrophages T cell homeostasis and activation/inflammation
DR4 Generally ubiquitous expression Yes TRAIL NK cells/T cells/DCs Host defence
DR5 Generally ubiquitous expression Yes TRAIL NK cells/T cells/DCs Host defence
DR6 T cells Yes ? ? ?
OcRl Generally ubiquitous expression No TRAIL NK cells/T cells/DCs Decoy receptor
DcR2 Generally ubiquitous expression No TRAIL NK cells/T cells/DCs Decoy receptor
DcR3 T cells No TL1A Endothelial cells Decoy receptor
41BB Activated T cells/monocytes/NK cells No 41BBL B cells/DCs/macrophages T/B cell activation
BAFFR B cells/T cells Yes BAFF T cells/DCs/monocytes/macrophages B cell homeostasis/autoimmunity
BCMA Immune cells No BAFF/APRIL Immune c ells B cell homeostasis/autoimmumty
CD27 T cells No CD27L NK cells/T cells/B cells T cell activation
CD30 Reed-sternberg cells No CD30L T cells/monocytes Th2 cell function
EOAR Ectodermal derivative Yes EDA2 Skin Hair/teeth morphogenesis
Fnl4 Endothelial cells/fibroblasts No TWEAK Monocytes Inflammation/cellular m igration/proliferation
GITR T cells No GITRL ? T cell homeostasis
HVEM T cells No LIGHT/LTa Immune cells Viral entry
NGFR Nervous system Yes ? ? CNS development
0X40 T cells No 0X40 L T cells/B cells T/B cell homeostasis
REIT Lymphoid tissues No ? ? T cell homeostasis
TACI Immune cells No BAFF/APRIL Immune cells B cell homeostasis
TROY Embryo skm/epithelium/hair follicles No ? ? Embromc development
XEDAR Ectodermal derivative No EDA2 Skin Hair/teeth morphogenesis
Table 1.1. TNFRSF members. A list of TNFRSF receptors and their ligands. Some general biological functions and patterns of cellular expression 
are listed. Produced using (Aggarwal 2003), (Bossen, Ingold et al 2006) and (MacEwan 2002).
TNF family ligands are type II proteins that may also be cleaved from the membrane 
under certain conditions to bring about their effects (Aggarwal et al., 2003). TNF 
family ligands share a region of homology of approximately 150 amino acids within 
their extracellular domains. 15%-35% of this region is conserved between different 
ligands (Orlinick and Chao, 1998).
1.1.2 Signalling
Prior to receptor interaction, all TNF ligands are thought to form homotrimers 
which either bind to their respective receptors via cell-cell contact or are cleaved 
from the membrane enabling them to bring about their effects at a distance from 
their local environment (MacEwan, 2002). Receptors also signal as trimer 
complexes following ligand interaction or as is the case with TNFR1 and TNFR2, may 
also form a complex prior to ligand association via a pre-ligand-binding assembly 
domain (Chan et al., 2000). Signalling through TNFRs is best exemplified using the 
well characterised TNFR1 receptor. This is depicted in figure 1.1.
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Figure 1.1. Signalling via TNF and TNFR1. TNFR1 signalling is 
mediated via the recruitment o f TRADD, FADD and TRAF2. Reproduced 
from (Ashkenazi and Dixit, 1998)
Following TNF-TNFR1 association, intracellular adaptor molecules are recruited to 
the complex to initiate downstream effects. In the death domain-containing 
receptors such as TNFR1, the death domain itself acts as the site for interaction 
with signalling molecules. Such molecules include TNFR-associated death domain 
(TRADD), Fas-associated death domain (FADD) and receptor-interacting protein 
(RIP) (MacEwan, 2002). TRADD associates with the death domains of the trimerised 
receptors and subsequently recruits TNFR-associated factor 2 (TRAF-2) and RIP 
which serve to initiate the NFkB pathway and cellular proliferation and 
differentiation (Hsu et al., 1996). TRADD can also recruit FADD resulting in the 
interaction of caspase 8 and the induction of downstream effector caspases 
subsequently initiating apoptosis (Hsu et al., 1996). However, TNFR1 generally only 
signals for apoptosis when protein synthesis is blocked (Ashkenazi and Dixit, 1998). 
Unlike TNFR1, Fas via FasL engagement, only signals for apoptosis via the 
recruitment of FADD (Ashkenazi and Dixit, 1998). Thus TNFRSF members are 
capable of initiating a range of responses from apoptosis to cellular proliferation 
and differentiation.
1.1.3 Knockout and Transgenic Models
Gene knockout and transgenic models of the TNFRSF and their ligands have 
provided useful insight into the non-redundant biological effects of these molecules 
and in assessing their role in disease. The characteristics of those models which 
have most relevance to this thesis will now be described.
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1.1.3.1 TNFRl/TNFa
TNFR1 is a ubiquitously expressed receptor which binds both TNFa and LTa. Its 
principle functions are however, generally ascribed to its association with TNFa and 
it is this interaction that will be considered. TNFR1 deficient mice are viable and 
develop into adulthood. They display both normal thymopoiesis and spleen and 
lymph node anatomy (Peschon et al., 1998). Cell numbers within the thymus, 
spleen, lymph nodes and bone marrow are also normal and the removal of 
autoreactive T cells from the thymus is not impaired (Pfeffer et al., 1993). However, 
when infected with the bacteria listeria monocytogenes at a sublethal dose, TNFR1 
deficient mice do not survive (Peschon et al., 1998). Additionally, they display a 
reduced accumulation of neutrophils within the lungs following inhalation of 
inflammatory agents (Peschon et al., 1998). TNFR1 deficient mice do however 
display resistance to endotoxic shock (Pfeffer et al., 1993).
In addition to TNFRl^' mice, transgenic mice which constitutively expressive the 
human TNFa gene have also been generated. Similar to the TNFR1 deficient 
animals, TNFa transgenics develop normally and survive into adulthood. However, 
an ankle swelling and impaired movement phenotype is evident in these mice with 
100% penetrance and progressive weight loss is also a common feature. 
Histopathological analysis of the joints from these animals shows consistence with 
arthritic disease with evidence of synovial hyperplasia and joint destruction. These 
features are all completely prevented via treatment with anti-TNF agents (Keffer et 
al., 1991).
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1.1.3.2 FAS
Both genetically engineered and naturally occurring FAS deficient mice exist. Lpr 
(lymphoproliferation) mutants contain a mutation within the FAS gene rendering it 
non-functional. Naturally occurring FASL mice also exist which have inactive FASL 
and these are termed gld (generalised lymphoproliferative disease) mice (Roths et 
al., 1984). All of these mice are characterised by lymphadenopathy and 
splenomegaly (Adachi et al., 1995). Genetically engineered Fas deficient animals 
develop lymphadenopathy and splenomegaly by 8 weeks of age and this is mainly 
attributed to the accumulation of T lymphocytes (Adachi et al., 1995). Hyperplasia 
of the liver is also present but thymus size and composition is normal (Adachi et al.,
1995). Lpr mutants are also characterised by autoimmune diseases including 
synovitis, pulmonary vasculitis and a syndrome similar to systemic lupus 
erythematosus. High levels of autoantibody production are also seen. Additionally 
they display a proliferative glomerulonephritis which may account for the 50% 
mortality at 5 months of age (Cohen and Eisenberg, 1991). Gld mice similarly 
display autoimmunity and a reduced lifespan (Cohen and Eisenberg, 1991).
1.1.3.3 RANK
Mice which are genetically deficient in RANK display a bone phenotype which is 
characterised by runted growth, an absence of tooth eruption and severe 
osteopetrosis (Dougall et al., 2008). Histological analysis revealed an absence of 
osteoclasts within the bone, and spleen cells from these animals cultured in vitro in 
the presence of RANKL and M-CSF fail to undergo osteoclastogenesis (Dougall et al.,
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2008). Thymus development is normal, however splenomegaly is evident and there 
is an absence of lymph nodes (Dougall et al., 2008).
1.1.3.40PG
OPG deficient mice develop normally from the embryonic stage, however they 
display an osteoporotic phenotype. Decreased bone mineral density is evident by 1 
month of age with the occurrence of multiple fractures. Gross morphological 
abnormalities are present in older mice. An increase in numbers of both osteoclasts 
and osteoblasts has been noted by researchers, indicating a high bone turnover 
state which is consistent with osteoporosis (Bucay et al., 1998).
1.2 Death Receptor 3
Death receptor 3 is member 25 of the TNFRSF and like other members of the family 
is capable of bringing about a wide range of responses from apoptosis to 
proliferation. It is the study of this receptor that forms the principle component of 
this thesis.
1.2.1 Human DR3
The human Death Receptor 3 (Wsl-1, APO-3, TRAMP, LARD, TR3, TNFRSF25) gene 
was originally cloned in 1996. Multiple research groups identified the gene at the 
same time resulting in its various names (Chinnaiyan et al., 1996, Kitson et al., 1996, 
Screaton et al., 1997, Marsters et al., 1996, Bodmer et al., 1997). The discovery of 
DR3 was principally achieved through searching expressed sequence tag (EST)
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databases for genes with homology to TNFR1 or FAS (Bodmer et al., 1997, 
Chinnaiyan et al., 1996, Marsters et al., 1996, Screaton et al., 1997). Kitson et al. 
(1996), however, used a combination of a yeast two-hybrid system, utilizing the 
death domain of TNFR1, and PCR to identify the gene (Kitson et al., 1996). The 
chromosomal location of human DR3 was assigned to chromosome lp36.2 via 
fluorescence in situ hybridization (FISH) (Bodmer et al., 1997). It is currently entered 
into the NCBI database as TNFRSF25 and comprises 1665 base pairs. It has a 
genomic structure of 10 exons, 6 of which are leader sequence and extracellular 
domain, 1 is transmembrane domain and the remaining 3 make up the cytoplasmic 
domain (Screaton et al., 1997).
DR3, like other members of the receptor superfamily, is a type I transmembrane 
protein. The originally discovered DR3 gene was predicted to contain 417 amino 
acids (Screaton et al., 1997) maintaining a high level of sequence homology with 
TNFR1, displaying 28% overall sequence identity, rising to 45% in the death domain 
(Kitson et al., 1996). Analysis of the hydrophobicity profile of the protein indicated 
the existence of a signal sequence, followed by an extracellular domain containing 
the characteristic cysteine-rich repeats of which there were 4, a transmembrane 
domain and a cytoplasmic portion comprising the death domain (Marsters et al.,
1996). Two potential N-linked glycosylation sites were also identified (Screaton et 
al., 1997).
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1.2.2 Murine DR3
The murine DR3 gene was cloned in 2001 by Wang et al. By screening a 129Sv 
mouse genomic library using the full length human DR3 gene, they isolated and 
sequenced a single clone of the gene. RT-PCR of mouse thymic cDNA was used to 
determine the intron.exon boundaries (Wang et al., 2001a). Murine DR3 was found 
to be 55% homologous to the human DR3 gene. It comprises 1619 base pairs and 
like human DR3 is composed of 10 exons (Wang et al., 2001a).
The murine DR3 protein is 63% homologous to its human counterpart with 
conservation of 52% sequence identity in the extracellular domain and 94% in the 
death domain (Wang et al., 2001a). Like human DR3, it contains 2 putative N- 
glycosylation sites and 25 of the 28 cysteines found in the human gene are present. 
The 3rd cysteine rich domain in murine DR3, however, was found to differ 
significantly from that in the human gene. In the 2nd half of this region, 2 cysteine 
residues present in human DR3, are absent due to a 9 amino acid deletion. 
Additionally, 2 amino acid substitutions are present, with the replacement of a 
cysteine and a phenylalanine with threonine and a cysteine respectively. These 
differences are not predicted to alter ligand binding properties compared to the 
human gene, as the first half of the 3rd cysteine-rich region is essentially conserved 
between the 2 genes and it is this region, along with cysteine-rich domain II that are 
involved in ligand interactions (Wang et al., 2001a).
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1.2.3 Expression
Northern blot analysis of human DR3 transcript expression originally indicated a 
restricted expression pattern. Transcripts of 3.4 - 4Kb were identified in spleen, 
thymus and peripheral blood leukocytes (Kitson et al., 1996, Screaton et al., 1997) 
leading researchers to believe that DR3 was the first member of the TNFRSF with 
lymphoid-organ restricted expression. However, further analysis identified DR3 
transcript expression in the colon and small intestine in addition to fetal lung, brain 
and kidney (Marsters et al., 1996, Chinnaiyan et al., 1996, Bodmer et al., 1997). 
Expression of murine DR3 by Northern blot analysis revealed signals in the brain, 
heart, kidney, spleen, liver, thymus and skin with transcripts ranging in size from 1.8 
-  7Kb, which was thought to result from the presence of untranslated sequence at 
the 5' end (Wang et al., 2001a).
Both human and murine DR3 have multiple splice variants, further complicating its 
pattern of expression. There are at least 13 human DR3 splice variants (Screaton et 
al., 1997, Warzocha et al., 1998), and 3 murine DR3 splice variants (Wang et al., 
2001a). The majority of the human DR3 splice variants produce truncated forms of 
the receptor, with a stop codon introduced before the trans-membrane domain 
(Screaton et al., 1997). In most cases this is achieved by the removal of 1 or more 
complete exons although 2 of the splice variants (-2 and -10) contain 101 and 200 
base pair insertions respectively and splice variant -lb  contains an additional 3 
nucleotides (CAG) (Screaton et al., 1997). The 13th variant was discovered later and 
was originally named DR30. This is the longest of the variants containing 2 
insertions of 20 and 7 bases at position 612 and 667 respectively, generating a 426 
amino acid protein compared to 417 amino acids of the second longest isoform
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(variant 1) (Warzocha et al., 1998). These 2 proteins are identical apart from 28 
amino acids in the extracellular domain and DR33 expression is more restricted 
(Warzocha et al., 1998). Interestingly, both T and B cells were found to 
predominantly express the truncated isoforms. However, following PHA blasting, 
variant 1 expression predominates (Screaton et al., 1997). Western blot analysis has 
revealed proteins ranging in size from 47 KDa to 59 KDa which may result from 
differing degrees of glycosylation (Marsters et al., 1996, Kitson et al., 1996, Bodmer 
et al., 1997).
Murine DR3 has 3 identified splice variants (Wang et al., 2001a), the longest of 
which encodes a 55 KDa protein. Variant 2 is a soluble form of the receptor in which 
exon 6 is absent, result in a stop site prior to the trans-membrane domain. Variant 
3 lacks both exon 5 and exon 6 resulting in the absence of cysteine-rich domain 4 
(Wang etal., 2001a).
1.2.4 Signalling
DR3 shares a similar signalling pathway to that of TNFR1. Chinnaiyan et al. (1996) 
investigated the signalling pathway of DR3 by studying the interactions of a 
glutathione-S-transferase (GST) -DR3 fusion protein with GST fusion proteins of 
TRADD, FADD and RIP. DR3 was found to specifically associate with TRADD but not 
with FADD or RIP. However, when DR3 was expressed in 293 cells in the presence of 
TRADD, there was an enhanced association with RIP, FADD and TRAF2 (Chinnaiyan 
et al., 1996). Through the recruitment of these signalling molecules, DR3 is able to 
initiate both apoptosis and NFkB activation. Overexpression of DR3 in 293 cells
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resulted in apoptosis, with cells displaying the associated characteristic morphology 
(Kitson et al., 1996, Bodmer et al., 1997, Chinnaiyan et al., 1996). Expression of a 
truncated form of the gene, lacking the death domain, did not result in apoptosis 
(Kitson et al., 1996). This DR3 mediated apoptosis could also be prevented by the 
use of 2 inhibitors of the ICE-like proteases and through the presence of dominant 
negative forms of FADD (Chinnaiyan et al., 1996). Therefore, DR3 is capable of 
signalling for apoptosis via the recruitment of TRADD, FADD and TRAF2, mirroring 
those pathways utilised by TNFR1. Although the signalling pathways employed by 
both TNFR1 and DR3 appear very similar, there have been reports of divergent 
downstream signalling pathways, notably in the regulation of IL-8 expression where 
separate kinase cascades are thought to be utilised (Su et al., 2006).
DR3 expression has also been shown to induce NFkB activation. In an NFkB 
luciferase reporter gene assay, DR3 expression dose-dependently induced reporter 
gene activity (Bodmer et al., 1997). In the presence of dominant negative forms of 
the signalling molecules RIP and TRAF2 but not FADD, NFkB activation was blocked 
(Chinnaiyan et al., 1996). The signalling pathways employed by DR3 are shown in 
figure 1.2.
In an attempt to clarify the effects of DR3 signalling in more physiologically relevant 
systems Wen et al (2003) tested the effect of adding the natural DR3 ligand, TL1A, 
to cultures of the erythroleukaemic cell line TF-1. TL1A stimulation preferentially 
caused the formation of a TRADD, TRAF-2 and RIP signalling complex rather than 
one containing FADD or procaspase 8 (Wen et al., 2003). NFkB activation was
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detected in addition to the induction of other downstream signalling molecules 
including JNK, p38 and ERK1,2 MAPK, resulting in gene expression (Wen et al., 
2003). Apoptosis could only be initiated following blockade of N FkB  signalling which 
was hypothesised to be due to NFKB-induced expression of the anti-apoptotic 
factor C-IAP2 (Wen et al., 2003). Thus DR3 may be capable of initiating both cell 
survival and cell death mechanisms but this is likely to be due to the environment in 
which DR3 is expressed.
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Figure 1.2. Signalling via DR3 and TL1A. Like TNFR1, DR3 initiates downstream 
effects via the recruitment of TRADD, FADD and TRAF2. Reproduced from 
(Ashkenazi and Dixit, 1998)
17
1.2.5 The DR3 Ligand
Identification of a ligand for DR3 has proven difficult and multiple candidates have 
been suggested. The first proposed ligand for DR3 was Apo3L. This ligand was 
identified through expressed sequence tag database searching. Northern blot 
analysis revealed a broad pattern of expression with positive detection in human 
blood, gut, reproductive organs, thymus, spleen, pancreas, kidney, liver, lung, brain 
and heart (Marsters et al., 1998). This ligand was shown to induce apoptosis 
through a FADD mediated signalling pathway and was capable of activating NFkB. 
Using a FLAG-epitope tagged version of the ligand, Apo3L was shown to specifically 
bind DR3 but not TNFR1, TNFR2, FAS or DR4 (Marsters et al., 1996). However, in 
2000, Kaptein et al. published the first report suggesting that Apo3L, which is also 
named TWEAK, was not the true ligand for DR3. In this study, DR3 did not bind a 
whole panel of TNF family ligands including FASL, RANKL and TWEAK using an ELISA 
based assay. Additionally, cells which were transfected with a DR3 expression 
vector resulting in both NFkB and apoptosis induction, were not affected by the 
addition of TWEAK nor were there any differences in the ability of TWEAK to bind 
peripheral blood lymphocytes from DR3 deficient and sufficient mice (Kaptein et al., 
2000). Thus Apo3L/TWEAK could no longer be considered the ligand for DR3. In 
2002, TNF-like protein 1A (TL1A) was discovered and this is the currently accepted 
ligand for DR3. TL1A was identified by searching expressed sequence tag sequences 
and was discovered to be a longer variant of the already cloned vascular endothelial 
growth inhibitor (VEGI) (Migone et al., 2002). It is produced as a membrane bound 
protein which is also capable of generation into a soluble form (Kim and Zhang,
2005). Analysis of mRNA expression of this protein is not reported to be as broad as
18
that of TWEAK, being predominantly detected on endothelial cells although low 
levels have also be seen in the human kidney, placenta, stomach, intestine, lung, 
spleen and thymus (Migone et al., 2002). TL1A was found to specifically bind to Fc- 
fusion proteins of DR3 and DcR3, a human decoy receptor, but not to any other 
TNFRSF members. This was further established by coimmunoprecipitation studies 
(Migone et al., 2002) and has more recently been confirmed in an extensive 
evaluation of the interations between ligands and receptors belonging to the TNF 
superfamily (Bossen et al., 2006). An equivalent protein to the DcR3 found in 
humans has yet to be identified in the mouse.
TL1A has been described as a T cell co-stimulator, increasing T cell responsiveness 
to IL-2 and inducing secretion of other cytokines including IFNy and GM-CSF 
(Migone et al., 2002). Additionally it has been shown to be expressed on monocytes 
and dendritic cells following FcyR stimulation (Prehn et al., 2007). TL1A also has a 
reported role in the upregulation of OX40L on a novel subset of cells akin to 
CD4*CD3' cells found in fetal lymphoid tissue (Kim et al., 2006). These cells are 
thought to play a role in the generation of antibody responses to protein antigens 
and have been localised to B cell areas and the B cell: T cell interface, where they 
interact with antigen-specific T cells within the spleen. They have been shown to 
upregulate their expression of 2 TNF family ligands, namely CD30L and OX40L in 
culture, and their interaction with 0X40 on CD4+ T cells, enhances survival of these 
T cells. In vivo studies have suggested that this signalling through 0X40 on T cells is 
imperative for maintaining T cell memory and antibody responses (Kim et al., 2003). 
DR3 is expressed on both adult and neonatal CD4+CD3‘ cells (Kim et al., 2006). The
addition of TL1A to these cells is reported to upregulate OX40L expression (Kim et 
al., 2006), implicating a role for TL1A via DR3 signalling in antibody responses.
1.2.6 DR3 knockout (DR37 ) mouse model
Mice deficient in DR3 were generated by Wang et al. in 2001. In order to generate 
these mice, the entire coding region of the DR3 gene was replaced with a construct 
containing an internal ribosomal entry site (iRES), the 3 galactosidase (LacZ) gene 
and the neo gene flanked by 2 lox P sites. By replacing the entire coding region, no 
DR3 protein, including any splice variants could be expressed. Instead, 3 
galactosidase expression in the DR37' mice would act as a useful tool for reporting 
wild-type DR3 expression. Embryonic stem cells containing the targeting construct 
were used to generate heterozygous mice on a C57BL/6 background, which could 
then be bred for the generation of DR3 null animals (Wang et al., 2001b).
Characterisation of the DR37' mice revealed normal development in all of the major 
organs including the brain, heart, kidney, thymus, spleen, lymph nodes and peyer's 
patches (Wang et al., 2001b). An increased thymus size compared to the DR3+/' 
mice was reported with 10% larger thymuses in DR37' animals at 2 to 5 weeks of 
age. Using bromodeoxyuridine (BrdU), which is incorporated into proliferating cells, 
this was shown not to be due to thymocyte turnover, as thymocytes from both 
DR3+/' and DR37' mice did not differ significantly in BrdU incorporation (Wang et al., 
2001b). As a result of this observation, DR3 was shown to have a regulatory role in 
thymocyte development with impaired negative selection in DR37', H-Y transgenic 
mice. Additionally, cross-linking of CD3 on thymocytes using low concentrations of
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antibody, resulted in reduced apoptosis in DR37' mice compared to DR3+/' mice 
(Wang et al., 2001b). Despite this role in negative selection during thymocyte 
development, DR37' mice do not show signs of autoimmunity.
1.2.7 In vivo Functions of DR3
The in vivo functions of DR3 have yet to be fully elucidated and similar to other 
TNFRSF members, are likely to be extremely diverse. DR3 is capable of initiating 
both cell death and cell survival signals through the activation of caspases and NFkB 
respectively (Chinnaiyan et al., 1996) but what the significance is of this in disease is 
poorly understood. DR37' mice do progress normally into adulthood and do not 
show signs of spontaneous disease development. However, data is beginning to 
emerge which suggests that DR3 might play an important role in a number of 
diseases including cancer, neurological and inflammatory disease states.
1.2.7.1DR3 and Cancer
DR3 expression has been identified in non-Hodgkin's lymphoma (Warzocha et al., 
1998) and colon carcinoma patient samples (Gout et al., 2006). In colon cancer, it 
has been proposed that DR3 contributes to cancer metastasis through interactions 
with the endothelial adhesion receptor, E-selectin. This interaction may trigger pro­
survival and pro-migratory signals via the activation of protein kinases (Gout et al., 
2006). However, an analysis of E-selectin ligands expressed on G-CSF mobilized 
peripheral blood leukocytes did not identify DR3 as a novel ligand (Dagia et al., 
2006) thus this requires further investigation. Researchers studying the role of DR3 
in neuroblastoma have reported the presence of a DR3 gene duplication which is
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tandemly linked to the DR3 gene on chromosome Ip36.2-lp36.3 and both of which 
are either deleted or translocated in certain neuroblastoma cell lines. In addition, 
low DR3 protein expression has been reported in 7 of 17 neuroblastoma cell lines 
(Grenet et al., 1998). Thus DR3 has been linked to a number of cancer types but its 
role in cancer development is unclear and complicated by duplications in the DR3 
gene.
1.2.7.2 DR3 and Inflammatory Diseases
An important role for DR3 in inflammatory disease states is beginning to emerge 
with links being made with inflammatory bowel disease (IBD) (Bamias et al., 2003, 
Bamias et al., 2006), Rheumatoid Arthritis (Osawa et al., 2004, Takami et al., 2006, 
Cassatella et al., 2007), atherosclerosis (Kang et al., 2005, Kim et al., 2008), allergic 
lung inflammation (Fang et al., 2008) and in renal inflammation (Al-Lamki et al., 
2008). Following the identification of TL1A as a T cell co-stimulator capable of 
inducing the expression of IFNy (Migone et al., 2002), Bamias et al (2003) sought to 
investigate the role of DR3/TL1A in inflammatory bowel disease which is typically 
described as a Thl-mediated disease. Via analysis of samples from Crohn's disease 
and ulcerative colitis patients, the authors reported an upregulation of TL1A protein 
expression in association with the degree of inflammation observed. This 
expression was associated with both CD4+ and CD8* T cells in addition to tissue 
macrophages in Crohn's disease patients but appeared to be expressed on plasma 
cells in ulcerative colitis. Additionally, DR3 expression was upregulated in both 
disease states and was localised to CD4* and CD8* lymphocytes in inflamed areas 
(Bamias et al., 2003). When lamina propria mononuclear cells were incubated with
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TL1A, an upregulation of IFNy was detected which was more pronounced when 
cells were isolated from Crohn's disease patients rather than controls (Bamias et al., 
2003). DR3 and TL1A upregulation has also been confirmed in mouse models of 
Crohn's disease (Bamias et al., 2006). By examining DR3 expression in the terminal 
ileum of mice in a model of chronic ileitis, a specific upregulation of full length DR3 
expression as opposed to other DR3 splice variants was observed (Bamias et al., 
2006). This upregulation of the full length DR3 splice variant was also illustrated 
upon T cell activation and may represent a control mechanism for DR3 signalling 
under normal physiological conditions. In the murine model of chronic ileitis, TL1A 
expression appeared to be restricted to lamina propria dendritic cells (Bamias et al.,
2006). Upregulation of IFNy by TL1A occurs in synergy with IL-12 and IL-18 
stimulation in CD4* T cells, CD8+ T cells and NK cells (Papadakis et al., 2004). A 
specific subset of T cells which are located in the lamina propria of the small 
intestine and are associated with IBD is a CCR9+ memory T cell subset. TL1A 
addition to these cells enhanced IFNy production following activation via CD3 and 
CD28 or CD2 and CD28 (Papadakis et al., 2005). IFNy production following TL1A 
administration was further enhanced when CCR9+ T cells were stimulated with IL-12 
and IL-18 and this was associated with upregulation of DR3 expression specifically 
on this cell subset (Papadakis et al., 2005). Thus the DR3/TL1A pathway may play a 
prominent role in the pathogenesis of IBD via its ability to enhance IFNy in synergy 
with IL-12 and IL-18 thus contributing to the inflammatory response.
In atherosclerosis, DR3 and TL1A expression has been reported in foam cell-rich 
regions of atherosclerotic plaques obtained from patients (Kim et al., 2008). Foam
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cells are derived from macrophages thus researchers have used the human 
monocytic THP-1 cell line as a model. Activation of the DR3 receptor on THP-1 cells 
via cross-linking with an immobilized antibody, in conjunction with IFN treatment 
resulted in the induction of TNFa, MCP-1 and IL-8 (Kang et al., 2005). Similar 
experiments have also shown that DR3 activation in THP-1 cells can induce the 
release of MMP-1, MMP-9 and MMP-13 which are proposed to contribute to the 
destabilization of the atherosclerotic plaques (Kim et al., 2001). Treatment of THP-1 
cells with TL1A also stimulated MMP-9 expression (Kang et al., 2005). Therefore, 
DR3 and TL1A appear to have an important role in the pathogenesis of 
atherosclerosis.
0R3 has also recently been linked with the inflammatory joint disease Rheumatoid 
Arthritis (RA) and much of the focus of this thesis will concentrate on this 
relationship. Prior to reviewing the current literature concerning the role of DR3 in 
RA, some background theory of the disease and the pathological joint changes with 
which it is associated will now be discussed.
1.3 The Normal Synovial Joint
In order to appreciate the pathological changes associated with RA, it is important 
to understand the anatomy and physiology of a normal synovial joint. The synovial 
joints (diarthrodial) are the most common joints in the human body, classified both 
by their ability to move and their encapsulation in a joint cavity lined with synovial 
tissue. These joints are capable of a wide range of movements and have 4 common 
features: synovial capsule; synovial membrane; articular cartilage and synovial fluid.
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Under normal physiological conditions, these function to produce a smooth 
frictionless movement (Wooley et al., 2005).
1.3.1 The Synovial Capsule
The outer layer of the synovial capsule is composed of dense connective tissue 
which provides support and stability to the joint (Ralphs and Benjamin, 1994). 
Ligaments form a component of this connective tissue, connecting 2 bones together 
and limiting the extent of joint motion. The inner layer of the synovial capsule is the 
synovial membrane.
1.3.2 The Synovium
The synovial membrane consists of 2 distinct layers, namely the intimal lining layer 
and the synovial sublining, which function both to provide nutritional support to 
the joint and to generate the synovial fluid necessary for smooth joint movements 
(Wooley et al., 2005). Under normal conditions, the intimal lining layer is only 1-2 
cells thick. It is generally accepted that this intimal lining layer is composed of 2 
principle cell types: Type A synoviocytes and type B synoviocytes (Iwanaga et al., 
2000). Type A synoviocytes, which are also termed macrophage-like synoviocytes, 
may function to absorb material from within the joint such as cell debris, bacteria 
and antigens (Iwanaga et al., 2000). Type B synoviocytes, also known as fibroblast­
like synoviocytes, function to secrete a number of factors into the synovial fluid 
including cytokines, matrix metalloproteinases (MMPs), hyaluronan and 
proteoglycans (Knedla et al., 2007). The synovial sublining is relatively acellular, 
consisting principally of blood vessels, fat cells and fibroblasts (Smith et al., 2003).
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The synovium has 3 membrane types: Areolar; adipose and fibrous. Areolar tissue 
has a folded surface with projections which are often termed synovial villi. Here the 
intimal lining layer is relatively thick. The adipose tissue has a single cell thick 
intimal layer and finally, the fibrous tissue contains a thin intimal layer in direct 
contact with dense collagenous tissue (Iwanaga et al., 2000).
1.3.3 Articular Cartilage
Articular cartilage is a mesenchymal tissue which overlies subchondral bone, 
functioning to provide smooth, low resistance surfaces within the joint that are 
capable of withstanding compression (Saxne and Bengt, 2000). The extracellular 
matrix of articular cartilage is organised into 4 layers namely the superficial, 
intermediate, deep and calcified layers (Eyre, 2002) which comprise collagens, 
proteoglycans and the sole cell type of articular cartilage, the chondrocyte (Hall et 
al., 1996). Collagen is an exceptionally strong structure due to its extensive network 
of cross-linking fibres. However, if it becomes disrupted or damaged it is not 
capable of efficient repair. The principle collagens of articular cartilage are types II, 
IX and XI (Eyre, 2002). The principle proteoglycan of articular cartilage is aggrecan. 
Other minor proteoglycans such as decorin and fibromodulin are also present 
within articular cartilage (Roughley, 2001). Chondrocytes are the only cell type 
present within articular cartilage and are capable of both the synthesis and the 
degradation of all the components of cartilage (Saxne and Bengt, 2000). The 
relative composition of the different components of cartilage varies throughout the 
layers. The superficial layers are relatively acellular and chondrocytes display a 
flattened shape lying in parallel with the surface. Within this layer, collagen fibres
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run in parallel with the surface. Conversely, in the deep layers, chondrocytes are 
quite abundant and display more of a rounded shape, with collagen fibres adopting 
a more vertical orientation (Saxne and Bengt, 2000). The properties of each of the 
components of articular cartilage enable its efficient functioning throughout the 
majority of an individual's life, providing that its physiological state is not 
compromised. However, cartilage is susceptible to degradation by multiple 
proteases that can be produced by chondrocytes and synovial fibroblasts during 
states of inflammation. Of these proteases, the matrix metalloproteases (MMPs) 
and the ADAMTSs (a disintegrin and a metalloprotease with thrombospondin 
motifs) are responsible for the degradation of collagen and aggrecan respectively 
(Mort and Billington, 2001).
1.3.4 Bone
Bone is a vital structure in the human body serving as a support frame, providing a 
protective shield for internal organs, generating blood cells and acting as a store for 
minerals and ions. It is a dynamic structure which is constantly undergoing a highly 
coordinated and complex remodeling process with approximately 10% of total bone 
content of adults being replaced per year (Takayanagi, 2007). Bone contains 2 
principle cell types namely the osteoblast and the osteoclast. Osteoblasts are bone 
forming cells of mesenchymal origin which are capable of secreting bone matrix 
proteins and of promoting bone mineralization (Harada and Rodan, 2003). 
Osteoclasts are the only cells capable of resorbing bone, specifically functioning to 
dissolve the crystalline hydroxyapatite of bone via hydrochloric acid secretion and 
to degrade the organic bone matrix through the release of enzymes (Schett, 2007).
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1.3.5 Physiological Bone Remodelling
Physiological bone remodelling (depicted in figure 1.3) can be divided into 5 stages 
(Fernandez-Tresguerres-Hernandez-Gil et al., 2006). During the quiescent phase, no 
processes of bone remodelling are occurring. The first processes occur during the 
activation phase when bone lining cells retract and the mineralized bone surface is 
exposed through the action of collagenases. Osteoclast precursors are subsequently 
recruited to the site and differentiate into functional osteoclasts, permitting the 
degradation of the mineralized matrix. This is termed the resorption phase. Pre­
osteoblasts then generate a cementing substance during the formation phase 
which enables the attachment of new osteoid material generated by osteoblasts 
within a few days. Finally, the material becomes mineralized to form new bone 
during the mineralization phase (Fernandez-Tresguerres-Hernandez-Gil et al., 
2006).
1.3.6 Osteoclasts
Osteoclasts are terminally differentiated cells derived from pluripotent 
hematopoietic stem cells and are considered to be of the monocyte-macrophage 
lineage. Osteoclasts can be recognized by their multinuclear appearance and 
characteristic expression of tartrate resistant acid phosphatase (TRAP) and 
calcitonin receptor (Fujikawa et al., 1996). In vitro studies have illustrated that 
multiple cell types have the capacity to differentiate into osteoclasts when provided 
with the right signals and that ascertaining the stage at which a precursor cell is 
committed to becoming an osteoclast has proven difficult to establish. The earliest 
osteoclast precursor is reported to be the colony forming unit-granulocyte
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macrophage (Kurihara et al., 1990). Husheem et al (2005) have shown that purified 
monocytes from human peripheral blood mononuclear cells can differentiate into 
osteoclasts when cultured on bovine bone cultures in the presence of RANKL, M- 
CSF, TNFcx and dexamethasone. Furthermore, the authors illustrated that various 
subpopulations of monocytes had differing capacities to differentiate, with 
osteoclast formation being 90, 30 and 20 times higher in CD14+, CD llb+ and CD61+ 
purified monocyte cell cultures respectively when compared to controls (Husheem 
et al., 2005). F4/80* macrophages have also been shown to have the capacity to 
differentiate into functional osteoclasts. By culturing murine bone marrow cells 
with the viral supernantant from cells infected with a RANKL expressing retroviral 
vector, Lean and colleagues were able to generate multinucleated osteoclasts from 
mononuclear cells that strongly expressed the macrophage marker F4/80 (Lean et 
al., 2000).
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from (Datta et al., 2008)
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The process of osteoclast differentiation from osteoclast precursor cells has been 
well documented. Early in vitro studies using co-cultures of murine spleen cells and 
osteoblasts in the presence of 1 alpha-dihydroxyvitamin D3 revealed that in order 
to develop functional bone resorbing osteoclasts, the presence of osteoblasts is 
essential (Takahashi et al., 1988). Using the murine osteopetrotic op/op model, it 
was further determined that the osteoblast/stromal cell derived factor macrophage 
colony-stimulating factor (M-CSF), through binding its receptor c-Fms, is central to 
osteoclast differentiation. Op/op mice are unable to generate functional M-CSF and 
therefore suffer from impaired bone resorption which can be recovered by the 
administration of recombinant M-CSF (Felix et al., 1990). Osteoblasts were 
determined to play a further role in the development of osteoclasts following the 
discovery of osteoprotegerin (OPG) and consequently osteoprotegerin ligand 
(OPGL) more commonly termed receptor activator of NFkB ligand (RANKL). In 1997, 
OPG was identified as a TNFRSF member, which is expressed as a secreted protein 
with mRNA transcripts detected within the bone of a 15 day old mouse embryo 
(Simonet et al., 1997). Transgenic mice expressing rat OPG developed an 
osteopetrotic phenotype and OPG administration in in vitro spleen cell cultures was 
capable of inhibiting osteoclastogenesis. Furthermore, the authors illustrated that 
administration of OPG to normal mice resulted in an excess accumulation of bone 
and cartilage indicating that OPG acts as a circulating factor which inhibits the bone 
resorbing properties of osteoclasts (Simonet et al., 1997). Investigators speculated 
from this study that OPG might be a receptor for a ligand molecule that had the 
capability of directing osteoclastogenesis and in 1998 such a ligand, named OPGL 
was identified. OPGL was found to be a member of the type II membrane bound
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TNF family of cytokines and was discovered by screening various cell lines with an 
OPG-Fc fusion protein. The identified protein was found to be identical to 2 
previously reported proteins TRANCE (Wong et al., 1999) and RANKL (Anderson et 
al., 1997) and occurred in both membrane bound and soluble forms, both 
interacting specifically with OPG (Lacey et al., 1998). In in vitro cultures of stromal 
cells and osteoclast precursors, OPGL treatment was capable of enhancing 
osteoclastogenesis and acted synergistically with M-CSF to produce functional bone 
resorbing osteoclasts (Lacey et al., 1998). Cell binding studies using a fluorescein 
conjugated OPGL revealed that OPGL binds directly to osteoclast precursors in 
order to promote osteoclastogenesis. When OPGL was injected directly into mice, a 
reduction in bone volume in the proximal tibia was reported. Interestingly, 
osteoclast numbers in these mice were not different to those of controls but the 
size and multinuclearity of osteoclasts was significantly greater (Lacey et al., 1998). 
The receptor for OPGL or RANKL as it will now be termed is RANK. RANK was 
originally described in dendritic cells, along with its ligand RANKL, as having a role in 
T-cell proliferation following dendritic cell interaction (Anderson et al., 1997). It was 
subsequently found to be expressed by osteoclast precursor cells and through 
binding RANKL, could initiate osteoclastogenesis (Hsu et al., 1999). Taken together, 
this data has resulted in the generation of the current model of osteoclast 
differentiation and is depicted in figure 1.4. Osteoclast precursors from the bone 
marrow are mobilized and recruited to sites where bone turnover is occurring. 
Here, precursor cells receive signals from osteoblasts via interaction of RANKL, 
expressed on the osteoblast and its receptor RANK, expressed on the osteoclast 
precursor cell to differentiate into osteoclasts. Additionally, osteoblasts and stromal
32
cells secrete M-CSF to enhance osteoclast differentiation. The soluble receptor OPG 
competes with RANK for RANKL binding thus acting as an osteoclast differentiation 
control mechanism. Although this is a heavily simplified model which does not take 
into account the effects of other factors, such as cytokines, it highlights the crucial 
factors involved in osteoclast differentiation.
Following osteoclast differentiation, the mature osteoclast is capable of active bone 
resorption. During this process, an osteoclast displays 4 distinct membrane domains 
as a result of polarization of the cell and reorganization of microtubules and 
microfilaments. The sealing zone attaches to the bone matrix and the ruffled border 
membrane forms, representing the resorption organ. A functional secretory domain 
also forms within the basolateral membrane (Vaananen and Laitala-Leinonen, 
2008). A vascular ATPase proton pump within the ruffled border membrane permits 
the release of hydrochloric acid from vesicles within the osteoclast into the 
resorption lacuna, ultimately resulting in the dissolution of bone (Schett, 2007). 
Additionally osteoclasts release matrix degrading enzymes such as matrix 
metalloproteinases and cathepsins which are capable of degrading molecules such 
as collagen. Normally this process occurs at sites where old bone is removed and 
replaced by new bone such as at the trabecular surface and within thin bone 
channels of cortical bone.
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Figure 1.4. The process of osteoclast differentiation. Osteoclast precursor cells 
interact with osteoblasts/stromal cells via RANK/RANKL in order to drive 
differentiation into mature osteoclasts. Adapted from (Yasuda et al., 1998).
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1.3.7 Osteoblasts
Osteoblasts are derived from mesenchymal stem cells in the bone marrow (Kassem 
et al., 2008). They are cuboid cells which resemble fibroblasts in morphology and 
which function to synthesise bone matrix proteins and enhance mineralization 
(Harada and Rodan, 2003). Their differentiation, like that of osteoclasts, is complex 
and highly coordinated involving numerous factors such as hormones and growth 
factors (Datta et al., 2008). Terminally differentiated osteoblasts that become 
encased within the matrix are termed osteocytes. These no longer function to 
generate new bone but are thought to play a role in sensing mechanical stress and 
regulating bone turnover (Datta et al., 2008).
1.4 Rheumatoid Arthritis -  Historical origin
Rheumatoid Arthritis (RA) was first described in Europe by Landre-Beauvais in his 
doctoral thesis in 1800. He named the disease "primary aesthenic gout", listing it as 
a disease of people with a "feeble constitution" and described its characteristic 
features in a number of female patients. These features are recognisable today as 
RA and included swelling, pain, stiffness and distortion of the joints, recurrence of 
disease and its polyarticular nature (Landre-Beauvais, 2001). Prior to this 
description, there is little historical evidence of the disease. However, suggestions 
of it can be traced as far as ancient Egypt, although the precise origin of the disease 
is a matter for debate (Short, 1974). Following the Landre-Beauvais's description in 
1800, RA was given its current name by Alfred Baring Garrod in 1859, differentiating 
it from rheumatism and rheumatic gout (Short, 1974). It is currently described as a 
systemic chronic inflammatory disease, typically characterised by inflammation,
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pain and stiffness of the synovial joints (Majithia and Geraci, 2007). RA currently 
has a 1% worldwide prevalence and is more commonly suffered by women in a 3:1 
ratio (Alamanos and Drosos, 2005). RA is an idiopathic autoimmune disease in 
which both auto-antibodies, such as rheumatoid factor, anti-collagen antibodies 
and anti-citrullinated antibodies, and auto-reactive T cells may play a role. Although 
the cause of RA is unknown, many theories have been proposed. Studies 
investigating a genetic cause of RA susceptibility identified alleles in the HLA-DRB1 
locus as being responsible, at least in part, for the disease (Wordsworth et al., 
1989). These are now known most commonly to be the HLA-DRB1*04 group of 
alleles which are identifiable by the existence of a shared epitope (QKRAA, GRRAA, 
RRRAA) in the 3rd hypervariable region of DRB1 (Orozco et al., 2006). In addition to 
a genetic component of the disease, environmental factors including the 
contraction of certain viruses and also several hormonal factors have been 
associated with the disease. However, it is likely that RA results from a combination 
of environmental and genetically predisposing factors.
1.4.1 Clinical Manifestations of Rheumatoid Arthritis
RA can affect both the small and large joints and is usually polyarticular. Those 
joints most commonly affected are the wrists, proximal interphalangeal (PIP) and 
metacarpophalangeal (MCP) joints of the hand (Rindfleisch and Muller, 2005). 
Extra-articular manifestations of disease may also be present such as the 
development of rheumatoid nodules and vasculitis (Akil and Amos, 1995). RA is 
diagnosed according to the criteria of the American Rheumatism Association (ARA). 
In 1987 the ARA revised the criteria for the classification of RA. Patients who met 4
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of the 7 criteria indicated in table 1.2 are diagnosed as having RA. If left untreated, 
RA can affect an increasing number of joints resulting in damage, deformity and 
severe disability.
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Criterion Definition
1. Morning stiffness Morning stiffness in and around the joints, lasting at 
least one hour before maximal improvement.
2. Arthritis of 3 or more
joint areas At least 3 joint areas simultaneously have had soft 
tissue swelling or fluid observed by a physician. The 14 
possible areas are right or left PIP, MCP, wrist, elbow, 
knee, ankle and MTP joints.
3. Arthritis of hand joints At least 1 area swollen in a wrist, MCP or PIP joint.
4. Symmetric arthritis Simultaneous involvement of the same joint areas on 
both sides of the body.
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or 
extensor surfaces, or in juxtaarticular regions 
observed by a physician.
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which the result 
has been positive in <5% of normal control subjects.
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7. Radiographic changes Radiographic changes typical of Rheumatoid Arthritis
on posteroanterior hand and wrist radiographs, which 
must include erosions or unequivocal bony 
decalcification localised in or most marked adjacent to 
the involved joints (osteoarthritis changes alone do 
not qualify).
Table 1.2. The ARA 1987 Revised Criteria for the Classification of RA.
PIP = proximal interphalangeal, MCP = metacarpophalageal, MTP =
metatarsopha la ngea I
Reproduced from (Arnett et al., 1988)
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1.4.2 The Rheumatoid Joint
Numerous characteristic pathological changes occur within the joints of RA 
patients, resulting in the clinical symptoms associated with the disease and the 
eventual destabilization and destruction of the joints. A diagram illustrating an RA 
joint compared to a normal joint is shown in figure 1.5.
1.4.2.1 The Joint Capsule
Swelling is one of the earliest symptoms of RA and can be attributed to oedema and 
fibrin deposition occurring within the joints (Weinberg et al., 1991). This causes 
distention of the joint capsule resulting in pain. Ligament damage may also arise.
1.4.2.2 The Synovium
Following oedema, the synovial lining layer proliferates, with both cell number and 
size increasing. The thickness of the synovium increases from 1-2 cells to 3-7 cells 
thick and displays an increased number of villi (Henderson et al., 1988). Endothelial 
cell swelling and vascular proliferation occurs resulting in an increase in the number 
of blood vessels present within the joint. Marked mononuclear cell infiltration is 
evident, displaying both a diffuse and nodular pattern and consisting primarily of 
neutrophils, lymphocytes, principally of the CD4+ memory cell phenotype with 
smaller numbers of CD8+ T cells, macrophages and plasma cells (Cush and Lipsky, 
1988). Synovial fibroblast cells become invasive and form the pannus at the 
synovium-cartilage interface.
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Although the trigger which results in the initial synovial infiltration is unclear, the 
importance of the infiltrating cells and the molecules they secrete is beginning to be 
understood and the central mediators of the disease are emerging. These are 
principally being revealed to be cytokines and more specifically interleukins and 
TNF superfamily members. TNFa and 1L-1 are two such mediators. In 1988, Buchan 
et al. demonstrated that IL-1, TNFa and lymphotoxin mRNA levels were all elevated 
in monocytes cultured from rheumatoid synovial fluid and synovial membrane 
compared with control PBMC (Buchan et al., 1988). In 1989, Brennan et al. 
extracted and cultured mononuclear cells from rheumatoid synovium and found 
that TNFa was produced by all samples in the absence of external stimuli and that 
this could be blocked by anti-TNFa treatment but not by anti-lymphotoxin. IL-1 was 
also detected in the cultures and interestingly, anti-TNFa treatment was shown to 
significantly inhibit IL-1 activity (Brennan et al., 1989). Anti-TNFa treatment in 
rheumatoid synovial cultures has since been shown to reduce the production of 
other pro-inflammatory cytokines including IL-6, IL-8 and GM-CSF (Feldmann et al., 
1996), which has led to the hypothesis that TNFa regulates a cytokine cascade 
within the rheumatoid joint, and that blocking its activity, and thus the activity of 
other pro-inflammatory cytokines, may alter the pathological outcome of the 
disease.
1.4.2.3 Articular Cartilage
Destruction of articular cartilage results from both the physical invasiveness of the 
pannus and the generation of enzymes such as MMPs. Further invasion into tissues 
such as the menisci, undermine the physical integrity of the joint and causes
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instability. Those mediators already considered central to the inflammation 
associated with RA are also likely culprits in the destruction of cartilage. TNFa has 
been shown to increase the expression of certain MMPs, the enzymes responsible 
for cartilage degradation. In 1985, Dayer et al. illustrated that the addition of TNFa 
to cultured synovial fibroblasts resulted in increased production of collagenase 
(Dayer et al., 1985). More specifically, treatment of cultured synovial fibroblasts 
with TNFa was shown to increase production of the active form of MMP-2, a 
gelatinase responsible for the degradation of types IV and V collagen (Migita et al., 
1996). IL-1 has also been linked with cartilage degradation as monocytes taken 
from IL-1 deficient mice were noted to have impaired expression of MMPs -3 and - 
13 (Zwerina et al., 2007). Similarly, in the absence of IL-6, cartilage structure 
according to positive safranin-0 staining, is preserved following antigen-induced 
arthritis, whereas in IL-6+/+ mice, marked cartilage destruction has been noted 
(Ohshima et al., 1998).
1.4.2.4 Bone
Bone erosion is present both at areas adjacent to and distant from pannus 
development in the rheumatoid joint resulting in deformity and disability (Goldring, 
2003). The mechanisms of bone erosion in the joint arise from a disruption in the 
physiological balance between bone formation and destruction, through the bone- 
producing activity of osteoblasts and bone-resorbing activity of osteoclasts. A 
number of cytokines are reportedly involved in this process. Mice genetically 
designed to over-express TNFa develop severe bone erosions by 6-8 weeks of age 
(Zwerina et al., 2007). The mechanisms by which TNFa causes this are complex and
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discussed in further detail in chapter 6. However, it should be mentioned that TNFa 
is proposed to induce osteoclastogenesis both directly, by increasing the size of the 
osteoclast precursor pool, and indirectly by inducing RANKL expression on synovial 
cells and osteoblasts to enhance osteoclast maturation (Boyce et al., 2005). In an 
attempt to uncouple the functions of TNFa and IL-1 in bone erosion, Zwerina et al. 
crossed mice genetically over-expressing TNFa (hTNFtg) with IL-1 deficient mice. 
These mice developed the characteristic synovial inflammation seen in hTNFtg mice 
but erosion of the bone was reduced by approximately 50%. This was attributed to 
a reduction in osteoclastogenesis and responsiveness of monocytes to RANKL but 
not to reduced osteoclast functionality (Zwerina et al., 2007). RANKL, via interaction 
with its receptor RANK on the surface of osteoclast precursor cells, is fundamental 
in the process of osteoclastogenesis. It is a member of the TNF family of cytokines 
and is normally produced by osteoblasts and stromal cells. Romas et al. investigated 
the expression of RANKL in the collagen-induced arthritis model using both in-situ 
hybridization in inflamed joints and by staining for the osteoclast specific markers 
TRAP and calcitonin receptor. Multinucleated TRAP positive cells were identified at 
all sites of focal bone erosion and these cells also stained positive for calcitonin 
receptor. Normal rat joints did not display any positive staining for these markers. 
RANKL mRNA expression was detected in all of the actively eroding joints, in most 
of the mononuclear cells contained in the synovial infiltrate and particularly at the 
point where bone and synovium form an interface. Osteoclasts and chondrocytes 
also expressed RANKL mRNA (Romas et al., 2000). Thus RANKL is highly expressed 
within the rheumatoid joint permitting the differentiation of osteoclasts and 
therefore the degradation of bone. The increased expression of RANKL may be
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attributed to the aforementioned cytokines which are highly expressed within the 
rheumatoid joint. The role of the novel cytokine IL-17 in bone destruction has 
recently been of particular interest. Sato et al. used a co-culture system containing 
murine osteoblasts and bone marrow cells and illustrated that the addition of IL-17 
producing Thl7 cells resulted in the generation of TRAP+ cells. The addition of IL-17 
in this co-culture system had the same effect. Addition of IL-17 was, however, 
unable to generate TRAP+ cells in a system containing bone marrow cells in the 
presence of RANKL and M-CSF, thus implying that IL-17 regulates 
osteoclastogenesis via an effect on osteoblasts (Sato et al., 2006). This has been 
supported in a separate study using an osteoblast and bone marrow co-culture 
system where IL-17 was only able to induce osteoclast formation when the 
osteoclast and bone marrow cells were in direct contact with each other (Kotake et 
al., 1999). Thus IL-17 may exert its effect on osteoclastogenesis via the positive 
regulation of RANKL expression on osteoblasts.
1.5 Experimental Models for Adverse Joint Pathologies
Both cell culture models and animal models of arthritis have been fundamental to 
furthering our understanding of the causes and pathological processes of RA. In 
vitro models have provided insight into the mediators involved in the processes of 
inflammation and joint destruction. Those cytokines which are currently considered 
centrally involved in these processes, such as TNFa and IL-1, were identified 
through synovial cell cultures (Buchan et al., 1988). Similarly, cultures of bone 
marrow cells with either osteoblasts or RANKL/M-CSF, have been used to study the 
process of osteoclastogenesis (Sato et al., 2006). In vivo models of RA are routinely
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used to investigate the pathological changes occurring during RA. Numerous 
models exist in multiple species and a comparison of the 3 most commonly used 
murine models of the disease are shown in table 1.3. Each model has its own merits 
in terms of similarity with the human disease and ease of induction and replication 
in available strains of mice. The collagen-induced arthritis (CIA) model is often 
considered as the benchmark model for RA and has been used to assess the efficacy 
of novel therapeutics. As a systemic model which relies on both immune and 
genetic components and displaying the histopathological features which are highly 
associated with the disease, it bears close resemblance to human RA. However, it is 
not easily inducible in all available strains of mice and therefore it is often not 
suitable for use. The antigen-induced arthritis model (AIA) is easily inducible in 
available mice strains. Its histopathological features mirror those of both human RA 
and CIA, however, it is only a local model of disease and thus does not mimic the 
systemic nature of RA.
1.6 Current RA Therapies
Multiple classes of drugs are currently used in the treatment of RA. Many of these 
drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), steroids and 
analgesics are used in the daily control of pain. However, the principle aim of RA 
therapy is to prevent the progression of disease and preserve joint architecture. 
The development of novel anti-TNF therapies has made significant improvements in 
the treatment of RA. Etanercept and Infliximab are 2 such anti-TNF agents which 
have been licensed for use in treatment of this disease (Jobanputra et al., 2002). 
Etanercept is a TNFR2-lgG Fc fusion protein that binds soluble and cell bound TNFa,
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and Infliximab is an anti-TNFa monoclonal antibody. Both of these function to block 
signalling via TNFa thus preventing the detrimental activities of TNFa in RA patients 
(Feldmann and Maini, 2001). Efficacy of anti-TNF treatment is evaluated using the 
American College of Rheumatology (ACR) response criteria which takes into account 
the number of affected joints, pain and the general assessment of the disease. 
Responses of ACR 20, ACR 50 and ACR 70 can be achieved, representing reductions 
of 20 %, 50 % and 70 % of the disease criteria respectively (Jobanputra et al., 2002). 
In the most successful clinical trials with Etanercept and Infliximab, 79% and 75% of 
patients achieved an ACR 20 response (Jobanputra et al., 2002). Although this 
represents substantial clinical improvement, approximately 30 % of patients do not 
show beneficial responses to this drug therapy. Furthermore, radiographic analysis 
of joint damage following treatment with these therapies illustrates that 
progression of destruction is not completely prevented (Bathon et al., 2000, Lipsky 
et al., 2000). Thus, there is certainly scope for the development of novel RA 
therapies which better preserve the architecture of the joint.
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Table 1.3. A comparison of the 3 principle murine models for RA with the human disease.
Rheumatoid Arthritis Characteristics Antigen-induced Arthritis
Induction via mBSA 
Administration
Collagen-induced Arthritis
Induction via Type II Collagen 
Administration
Adjuvant-induced Arthritis
Induced via Mycobacterium 
Administration
Polyarticular No Yes Yes
Cellular Infiltration Yes Yes Yes
Synovial Hyperplasia and Pannus 
Formation Yes Yes Yes
Bone and Cartilage Erosion Yes Yes Yes
Genetic Susceptibility No Yes Yes
T cell Involvement Yes Yes Yes
Autoantibody Involvement No Yes No
Alleviated Via Anti-cytokine Therapy Yes Yes Yes
1.7 The Role of DR3 in Rheumatoid Arthritis
DR3 has been identified as a candidate gene for association with RA. Using 
fluorescence-based microsatellite marker analysis and affected sib-pair linkage 
analysis in RA patients Shiozawa et al. (2000) identified the region D1S214/252 on 
chromosome 1 as having a genetic link with the disease. As DR3 resides very close 
to this region, they investigated the expression of DR3 mRNA in affected 
individuals. An increase in mRNA in RA patients for the transmembrane portion of 
DR3 compared with controls was discovered. However, no such difference was 
observed in mRNA for the death domain portion of DR3, suggesting a complex role 
for DR3 in RA (Shiozawa et al., 2000). In 2004, the same group further implicated a 
role for DR3 in RA by using fluorescence in situ hybridisation to identify a 
duplication of the DR3 gene approximately 200kb upstream of the original. This 
duplication occurred in 78% of RA patients examined compared to only 39% of 
controls (Osawa et al., 2004). In a separate study based on comparative modeling of 
DR3, mutations in the DR3 gene thought to be associated with RA were predicted to 
cause reduced stability in the ligand binding domain of the receptor, potentially 
reducing its activation during the disease. However, as this is only a predicted 
model and because DR3 signalling is complicated by the existence of both soluble 
and membrane bound forms (Kitson et al., 1996), the effect this would have is 
uncertain (Borysenko et al., 2005). Most recently, the only known ligand for DR3, 
TL1A, has been linked with RA. Having determined that soluble TL1A release by 
human monocytes could be induced in vitro by stimulation with insoluble immune 
complexes, Cassatelia et al. (2007) investigated the expression of soluble TL1A in RA 
patients. Those patients that were rheumatoid factor positive displayed strong TL1A
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expression in their synovium. The cells displaying this staining had monocyte- 
macrophage morphology and expressed CD68 and CD14. This staining was less 
intense in rheumatoid factor negative patients. Additionally, monocytes from 
healthy donors which were cultured with purified insoluble immune complexes and 
PEG precipitates from rheumatoid factor positive patients, released high amounts 
of soluble TL1A (Cassatella et al., 2007). Thus increased TL1A expression in RA may 
increase DR3 activation and contribute to the progression of the disease. 
Interestingly, it was also determined in this study that monocyte production of 
soluble TL1A by immune complex stimulation, occurred with slower kinetics than 
that of either TNFa or IL-1 production and was not affected by the addition of anti- 
TNFa neutralising antibodies (Cassatella et al., 2007). Therefore, soluble TL1A 
production by monocytes may occur via a distinct pathway to TNFa providing a 
potentially important function for DR3 in RA. The mechanism by which DR3 and 
TL1A might contribute to the pathogenesis of RA is unknown. Recent data has 
implicated a role for DR3 in osteoblast regulation. Both soluble and full length 
versions of DR3 are expressed on human osteoblasts and the human osteosarcoma 
cell line MG63. The latter represents a model of mid-differentiation osteoblasts 
(Borysenko et al., 2006). At low density cultures of MG63 cells, DR3 activation via 
receptor cross-linking has been shown to result in apoptosis and reduced bone 
matrix synthesis. This could be blocked via the addition of media containing soluble 
DR3 (Borysenko et al., 2006). However, to date neither expression of DR3 on 
osteoclasts nor a potential role for DR3 in osteoclast differentiation and function 
has been identified.
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1.8 Aims of the thesis
DR3 has been implicated in multiple inflammatory diseases, however, few in vivo 
studies have been carried out in order to fully elucidate the role of DR3 in 
inflammatory disease states. This is in part due to a lack of available reagents with 
which to study DR3 function.
The aims of this thesis are to address the issue of reagent availability, by carrying 
out gene cloning and antibody generation for use in scientific research, and to 
determine the in vivo role of DR3 in an inflammatory disease state namely, RA, 
using a murine model for the disease. The in vivo study should also be 
complimented by the generation of reagents. The specific aims of this thesis are:
•  To clone DR3 genes and express them in eukaryotic systems. Both murine 
and human DR3 genes will be cloned by PCR and subcloned into eukaryotic 
expression vectors for the generation of soluble proteins and stable cell 
lines.
•  To generate antibodies to murine and human DR3. Soluble proteins and 
stable cell lines will be used to immunize mice for the generation of 
antibodies via the Kohler and Milstein hybridoma method of antibody 
generation.
•  To investigate the role of DR3 in the murine antigen-induced arthritis (AIA) 
model of Rheumatoid Arthritis. Mice genetically deficient in DR3 will be 
induced to develop AIA and the resulting inflammatory response will be 
evaluated via measurement of joint swelling and histological analysis.
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2. Materials and Methods
2.1 Solutions
Unless otherwise indicated, all reagents given below were supplied by Sigma- 
Aldrich (Poole, Dorset).
Acetate Buffer:
35.2ml 0.2M sodium acetate (Fisher Scientific, Loughborough, UK) 14.8ml 0.2M 
acetic acid solution, 50ml dH20.
Ampicillin Solution:
Ampicillin (Roche, Germany) was dissolved in dH20  at a concentration of 50mg/ml 
before being sterilised through a 0.22pm filter and stored at-20°C.
DABCO;
2% (w/v) l,4-Diazabicyclo[2.2.2]octane (DABCO), 10% (v/v) phosphate buffered 
saline (PBS) (Oxoid, Hampshire) in glycerol.
Disodium Hydrogen Orthophosphate Solution (Fisher Scientific):
28.4mg/ml dissolved in dH20.
DNA Loading Buffer-Orange G:
2.5mg/ml Orange G loading dye in 2X TBE containing 30% glycerol.
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EDTA Decalcification Solution:
70g EDTA was dissolved in 140ml of sodium dihydrogen orthophosphate solution 
and 340ml disodium hydrogen orthophosphate which was then made up to 1L with 
dH20.
Eosin Solution:
lOmg/ml Eosin (Fisher Scientific) dissolved in dH20.
Fast Green Staining Solution:
0.5mg/ml dissolved in dH20.
Formic Acid Decalcification Solution:
100ml formic acid and 50ml formaldehyde (Fisher Scientific) mixed with 850ml of 
dH20.
Freezing Media:
Foetal Calf Serum (FCS) 90% (v/v) (Invitrogen, Netherlands) mixed with 10% 
dimethyl sulphoxide (DMSO) and filtered through a 0.22pm filter.
Kanamycin Solution;
Kanamycin (Roche) was dissolved in dH20  at a concentration of 50mg/ml before 
being sterilised through a 0.22pm filter and stored at -20°C.
54
Lauria Bertani (LB) Agar;
1.5% agar (w/v) (Oxoid) was added to LB broth. Ampicillin or Kanamycin (50pg/ml) 
was added if required when the broth had cooled to 50°C.
LB Broth:
20g LB broth low salt powder (Melford, Suffolk, UK) was dissolved in 1L H20  and 
autoclaved. Ampicillin or Kanamycin was added at lOOpg/ml if required when the 
broth had cooled to 50°C.
LB X-gal Plates;
40pl of X-gal solution was spread on pre-warmed LB agar plates.
Lysis Buffer:
0.5ml TRIS-HCI (pH 8.0), 1 ml 10% SDS, 2ml 0.5M EDTA, 1ml 1M NaCI, lOOpI 
proteinase K, 5ml dH20.
PBS;
8% (w/v) sodium chloride, 0.2% (w/v) potassium chloride, 0.12% (v/v) anhydrous 
sodium hydrogen phosphate at pH 7.4.
PBS-T:
PBS containing 0.1% (v/v) Tween-20.
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RIPA Buffer:
0.5% NP40, 0.1% SDS, 0.5% deoxycholic acid, 150mM NaCI, lOmM Tris pH 8.0, 5mM 
EDTA made up to 50ml with dH20.
Safranin 0  Staining Solution: 
lmg/ml safranin O dissolved in dH20.
SOC:
2% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.05% (w/v) NaCI and 2.5mM KCI was 
autoclaved. Filter sterilised 2M MgCI2 and 1M glucose was then added to a final 
concentration of lOmM and 20mM, respectively.
Sodium Dihydrogen Orthophosphate Solution;
31.2mg/ml sodium dihydrogen orthophosphate (Fisher Scientific) dissolved in dH20. 
TBE (lOx):
54g Tris, 27.5g boric acid dissolved in dH20  to a final volume of 990ml and then 
10ml 1M EDTA pH 8.0 added.
TBE Agarose Gels:
1 x TBE containing 1% (w/v) agarose.
TBS Solution:
1L dH20  containing 61g Tris and 90g NaCI pH 7.6.
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Towbin Buffer:
28.8g glycine, 6g TRIS, 400ml methanol, made up to 2L with dH20.
TRAP Staining Solution:
50ml 0.1M acetate buffer, 10ml 0.3M sodium tartrate, 1ml lOmg/ml naphtol AS-MX 
phosphate, lOOpI Triton X-100, 38.9ml dH20,0.3mg/ml Fast Red Violet LB salt.
X-gal Solution;
40mg/ml 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside in 100ml N, N- 
dimethyl formamide (DMF).
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2.2 Molecular Cloning
2.2.1 Agarose Gel Electrophoresis
DNA fragments were separated according to size by electrophoresis on a 1% (v/v) 
TBE agarose gel containing 10% ethidium bromide (Sigma-Aldrich). Gels were set in 
trays for 1 hour prior to placing them into gel tanks and submerging them in TBE 
buffer. Samples were mixed with gel loading solution (Sigma-Aldrich) or Orange G 
DNA loading buffer and pipetted into wells alongside a wide range DNA marker 
(Sigma-Aldrich). Electrophoresis was carried out at a constant voltage of 100 volts 
for 40 minutes to 1 hour. Bands were then visualised by ultraviolet (UV) 
illumination at 365nm.
2.2.2 Plasmid Vectors
Signal plgplus was a commercial vector made originally by R&D systems. 
pDR26EFla was a gift from Dr. I. Anegon (INSERM U437, Nantes, France) (Charreau 
et al., 1994). pAL190 (pEGFP-Nl, Clontech) was a gift from Dr Richard Stanton 
(Medical Microbiology, Cardiff University). hDR3 in pcDNA3.1 was a gift from Stuart 
Farrow (Glaxo Wellcome, Herts, UK).
2.2.3 Polymerase Chain Reaction for human DR3 and murine DR3 from plasmid 
DNA
All PCR reactions were carried out using a PX2 Thermal Cycler (Thermo Electron 
Corp., USA). PCR reactions using plasmid DNA as the template were carried out 
using Taq DNA polymerase (NEB, USA). Reaction mixtures contained the 
manufacturer's supplied buffer, dNTPs (ImM) (NEB), forward and reverse primers
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(lOpmol of each) and DMSO (5%) (Sigma-Aldrich). For human DR3 cloning, plasmids 
were linearized via restriction enzyme digest prior to PCR reaction. The following 
thermocycling reaction was used:
Initial Denaturation: 94°C 5 minutes
Denaturation: 94#C 1 minute
Annealing: 50°C 1 minute
Extension: 72°C 1 minute
Final Extension: 72°C 10 minutes
Hold: 4#C
x 35
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Product Primer Sequence Predicted Size (bp)
Dominant 5' gga eta gta acc acg acg ggc aga gag c 812
negative (DN) 3'
hDR3 5' egg ate ctt att ttt cga act geg ggt ggc
tcc aag ege tee cag ctt cat ctg cag taa c 
3'
Soluble (Sol) 5' gga eta gta acc acg acg ggc aga gag c 663
hDR3 3'
5' egg ate ctg cca gaa cat ctg cct cca gee 
3'
Sol hDR3 + 5' gga eta gta acc acg acg ggc aga gag c 696
streptag 3'
5' egg ate ctg tta ttt ttc gaa ctg egg gtg 
get cca age get cca gaa cat ctg cct cca 
gee 3'
Sol hDR3 + 5' gga eta gta acc acg acg ggc aga gag c 693
streptag (no stop 3'
codon) 5' egg ate ctg ttt ttc gaa ctg egg gtg get
cca age get cca gaa cat ctg cct cca gee 3'
Table 2.1: List of primers used in hDR3 cloning. All forward primers contain an Spel 
enzyme site and all reverse primers contain a BamHI enzyme site.
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2.2.4 Polymerase Chain Reaction for Cloning Soluble Human and Murine DR3 from 
Signal Pigplus into pDR26EFla
Reactions were carried out using Platinum Pfx DNA polymerase (Invitrogen) with 
the manufacturer's supplied buffer, dNTPs (ImM) (NEB), forward and reverse 
primers (lOpmol of each) and DMSO (5%) (Sigma-Aldrich). The following 
thermocycling reaction was used:
Initial Denaturation: 94°C 5 minutes
Denaturation: 94°C 1 minute
Annealing: 50°C 1 minute
Extension: 72°C 2 minutes
Final Extension: 72°C 10 minutes
Hold: 4°C
Forward primers were designed for human and murine soluble DR3 including Xbal 
and Spel restriction enzyme sites respectively. The same reverse primer was used in 
both reactions and contained an EcoRV restriction enzyme site.
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Table 2.2: Primers used in cloning soluble hDR3 and mDR3 from Signal plgplus into 
pDR26EFla
Product Primer Sequences Predicted Size (bp)
Soluble hDR3 5' cga tct aga taa eta gag aac cca ctg 3' 1523
5' cga gat ate gca ttt agg tga cac tat 3'
Soluble mDR3 5' cga act agt taa eta gag aac cca ctg 3' 1547
5' cga gat ate gca ttt agg tga cac tat
3'
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2.2.5 Reverse Transcription -  Polymerase Chain Reaction for murine DR3
2.2.5.1 RNA extraction
Prior to all RNA work, plastlcware, benches and pipettes were treated with RNase 
Away (Invitrogen, Groningen, Netherlands). All centrifuge steps were carried out at 
10000 x g. Total RNA was extracted from murine thymus tissue using an RNeasy 
Midi Kit (Qiagen, West Sussex, UK) according to manufacturer's instructions. Briefly, 
freshly removed and flash frozen tissue was ground under liquid nitrogen in a 
mortar and pestle. Following transfer to a 15ml falcon, 2ml of buffer RLT containing 
20pl 2-mercaptoethanol (Sigma-Aldrich) was added and vortexed. A 21 gauge 
needle was then used to homogenize the tissue. Samples were centrifuged and 
supernatant discarded. Ethanol (70%) (2ml) was added and samples were 
vigorously shaken. Samples were then added to an RNeasy column and centrifuged 
and the flow through was discarded. RW1 (4ml) was added and columns were 
centrifuged again, followed by 2.5ml of RPE and another centrifugation step. All 
flow throughs were discarded. The column was transferred to a collection tube and 
RNA was eluted into 300pl of RNAse free water (Invitrogen), allowing a minute to 
stand following the addition of the water, prior to centrifugation. If storage was 
necessary, RNA was stored at -70°C.
2.2.5.2 Reverse Transcription
cDNA was generated via a reverse transcription reaction using Superscript II 
Reverse Transcriptase (Invitrogen). RNA (lpg) was used in each reaction and its 
concentration was determined by measuring absorbance at 260nm. Reaction 
mixtures also contained the manufacturer's supplied buffer, random primers
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(250ng) (Invitrogen), dNTPs (ImM) (NEB), DTTs (0.1M) (Invitrogen) and RNase Out 
(40U) (Invitrogen). Following addition of the random primers and dNTPs to the RNA, 
the reaction was heated to 65°C for 5 minutes and then placed on ice. Buffer, DTTs 
and RNase out were then added and the reaction held at 25°C for 2 minutes prior to 
the addition of Superscript II reverse transcriptase. The thermocycling reaction then 
proceeded at 25#C for 10 minutes, 42#C for 50 minutes and 70°C for 50 minutes. 
cDNA was stored at -70°C.
2.2.5.3 Polymerase chain reaction
Murine DR3 was cloned via PCR reaction from cDNA using a version of the 
"slowdown PCR" technique adapted from Bachmann et al (2003). Reactions were 
carried out using Platinum Pfx DNA polymerase (Invitrogen) with the 
manufacturer's supplied buffer, dNTPs (Im M ) (NEB), forward and reverse primers 
(lOpmol of each) and DMSO (5%) (Sigma-Aldrich). The following thermocycling 
reaction was used:
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Initial denaturation: 
48 cycles of: 
Denaturation:
Annealing:
Extension:
15 cycles of: 
Denaturation:
Annealing:
Extension:
Final Extension: 
Hold
95°C
95°C
70°C -  1°C every 3rd cycle
68#C
95°C
58°C
68#C
68°C
5 minutes
30 seconds 
Ramp Rate 2.5°C 
30 seconds 
Ramp Rate 1.5°C 
1 minute 45 s 
Ramp Rate 2.5°C
30 seconds 
Ramp Rate 2.5°C 
30 seconds 
Ramp Rate 1.5°C 
1 minute 45 seconds 
Ramp Rate 2.5°C
5 minutes 
Ramp Rate 2.5°C
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Table 2.3: Primers used in cloning mDR3.
Product Primer Sequences 1Predicted Size (bp)
Full length mDR3 5' gga eta gta ccg caa tgg agg cac ggc tg 3' 
5' egg ate ege aga taa gca aaa gtg agg 3'
1392
DN mDR3 for pall90 5' etc gag acc gca atg gag gca egg 3'
5' gga tcc gcc aga gga gtt cca aga gtt c 3'
925
DN mDR3 for 
pDR26EFla
5' etc gag acc gca atg gag gca egg 3'
5' gga tcc tta ttt ttc gaa ctg egg gtg get cca 
age get tgc cag agg agt tcc aag agt tc 3'
958
Sol mDR3 5' etc gag acc gca atg gag gca egg 3'
5' ggt eta gac aag get gcc ate gac aa 3'
632
Sol mDR3 + ct streptag 5' etc gag acc gca atg gag gca egg 3'
5' tct aga ttt ttc gaa ctg egg gtg get cca caa 
ggc tgc cat cga caa 3'
703
Sol mDR3 + nt streptag 5' etc gag tgg age cac ccg cag ttc gaa aaa 
acc gca atg gag gca egg 3"
5' ggt eta gac aag get gcc ate gac aa 3'
703
mDR3 -  exon 5 and 6 5' gta eta gta ege gac cga cca gag cc 3'
5' egg ate ege aga taa gca aaa gtg agg 3'
1326
mDR3 exon 3 5' geg cag aac cct gtg gc 3' 
5' cat cac aga ctt ggc age 3'
107
mDR3 exon 10 5' ccg cag etc tac gat gtg 3' 
5' cct egg cac age ctt cc 3'
225
A variety of enzyme sites were included into the primers including: Spel; BamHI; 
Xhol and Xbal.
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2.2.6 Strep-Tag
A strep-tag II (IBA, USA) DNA sequence was incorporated into a number of PCR 
primers for use in protein detection and purification. The DNA sequence 
corresponds to an 8 amino acid sequence (WSHPQFEK).
2.2.7 PCR DNA and Gel Band Purification Using GFX Columns (Amersham, 
Buckinghamshire, UK)
This kit was used for the purification of DNA from solution or gel bands, via the use 
of a chaotropic agent and a glass fibre matrix column. Gel bands were weighed and 
dissolved at 65°C in an equivalent volume of capture buffer and centrifuged at 
10000 x g in the column. DNA in solution was mixed with 500pl of capture buffer 
before following the same protocol as the gel bands. Columns were then washed in 
wash buffer containing 80% ethanol. DNA was eluted into 50pl of distilled water 
following a 1 minute incubation step at room temperature and stored at -20°C.
2.2.8 Topo TA Cloning Kit (Invitrogen)
All DNA generated by PCR reaction was immediately cloned into the TOPO TA 
vector pCR2.1-TOPO vector (Invitrogen). This vector is provided linearised with 3' T 
overhangs, which enables efficient ligation to the single deoxyadenosine overhang 
on PCR products generated with Taq DNA polymerase. Briefly, PCR products were 
incubated at room temperature with the vector in the presence of a salt solution 
provided by the manufacturer for 30 minutes. TOP10 chemically competent E.Coli, 
also provided with the kit, were thawed on ice and 3pl of the cloning reaction 
added to it. This was incubated on ice for 30 minutes. E.Coli was then transformed
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via a 30 second heat shock reaction at 42°C and recovered in an orbital shaker in 
200pl LB at 37°C for one hour. The transformation reaction (200pl) was spread onto 
prewarmed ampicillin or kanamycin selective LB plates containing 40mg/ml X-gal. 
Plates were incubated overnight at 37°C and white colonies selected the following 
day for analysis and selection.
2.2.9 Plasmid DNA Miniprep
The QIAprep Spin Miniprep kit (Qiagen) was used for the small scale production of 
plasmid DNA. Bacterial cultures were cultured overnight in 5ml of LB medium 
containing a 1/1000 dilution of antibiotic (50mg/ml) corresponding to the 
resistance of the plasmid. This culture was then used to generate plasmid DNA. The 
QIAprep Spin Miniprep kit is based on an alkaline lysis of bacterial cells followed by 
the adsorption of DNA to the silica membrane column in the presence of high salt. 
All centrifugation steps were carried out at 10000 x g. The centrifuged bacterial 
culture was resuspended in buffer PI (250pl) containing RNaseA and mixed by 
pipetting. Bacteria were then lysed by the addition of buffer P2 (250pl) and mixed 
by inversion. The reaction was not allowed to proceed beyond 5 minutes before the 
addition of neutralization buffer (350pl) and mixture by inversion. The colourless 
precipitate was centrifuged and the supernatant decanted into the columns 
provided. Centrifugation of the columns permitted the adsorption of DNA to the 
silica membrane and the flow through was discarded. Salts were removed by a 
washing step in buffer PE (750pl) before DNA was eluted into a low salt buffer 
(buffer EB or distilled water) (50pl).
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2.2.10 Restriction Enzyme Digest
DNA was digested via the use of restriction enzymes (NEB). All digestions were 
carried out in a volume of 20pl containing supplied enzyme buffer (2pl), restriction 
enzyme (20 units) and DNA. BSA (Sigma-Aldrich) was also used in reactions 
requiring its presence. Double digestions were carried out in the recommended 
compatible buffer or by sequential digestion. Reaction mixtures were incubated at 
37#C for 1-2 hours prior to separation by agarose gel electrophoresis. DNA bands of 
the desired size were gel purified using Amersham GFX columns.
2.2.11 Production of Competent E.Coli
A sample of XLl-Blue E.Coli was provided by Dr Richard Stanton (Medical 
Microbiology, Cardiff University) and grown overnight on a tetracycline resistant LB 
plate. A single colony was selected and grown in LB (5ml) media containing 
tetracycline (0.1%) overnight at 37°C in an orbital shaker (Weiss-Gallenkamp, 
Loughborough, UK). The overnight culture (2.5ml) was inoculated into LB media 
(500ml) in a conical flask containing 20% glucose (10ml) and 1 M MgCh (5ml). This 
was incubated at 37°C in an orbital shaker until the optical density at 600nm was 
equal to 0.7-0.8, as measured on an Ultrospec 3000 spectrophotometer (Pharmacia 
Biotech, Cambridge, UK). The culture was then chilled on ice before washing twice 
in 10% glycerol (250ml) and centrifuging at 6000 x g for 20 minutes at 4°C. A third 
washing step in 10% glycerol (25ml) was carried out before resuspending the 
culture in 10% glycerol (5ml) and snap freezing in lOOpI volumes. E.Coli was stored 
at -80°C.
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2.2.12 Transformation of E.Coli
Bacterial cells were transformed via an electroporation method. Approximately 
50ng of plasmid were pipetted into competent E.Coli on ice in an electroporation 
cuvette (Bio-Rad, USA). After 5 minutes, bacteria were electroporated at 2.5 volts 
and recovered via the addition of SOC media (950pl) in an orbital shaker at 37°C for 
1 hour. Cultures (50-250pl) were grown overnight on a selective LB plate at 37°C.
2.2.13 Ligation Reactions
Both vector and insert DNA were digested with appropriate restriction enzymes and 
vector DNA was subsequently dephosphorylated with 5 units Antarctic Phosphatase 
(NEB) in the manufacturer's supplied buffer. Vector DNA (lOOng) was mixed with 
insert DNA in a molar ration of 3:1 to give a total reaction volume of 30pl containing 
T4 DNA ligase (1 unit) (Roche), supplied buffer (3pl) and water. The reaction was 
incubated at 16°C overnight prior to use in transformation reactions.
2.2.14 DNA Concentration Estimation
DNA concentration was analysed by a spectrophotometer, which measures the 
absorbance of a DNA solution at 260nm compared to a control solution containing 
no DNA. In situations where DNA concentration was too low to accurately 
determine using the spectrophotometer, it was run on a TBE agarose gel alongside 
a smart ladder marker (Eurogentec, Southampton) which contains DNA fragments 
of defined size and concentration.
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2.2.15 Removal of Single Stranded Extensions
Out of frame soluble hDR3 Signal Pigplus constructs were treated with mung bean 
nuclease (NEB) in order to put the hDR3 sequence in frame with the CD33 signal 
peptide. Constructs were digested with the restriction enzyme Hind III, as described 
in 2.2.10. The linear DNA (lOpg) was then incubated with 10 units of mung bean 
nuclease in the manufacturer's supplied buffer for 30 minutes at 30°C. Following 
DNA purification as described in 2.2.7, constructs were blunt end ligated as 
described in 2.2.13.
2.2.16 BigDye Sequencing
All constructs were sequenced using the "BigDye" terminator v3.1 cycle sequencing 
kit (Perkin-Elmer, USA). A 10|il reaction mixture was prepared containing DNA 
(50ng), BigDye ready reaction mixture (4pl), primer (3.2pm) and water. The 
following thermocycling program was used:
Denaturation:
Annealing:
Extension:
96°C for 30 seconds 
50°C for 15 seconds 
60°C for 4 minutes
25 cycles
DNA was subsequently precipitated (see section 2.2.17) and analysed on an ABI 
PRIZM 377 DNA sequencer (Applied Biosystems, USA).
2.2.17 Precipitation of DNA
DNA for sequencing was precipitated via the addition of 10% (v/v) sodium acetate
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and 100% (v/v) ethanol (2.5 x total volume) and mixed by pipetting. The sample was 
centrifuged at 4°C for 20 minutes at 10000 x g. The supernatant was removed and 2 
washing steps were carried out in 70% (v/v) ethanol (750pl) and spun for 10 
minutes at 10000 x g between each wash. Supernatant was removed and the DNA 
was air dried.
2.2.18 Glycerol Stocks
In addition to purified plasmid DNA, plasmids were stored as glycerol stocks. 
Overnight cultures (500pl) were mixed well with an equal volume of 65% (v/v) 
glycerol and stored at -80°C in cryovials (Greiner, Gloucestershire, UK).
2.2.19 Genes Ordered Commercially
In addition to cloning mDR3 by RT-PCR, two of the mDR3 splice variants were also 
synthesized commercially by Genscript (USA). Full length mDR3 and soluble mDR3 
(lacking exon 6) were ordered flanked by Spel and BamHI enzyme sites. Both genes 
had been cloned into the vector pUC57 upon receipt.
2.2.20 Peptide Design
Peptides to mDR3 were designed with the aid of the online Peptide Select tool 
(Invitrogen) and assistance from Professor B. Paul Morgan (Medical Biochemistry 
and Immunology, Cardiff University). This is further described in chapter 4.
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2.2.21 Genotyping
Tail samples measuring approximately 2mm were lysed overnight at 56°C in lysis 
buffer. Genomic DNA was phenol-chloroform extracted in an equal volume of 
phenol:chloroform:isoamyl alcohol (Fisher), shaken for 10 minutes and centrifuged 
at 10000 x g for 10 minutes. An equal volume of ice cold isopropanol was added to 
the aqueous layer and inverted 20 times to clot the DNA. This was centrifuged at 
10000 x g for 10 minutes and the supernatant poured off. Ethanol (70%) (0.5ml) 
was added and left to stand for 30 minutes at room temperature prior to 
centrifugation. Ethanol was carefully removed and the DNA was air dried before 
being resuspended in lOmM Tris. Genomic DNA (2pl) was used in a PCR reaction 
containing Taq DNA polymerase (2.5 units) (Invitrogen), supplied buffer (4pl), MgCI2 
(1.2pl), Im M  dNTPs (5pl) (NEB) primer F8 (0.2pl), primer 4f (0.2pl), primer 2r (0.4pl) 
and water. The following thermocycling reaction was used:
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Denaturation: 94°C for 5 miuntes
Annealing:
Extension:
62.5#C for 30 seconds 
72#C for 40 seconds
1 cycle
Denaturation:
Annealing:
Extension:
94#C for 30 seconds 
62.5#C for 30 seconds 
72°C for 40 seconds
33 cycles
Denaturation:
Annealing:
Extension:
95°C for 30 seconds - 
62.5°C for 30 seconds 
72°C for 5 minutes
1 cycle
Primers F8 (5' tct cct gtc ate tea cct tgc 3'), 4F (5' aga agg aga aag tea gta gga ccg 3') 
and 2R (5' gaa agg atg aaa ctt gcc tgt tgg 3') were used for genotyping.
74
2.3 Cell Culture
2.3.1 Cell Lines
Chinese Hamster Ovary (CHO) cells, HEK-293 cells and NIH-3T3 cells (provided by 
Sian Llewellyn-Lacey, MRC Tissue Culture Technician, Cellular and Viral Immunology 
Resource, Cardiff), were grown in 175cm2 tissue culture flasks. X63.Ag8.653 mouse 
myeloma cells (provided by Sian Llewellyn-Lacey, MRC Tissue Culture Technician, 
Cardiff) were maintained in 75cm2 tissue culture flasks. All cells were cultured at 
37°C in 5% CO2 in humidified incubators. All tissue culture plasticware was provided 
by Corning, USA. CHO cells were maintained in Roswell Park Memorial Institute 
(RPMI) 1640 (Invitrogen) supplemented with L-glutamine (2 mM) (Invitrogen), 
penicillin (1 x 10s lU/ml) (Invitrogen) and 10% (v/v) FCS (Invitrogen). FCS-free RPMI 
was also used in the generation of soluble proteins. 293 cells and NIH-3T3 cells 
were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen) 
supplemented with penicillin (1 x 10s lU/ml) and 10% (v/v) FCS. Mouse myeloma 
cells were maintained in DMEM supplemented with L-glutamine (2mM) 
(Invitrogen), penicillin (1 x 10s lU/ml) (Invitrogen), 10% (v/v) FCS (Invitrogen), 
glucose (4.5g/L) (Sigma-Aldrich), sodium pyruvate (2mM) (Invitrogen), HEPES 
(lOmM) (Sigma-Aldrich) and sodium bicarbonate (1.5g/L) (Sigma-Aldrich). FCS-free 
DMEM and complete selective medium, supplemented as for myeloma cell 
maintainance, was also used in hybridoma generation. Selective medium 
additionally contained azaserine-hypoxanthine (1 vial) (Sigma-Aldrich) and BM- 
Condimed H I (10% v/v) (Roche). Upon reaching confluence, adherent cells were 
passaged and divided 1:10 by removing medium, washing the cells with PBS and
75
incubating the cells with 8ml of Trypsin/EDTA (Invitrogen) until the cells were no 
longer adherent. Suspension cells were divided 1:5.
2.3.2 Cell Counting
lOOpI of cell suspension was diluted 1:1 with Trypan Blue (Sigma-Aldrich) and 
applied to a haemocytometer (Reichert, USA). Viable cells were identified under 
white light by the exclusion of blue dye and the total number of cells present was 
calculated using the following equation:
Total no. cells/ml = (No cells/no of squares counted) x 2 x (1 x 104)
2.3.3 Cryopreservation of Cells
Cells were washed in PBS prior to the addition of Trypsin/EDTA to put the cells into 
suspension. Cells were centrifuged at 4°C for 5 minutes at 300 x g and the 
Trypsin/EDTA poured off. Cells were then re-suspended in 1ml of freezing media for 
each confluent 25cm2 tissue culture flask. Each 1ml aliquot of cells was transferred 
to a cryovial (Greiner) and placed in a Nalgene 5100 Cryo 1°C freezing container 
(Merck, West Drayton) containing isopropanol at room temperature. This was then 
placed in a -70°C freezer overnight before the cryovials were stored in liquid 
nitrogen. Cells were recovered from liquid nitrogen by rapidly thawing in a 37°C 
H2O bath. Cells were then transferred to a 15ml falcon tube (Greiner) and 10ml of 
37°C media was added. The cells were centrifuged at 300 x g for 5 minutes and 
resuspended in media for counting prior to seeding in an appropriate tissue culture 
flask at the required density.
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2.3.4 Transfection Methods
Two methods were used for the transfection of plasmid DNA constructs into 
mammalian cell lines: calcium phosphate transfection using the Calcium Phosphate 
Transfection Kit (Invitrogen) and a non-liposomal lipid method using Effectene 
Transfection Reagent (Qiagen). For both methods, cells were seeded at a density of 
0.5 x 106 cells per 25cm2 tissue culture flask on day 0. Fresh media was placed onto 
the cells 3 hours prior to transfection on day 1. The calcium phosphate transfection 
method is based on the formation of a calcium phosphate - DNA precipitate, which 
binds DNA to the ceil surface and enters the cells by endocytosis. Plasmid DNA 
(lOpg) was mixed with calcium chloride (18pl) and made up to 150pl with distilled 
water. This mixture was added dropwise to Hepes buffered saline (150pl) whilst 
vortexing and incubated at room temperature for 30 minutes in order for a 
precipitate to form. The precipitate was added dropwise to the media of the cells. 
16 hours post transfection, the media was removed from the cells and they were 
washed twice in PBS. Glycerol (5ml of 15% (v/v)) was added to the cells for precisely 
2 minutes before 2 further washes in PBS. Normal media was returned to the cells. 
48 hours post - transfection, cells were split 1:3 and placed in selective media. The 
Effectene method is based upon the condensation of DNA by interaction with the 
manufacturer's supplied enhancer which then complexes with Effectene and can be 
taken up by the cells. Plasmid DNA (2pg) was added to the manufacturer's supplied 
buffer (298pl) and mixed with the enhancer (16pl) before vortexing and incubating 
for 5 minutes at room temperature. Effectene reagent (50pl) was added to the 
mixture and vortexed before incubation at room temperature for 10 minutes. 
Normal media (1ml) was added and the mixture placed dropwise onto the media of
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the cells. After 24 hours, the media was replaced with normal growth media and 
after 48 hours, cells were passaged 1:3 into selective media.
2.3.5 Cell Selection
Transfected cells were selected in media containing the appropriate drug for the 
resistance gene contained within the plasmid in order to generate stably selected 
cell lines. In order to determine the concentration of drug required, a "kill curve" 
was generated. Untransfected cells were seeded in a 24-well tissue culture plate at 
a concentration of 1 x 105 cells per well. After 24 hours, doubling dilutions of either 
G418 (Autogen Bioclear, Wiltshire, UK) or Hygromycin (Autogen Bioclear) were 
added to the wells. Cells were observed for 14 days and the extent of cell killing was 
measured. It was determined that 300pg/ml G418 be used on transfected CHO cells 
and 200pg/ml hygromycin be used on transfected NIH-3T3 cells and 293 cells.
2.3.6 Isolation of GFP expressing cells
Transfected cells expressing GFP were isolated from bulk cultures as follows. 
Adherent cells in 25cm2 tissue culture flasks were washed in PBS and then put into 
solution via the addition of 2ml Trypsin/EDTA. Cells were filtered with a 40pm cell 
strainer and re-suspended at a final concentration of 1 x 106 cells per ml in the 
appropriate culture media. Cells were sorted using a MoFlo cell sorter (Beckman 
Coulter) into a 15ml falcon containing culture media.
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2.3.7 Hybridoma Generation
The day prior to spleen and myeloma cell fusion, all vessels and media were pre­
warmed to 37°C and lOOpI of complete selective medium was dispensed into each 
well of 12 x 96-well plates and allowed to equilibrate overnight at 37°C. Mouse 
myeloma cells (X63.Ag8.653) were cultured for 2 weeks prior to fusion and 1 x 107 
cells were used for each mouse spleen fusion. Myeloma cells were centrifuged at 
300 x g for 5 minutes and resuspended in 10ml of serum-free media. Spleen cells 
were released from the intact spleen into 5ml DMEM by gently teasing it apart with 
two needles in a Petri dish and transferring the cells to a 15ml falcon tube. A further 
5m! DMEM was used to rinse the Petri dish and this was added to the falcon tube. 
Both spleen cells and myeloma cells were then centrifuged at 300 x g for 5 minutes 
and resuspended in 5ml of serum-free DMEM. Both cell preparations were then 
mixed with each other and centrifuged for 10 minutes at 300 x g to give a pellet 
containing both cell types. 300pl of Hybri-max PEG (Sigma-Aldrich) was added to 
the pellet which was gently resuspended by flicking the tube. Cells were left in the 
PEG for at least 3 minutes but no more than 8 minutes so following a 3 minute 
incubation, cells were centrifuged for 5 minutes at 300 x g and the PEG was 
removed using a Pasteur pipette. Ceils were resuspended in complete selective 
media (5ml) and then added to 95ml of selective media in a pre-warmed glass 
bottle. Cells were left to stand at 37°C for 30 minutes prior to adding lOOpI of cells 
to each well of the previously prepared 96 well plates and culturing at 37°C in 5% 
C02 One control well per plate contained myeloma cells only. Cells were cultured 
for approximately 8-10 days changing the media regularly until clones were easily 
visible. Screening of wells via ELISA was then undertaken as described in 2.4.3.
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Positive clones were transferred to 24 well plates and re-screened. Any positive 
clones were then grown in 25cm2 flasks for further analysis and freezing.
2.4 Immunodetection Methods
2.4.1 SDS-Page and Western Blotting
2.4.1.1 Production of Cell Lysate
Confluent cells in 25cm2 tissue culture flasks were removed from the incubator and 
washed twice in ice cold PBS. A further 5ml of ice cold PBS was added to the flasks 
and cells were scraped off using a cell scraper (Greiner). Suspensions of cells were 
then transferred to 15ml falcons and centrifuged at 4°C for 5 minutes at 300 x g. 
PBS was poured off and 200pl RIPA buffer containing 5pl 2-mercaptoethanol was 
added. Cells were lysed on ice for 10 minutes and lOOpI NuPage (Invitrogen) buffer 
was added and mixed by pipetting. Samples were transferred to 0.5ml eppendorfs 
and heated to 99°C for 10 minutes. Samples were used immediately or stored at 
-20°C.
2.4.1.2 SDS - Polyacrylamide Gel Electrophoresis (PAGE)
Proteins were resolved by SDS-PAGE in NuPAGE MOPS SDS running buffer 
(Invitrogen) using the NuPAGE Novex 4-12% Bis-Tris pre-cast gel system 
(Invitrogen). Each sample (15pl) was loaded into the wells of a gel alongside a 
SeeBlue Plus2 pre-stained protein marker (lOpI) (Invitrogen) and resolved at a 
constant voltage of 200V for 1 hour.
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2.4.1.3 Western Blotting
Proteins were transferred to a PVDF membrane (Invitrogen) in Towbin buffer using 
the XCell II Blot Module (Invitrogen) at a constant voltage of 30 volts for 1 hour. The 
transfer membrane was pre-soaked in methanol and the filter paper and blotting 
pads in transfer buffer prior to transfer. The gel, membrane and blotting pads were 
placed into the XCell II Blot Module according to the manufacturer's instructions, 
which was then filled with transfer buffer. The module was then surrounded with 
distilled water in order to keep it cool during transfer. Immediately after transfer, 
the pre-stained protein marker was marked with an antigen-antibody pen for 
mouse (Alpha Diagnostics International, USA) in order to visualize the bands. The 
membrane was then blocked in PBS-T containing 5% Marvel milk powder (w/v) 
overnight at 4°C. Membranes were incubated in primary antibody diluted 1/1000 in 
PBS-T 5% milk for 1 hour at room temperature and then washed in 3 changes of 
PBS-T 5% milk powder for an hour. The appropriate horse-radish peroxidase 
conjugated secondary antibody was then added to the membrane diluted to the 
required concentration in PBS-T 5% milk for 1 hour at room temperature. A further 
1 hour wash as described above was then carried out. Proteins were visualized via 
the addition of ECL Western Blotting Substrate (Perbio Pierce, Belgium) according 
to the manufacturer's instructions.
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Table 2.4: Antibodies used in Western Blotting
Antibody Supplier Raised in Dilution
IgGl Fc Chemicon Mouse 1/1000
GFP Santa Cruz Rabbit 1/2000
Actin Sigma Rabbit 1/5000
DR3 RandD Goat 1/500
Streptag II IBA Mouse 1/1000
Antibody Supplier Dilution
Anti-mouse HRP Biorad 1/1000
Anti-rabbit HRP Biorad 1/5000
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2.4.2 Fluorescence Microscopy
Cells which had been seeded onto glass coverslips were washed twice in PBS and 
then fixed in paraformaldehyde (2%) for 20 minutes at room temperature. 
Following washing in PBS, cells were permeabilised in Triton X-100 (0.1%) and then 
incubated with anti-streptag II (1/100) (IBA) primary antibody for 1 hour at 37°C in a 
humidifying chamber. Cells were washed 6 times in PBS and then incubated with 
anti-mouse Alexafluor 594 (1/1000) (Invitrogen) secondary antibody (1/1000) at 
37°C as previously described. Cells were again washed 6 times in PBS and finally 
mounted under the coverslip in 2% (w/v) DABCO. All slides were visualised using a 
Leica DM IRBE microscope (Leica, Germany) attached to a Hamamatsu ORCA-ER 
camera (Hamamatsu, Japan) and Improvision Openlab 3 software (Improvision, 
Coventry).
2.4.3 ELISA
2.4.3.1 Hybridoma Screening
Peptide antigens (lOpg/ml) were coated onto Nunc-lmmuno Maxisorp 96 well 
plates and incubated overnight at 4°C. Blocking media (5mg/ml BSA in PBS) (lOOpI) 
was then added to each well and incubated a room temperature for 1 hour. Plates 
were washed 3 times in PBS-Tween 20 (0.1%) and left inverted to dry for 30 
minutes. Either 50pl of hybridoma supernatant or lOOpI of mouse serum was added 
to the appropriate wells. Mouse serum from immunised animals or a non­
immunised control was diluted in 5mg/ml BSA in PBS-Tween 20 and added to the 
wells at doubling dilutions in duplicate. A row of wells containing no serum was also 
left as a blank control. Serum and supernatant were incubated at room
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temperature for 1 hour and then plates were again washed as described. Secondary 
HRP conjugated anti-mouse antibody (Biorad) was diluted in 5mg/ml BSA in PBS- 
Tween 20 (1/1000) and added to each well (lOOpI). This was incubated at room 
temperature for 1 hour before a final wash as described. ABTS substrate (Sigma) 
(lOOpI) was added to each well and allowed to develop for 10 minutes at room 
temperature before the reaction was stopped via the addition of 1% (w/v) SDS. 
Plates were read in a plate reader at 405nm.
2.4.B.2 Anti-mBSA litre  Analysis
Methylated BSA was coated onto Nunc-lmmuno Maxisorp 96 well plates and 
incubated overnight at 4°C. Blocking media (PBS-5% milk) (lOOpI) was then added 
to each well and incubated at room temperature for 1 hour. Plates were washed 3 
times in PBS-Tween 20 (0.1%) and left inverted to dry for 30 minutes. 50pl of mouse 
serum from immunised or non-immunised control mice was added to the 
appropriate wells at doubling dilutions in duplicate. Mouse serum was diluted in 
blocking media. A row of wells containing no serum was also left as a blank control. 
Serum was incubated at room temperature for 1 hour and then plates were again 
washed as described. Secondary HRP conjugated anti-mouse antibody (Biorad) was 
diluted in blocking media (1/1000) and added to each well (lOOpI). This was 
incubated at room temperature for 1 hour before a final wash as described. ABTS 
substrate (Sigma) (lOOpI) was added to each well and allowed to develop for 10 
minutes at room temperature before the reaction was stopped via the addition of 
1% (w/v) SDS. Plates were read in a plate reader at 405nm.
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2.5 Animals
2.5.1 Housing and Home Office Approval
Animals were housed in the Joint Biological Services Unit (Cardiff University) at 
constant temperature and humidity on a 12 hour light/dark cycle. All animals were 
kept in filter top containers until they were entered into the antigen-induced 
arthritis study when they were transferred to conventional housing. Food and 
water was available to the animals ad libitum. DR3/_ animals were bred in house on 
a C57/BL6J background. All experimental procedures were consistent with Home 
Office approved license 30/1999.
2.5.2 Peptide Immunisation Protocol
Peptides were dissolved in water and emulsified in either complete Freund's 
adjuvant (CFA) (Sigma-Aldrich) or incomplete Freund's adjuvant (IFA) (Sigma- 
Aldrich) to a final concentration of lmg/ml. DR37' mice were immunised initially 
with peptide in CFA and subsequently with peptide in IFA no less than 2 weeks 
between each immunisation. Injections were administered subcutaneously at 2 
distinct sites per immunisation in 50pl volumes. Immunisations continued until 
positive screening results were observed and mice were selected for hybridoma 
generation. Mice were culled via schedule 1 three days after a booster 
immunisation was administered and spleens were removed and placed into DMEM 
media. A serum sample was also taken via cardiac puncture.
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2.5.3 Tail Bleeds for Analysis of Antibody Production
Mice were test bled by venesection after the 3rd peptide immunisation and again 4 
weeks later to assess antibody titres. No more than 10% of total blood volume was 
taken at any one time.
2.5.4 Murine Antigen-Induced Arthritis
Mice were immunised on 2 occasions, 1 week apart, with methylated bovine serum 
albumin (mBSA) (lmg/ml) (Sigma-Aldrich) dissolved in distilled water and 
emulsified with CFA. Injections were given subcutaneously in two 50pl volumes. An 
intra-peritoneal injection of heat killed bordetella pertussis toxin (40pg/ml) (Sigma- 
Aldrich) was given as an additional adjuvant with the first mBSA injection. This was 
administered as a single lOOpI injection. Fourteen days after the second mBSA 
immunisation (day 0), following baseline measurements of knee joint diameters, 
mice received a 6pl intra-articular injection of mBSA in distilled water (lOmgs/ml) 
into the hind right knee joint. Knee joint diameters were then measured on days, 1, 
2, 3, 5, 7,14 and 21 as the difference between right knee joint and control left knee 
joint, using a POCO 2T analogue micrometer (Kroeplin, Germany). Mice were 
sacrificed on days 3 or 21 and joints were retained for analysis. A serum sample was 
also taken via cardiac puncture. In experiments conducted in order to assess the 
effect of TL1A on the model, increasing concentrations of TL1A protein (lng, lOng, 
lOOng) (R and D Systems) diluted in PBS-BSA (0.1%) were also administered into the 
joint in the intra-articular mBSA injection on day 0.
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2.6 Histological Techniques
2.6.1 Joint Harvest and Processing
2.6.1.1 Joint Harvest
Murine knee joints were harvested, placed into tissue biopsy cassettes (Thermo 
Electron) and immediately fixed in neutral buffered formal saline (Sigma-Aldrich) at 
4°C for 1 week. Joints were then decalcified for 2 weeks via one of two methods: 
formic acid decalcification or EDTA decalcification using appropriate decalcification 
solutions. Both methods were carried out at 4°C.
2.6.1.2 Determination of Endpoint of Decalcification
A sample of decalcifying solution was neutralized with concentrated sodium 
hydroxide. An equal volume of saturated ammonium oxalate solution (Fisher) was 
then added and allowed to stand for 30 minutes. The formation of a white 
precipitate indicated the presence of calcium ions in the solution as calcium oxalate 
is formed. Decalcification was continued until no precipitate was seen.
2.6.1.3 Shandon Tissue Processor Cycle
Joint tissues were infiltrated with paraffin wax via the following processing cycle: 70 
% alcohol (30 minutes), 90% alcohol (1 hour), 5 x 100% alcohol (1 hour each), 2 x 
xylene (1 hour each at 37°C), xylene (1 hour at 45°C), 4 x wax (1 hour each at 60°C). 
Following processing, joints were embedded in paraffin wax blocks using a Shandon 
Histocentre.
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2.6.2 Paraffin Wax Sections
Mouse knee joints were harvested and processed. Serial sections (7pm) were cut 
on a microtome and floated onto distilled water (50°C) prior to collection on pre­
cleaned X-tra adhesive microslides (Surgipath, USA). Slides were incubated 
overnight at 60°C and then stored at room temperature until required.
2.6.3 Haematoxylin and Eosin (H+E) Staining
Paraffin wax sections on glass slides were deparaffinised through 3 rinses in xylene 
(5 minutes) followed by 3 minutes in each descending grade of methanol (2 x 100%, 
1 x 90% and 1 x 70%). Sections were then rinsed in running water for 5 minutes and 
dipped into distilled water prior to immersing in Harris's Haematoxylin solution 
(BDH, Poole, UK) for 1 minute and 30 seconds. Sections were again washed in 
running water and dipped in distilled water as described above before placing in 
Scott's tap water (30 seconds) to blue. After another wash step in water, sections 
were immersed in Eosin solution for 1 minute and washed quickly in running tap 
water. Sections were dehydrated through an ascending series of methanol as 
described above but omitting the first 70% wash and including a third 100% wash, 
and immersed in 3 changes of xylene. Slides were mounted in Ralmounts (BDH, UK) 
or DPX (Sigma-Aldrich) mounting media and left to set overnight at 60°C.
2.6.4 Histological Analysis
Following haematoxylin and eosin staining, two blinded independent observers 
scored sections for the arthritis index. The arthritis index is a sum of 4 parameters 
which reflect the degree of arthritis severity in the joint. These are cellular exudate,
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synovial hyperplasia and bone erosion, all scored from 0 (normal) to 3 (severe) and 
cellular infiltrate scored from 0 to 5. As histological sections were scored relative to 
the other sections in each experimental group, this data could not be normally 
distributed.
2.6.5 Tartrate Resistant Acid Phosphatase (TRAP) Staining
EDTA decalcified sections were deparaffinised as described in section 2.6.3 and 
washed in running water for 5 minutes. Sections were then incubated in pre­
warmed TRAP staining solution at 37#C for 3 hours. Sections were washed in 
running water for 5 minutes, counterstained in Haematoxylin and "blued" in Scott's 
Tap water as described in section 2.6.3. After washing in running tap water for 5 
minutes and dipping in distilled water, sections were air dried and mounted in 
Ralmounts or DPX medium and set overnight at 60°C. Images were captured using 
an Olympus N457 digital camera. Randomly selected areas were assessed for TRAP 
positive staining using Adobe Photoshop CS3.
2.6.6 Safranin O/Fast Green Staining for Cartilage Depletion
EDTA decalcified sections were deparaffinised as described in section 2.6.3 and 
washed in running water for 5 minutes before a brief immersion in distilled water. 
Sections were then stained in Harris's Haematoxylin solution (2 minutes) and again 
washed in running tap water before placing in Scott's tap water (30 seconds) to 
blue. After washing in distilled water (2 minutes), sections were placed into Fast 
Green staining solution (0.2mg/ml) for 10 minutes, acetic acid (1%) for 10 seconds, 
and finally into Safranin-0 staining solution (lmg/ml) for 5 minutes. Sections were
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washed in distilled water for 2 minutes and dehydrated in 90% methanol, 100% 
methanol and xyiene for 1 minute each. Sections were mounted using DPX 
mounting media. Cartilage depletion was measured as a percentage of total 
cartilage (safranin O positive) under x40 magnification using an eye piece with a 
line-graduated scale.
2.6.7 F4/80 Staining
F4/80 is used as a marker for macrophages. Staining of processed and paraffin wax 
embedded joint sections was carried out using anti-mouse F4/80 (Invitrogen) and 
an anti-rat HRP-DAB cell and tissue staining kit (R&D Systems). Sections were 
deparaffinised as described in section 2.6.3 and rinsed in running tap water for 5 
minutes. Sections were then placed into TBS solution for 30 minutes before being 
encircled with a hydrophobic barrier from a Pap pen (Sigma-Aldrich). A peroxidase 
blocking step using reagents supplied in the kit was carried out as described in the 
manufacturer's instructions. Antigen unmasking was achieved by incubating the 
sections in pre-warmed Trypsin/EDTA (0.1%) in TBS for 30 minutes at 37°C. Sections 
were washed twice in TBS for 5 minutes and then serum, avidin and biotin blocking 
steps were carried out as described in the manufacturer's instructions. Following 
rinsing in TBS, either anti-mouse F4/80 antibody (1/50) or isotype control (1/400) 
were added to the sections and incubated at 4°C overnight. Sections were washed 
in TBS 3 times for 15 minutes each and the biotinylated secondary antibody was 
then applied and incubated at room temperature for 1 hour. Sections were again 
washed 3 times for 15 minutes each in TBS and HSS-HRP from the kit was then 
applied for 30 minutes at room temperature. DAB chromogen and DAB chromogen
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buffer were mixed as described in the manufacturer's instructions and 3 drops were 
applied to each section and incubated for 20 minutes before washing in distilled 
water. Sections were counterstained in Haematoxylin and "blued" in Scott's Tap 
water before dehydrating in an ascending series of alcohol and xylene and 
mounting in Ralmounts or DPX medium as described in section 2.6.3. Images were 
captured using an Olympus N457 digital camera. Randomly selected areas were 
assessed for F4/80 positive staining using Adobe Photoshop CS3.
2.7 Statistical Analysis
All results were graphically illustrated as the mean ± standard error of the mean 
(SEM) and were statistically analysed using GraphPad Prizm v4. p values of < 0.05 
were considered significant and those of £ 0.01 were considered highly significant. 
The statistical tests used in this study were the Mann-Whitney-U test, which was 
used when comparing the means of two unpaired groups of non-normally 
distributed data and the one-way and two-way ANOVAs were used when 
comparing more than 2 groups or variables respectively.
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3. Results -  Molecular Cloning of Murine and Human DR3 Genes
3.1 Introduction
Prior to the commencement of this work, there were no commercially available 
antibodies with which to study mDR3 function and only 1 polyclonal anti-human 
DR3 antibody. Therefore, a principle aim of this study was the generation of 
reagents for use in DR3 research. In order to facilitate this work, human DR3 and 
murine DR3 were both amplified via PCR reaction and cloned into suitable 
eukaryotic expression vectors. They were subsequently transfected into 
mammalian cells, which were then analysed for protein expression via Western blot 
and immunofluorescence.
3.2 PCR Amplification of hDR3
The strategy employed to generate the hDR3 gene is illustrated in Figure 3.1. 
Human DR3 was obtained via PCR amplification from a pcDNA3.1 construct 
containing the full length human gene. A dominant negative form of the gene, in 
which the death domain was absent was amplified using primer pairs described in 
section 2.2. The primers were engineered to insert 2 restriction enzyme sites into 
the PCR product which were Spel and BamHI in the forward and reverse positions 
respectively. A streptag sequence was also included in the reverse primer in order 
to facilitate protein detection. Due to the lack of antibodies against DR3, adding a 
tag sequence was the only method available for detecting protein. The resulting 
PCR product was 826 base pairs in size. The gene was subsequently Topo cloned 
into the pCR2.1 Topo vector and sequenced to confirm that it matched the 
published sequence (Figure 3.2).
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The hDR3 gene was PCR amplified 
from vector DNA and TOPO cloned 
into the pCR2.1 TOPO vector.
I
hDR3 was isolated from 
the TOPO vector by 
restriction digest using 
enzyme sites Spel and 
BamHI
§-( Signal plgplus 
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pDR2EF1 
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Soluble hDR3 with or without a streptag Dominant negative hDR3 with a streptag
was ligated into signal plgplus was ligated into pDR26EFla
Figure 3.1. Cloning strategy for hDR3 construct generation. Human DR3 was PCR
amplified from vector DNA in both dominant negative (no death domain) and 
soluble (no transmembrane domain) forms. The genes were TOPO-TA cloned into 
the pCR2.1 vector. The genes were then cut from this vector using Spel and BamHI 
restriction enzyme sites which were engineered in the primers. Genes were then 
ligated into pDR26EFla and Signal plgplus vectors.
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A soluble form of the gene in which the transmembrane domain was absent was 
also PCR amplified. Three versions of the soluble gene were generated either with a 
Streptag sequence included or not. The third version of the soluble gene contained 
a Streptag sequence in which a stop codon was included after the Streptag 
sequence (primer sequences described in section 2.2). The 3 resulting PCR products 
were 711 base pairs, 681 base pairs and 714 base pairs in size respectively. The 
soluble versions of the gene were Topo cloned into the pCR2.1 Topo vector and 
sequenced to confirm they matched the published sequence (Figure 3.2).
3.3 Subcloning HDR3 into Eukaryote Expression Vectors
In order to facilitate protein expression in an eukaryotic system, the PCR amplified 
hDR3 genes were subcloned into appropriate eukaryotic expression vectors. 
Dominant negative hDR3 was excised from the pCR2.1 Topo vector using Spel and 
BamHI restriction enzymes. The pDR26EFla vector was digested using Xbal and 
BamHI (Spel and Xbal produce compatible ends) restriction enzymes. The 
dominant negative hDR3 gene was then ligated into the pDR26EFla vector and re- 
sequenced to confirm that it still matched the published sequence (Figure 3.3).
Soluble hDR3 was excised from the pCR2.1 Topo vector using Spel and BamHI 
restriction enzymes and ligated into the Nhel and BamHI (Spel and Nhel produce 
compatible ends) enzyme sites in the Signal Pigplus vector. Soluble hDR3 was re­
sequenced to confirm that it matched the published sequence (Figure 3.3).
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Figure 3.3 Subcloning of hDR3 into eukaryotic expression vectors.
Agarose gel electrophoresis on 1% (v/v) TBE agarose gel. The 
successful cloning of dominant negative and soluble hDR3 into 
eukaryotic expression vectors is illustrated via restriction digest 
analysis. Upper bands show the vector and lower bands show the 
excised DR3 genes. Vectors analysed from 4 colonies for each gene 
insert. DN hDR3 was excised using BamHI/Xhol and sol hDR3 was 
excised using BamHI/Hindlll.
Due to the difficulties in detecting protein expression via Western blot and 
immunofluorescence, both soluble and dominant negative forms of the human DR3 
gene were also subcloned into the vector pEGFP-Nl. This vector contains a GFP 
sequence which enables the expression of GFP in an eukaryotic system and allows 
easy visualization of transfected cells using a fluorescence microscope. GFP is a 
large protein that may affect the folding or solubility of the protein of interest. 
However, it does enable confirmation of both a successful transfection protocol and 
a correctly inserted in frame sequence.
3.4 Removal of Hindlll site in the soluble hDR3 constructs
The Signal Pigplus vector contains an IgGl Fc sequence at the 3" end of the multiple 
cloning site which enables the generation of a fusion protein. Additionally the 
vector contains its own ATG translation start site in a CD33 signal peptide which 
enhances the secretion of soluble proteins. In order to generate a soluble protein 
with an IgGl Fc tail, the amplified hDR3 PCR products must be cloned "in frame" 
with both the CD33 signal peptide and the IgGl Fc tail. When the primers were 
originally designed, they were only engineered to generate a soluble hDR3 PCR 
product that would be "in frame" with the IgGl Fc tail and not with the CD33 signal 
peptide. In order to correct this over sight, 1 or 4 bases needed to be removed from 
the sequence. A Hindlll site was selected which was 5' of the hDR3 sequence and an 
unused enzyme site in the multiple cloning site. The Hindlll site was digested with 
Hindlll to generate a linear vector which was subsequently treated with Mung Bean 
nuclease which removes "sticky ends". The vector was then relegated via blunt end 
ligation and analysed for Hindlll site removal by enzymatic digest with Hindlll and
99
Notl. Those vectors in which Hindlll had successfully been removed produced a 
linearised vector and those in which the Hindlll site was retained produced an 
excised band of DNA which was 87bp in size. The successful removal of the Hindlll 
site from all soluble hDR3 Signal Pigplus vectors is illustrated in Figure 3.4.
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Figure 3.4 Removal of Hindlll sites from soluble hDR3 in signal plgplus 
vectors. Agarose gel electrophoresis on 1% (v/v) TBE agarose gel. In 
order to produce a DR3 gene sequence which was 'in frame' with the 
CD33 signal sequence in Signal plgplus, the Hindlll site in the vectors was 
digested and blunt ended via mung bean nuclease treatment prior to 
religation. Confirmation of removal of this enzyme site is illustrated via 
restriction digest analysis with Hindlll and Notl.
3.5 PCR amplification of mDR3
The strategies employed to generate dominant negative and soluble versions of the 
murine DR3 gene are shown in Figures 3.5 and 3.6 respectively. Prior to the 
commencement of this work, the mDR3 gene was not available to us in a vector 
construct. Therefore, it had to be amplified via RT-PCR from murine tissue. Thymus 
tissue from C57BL/6 mice was chosen for RT-PCR as it has confirmed expression of 
mDR3. Despite multiple attempts at RT-PCR using many primer combinations, we 
failed to clone mDR3. Upon employment of the "slow-down" PCR method (Section 
2.2.5.3) using primers described in Section 2.2, full length mDR3 was RT-PCR 
amplified and Topo cloned into the pCR2.1 Topo vector. However, upon sequence 
analysis, both exons 5 and 6 were found to be absent, corresponding to the 
sequence for mDR3 splice variant 3 (Wang et al., 2001a). Following 26 repeats of 
this PCR, full length mDR3 was finally isolated and was Topo cloned into pCR2.1. A 
second PCR was subsequently carried out to generate dominant negative mDR3 
using the full length mDR3 gene in the Topo vector as a template. Xhol and a 
BamHI restriction enzyme sites were engineered into the sequence. The resulting 
dominant negative mDR3 PCR product was 938bp in size and was Topo cloned into 
the pCR3.1 Topo vector (Figure 3.7). It was subsequently analysed to confirm that it 
matched the published sequence.
1 0 2
A naturally occurring soluble form of mDR3 exists as a splice variant of the full 
length receptor. This splice variant is termed variant 2 and is missing exon 6, which 
results in an early stop codon just upstream of the transmembrane domain. In 
order to investigate the role of this splice variant, the gene which encodes it was 
commercially manufactured by Genscript (USA) and used as a template to PCR 
amplify 3 versions of the gene either containing a c terminal streptag, an n terminal 
streptag or no streptag at all. Both n terminal and c terminal streptag constructs 
were generated in case one permitted greater protein detection than the other. All 
3 genes were also engineered to contain an Xhol and an Xbal restriction enzyme 
site. The 3 resulting PCR products were 654bp, 656bp and 633bp in size and were 
Topo cloned into the PCR3.1 Topo vector (Figure 3.7). They were subsequently 
analysed to confirm that they matched the published sequence.
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The dominant negative mDR3 
gene was amplified by RT-PCR 
from C57/BI6 mouse thymus 
tissue and Topo cloned into the 
pCR3.1Topo vector.
Dominant negative mDR3 was excised 
from the Topo vector using Xhol and 
BamHI restriction enzymes and 
subcloned into the corresponding 
enzyme sites of the pEGFP-Nl vector.
i
Pro,
Dominant negative 
mDR3 was ligated into 
pEGFP-Nl.
Figure 3.5. Cloning strategy for mDR3 dominant negative construct generation.
Dominant negative murine DR3 was RT-PCR amplified from thymus tissue. The gene 
was TOPO-TA cloned into the pCR3.1 vector. The gene was then cut from this vector 
using Xhol and BamHI restriction enzyme sites which were engineered in the 
primers and was then ligated into the Xhol and BamHI sites of pEGFP-Nl.
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■  Xhol
■  Soluble mDR3
■  Streptag
■  Xbal
Soluble mDR3 in which exon 6 is 
absent was PCR amplified from 
vector DNA and Topo cloned into the 
pCR3.1 Topo vector.
Soluble DR3 was excised from the 
Topo vector using Xhol and Xbal 
restriction enzymes.
Soluble mDR3 with or without 
a streptag was ligated into 
Signal plgplus in frame with the 
IgGl Fc tail.
Figure 3.6. Cloning strategy for soluble mDR3 construct generation. Soluble 
murine DR3 was PCR amplified from vector DNA which included the complete 
mDR3 gene minus exon 6. Three products were generated either with no streptag, 
a c terminus streptag or an n terminus streptag. The genes were TOPO-TA cloned 
into the pCR3.1 vector. They were then cut from this vector using Xhol and Xbal 
restriction enzyme sites which were engineered in the primers and were then 
ligated into the Xhol and Xbal sites of signal plgplus.
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Dominant Negative mDR3 Soluble mDR3
654bp
Figure 3.7. RT-PCR and PCR amplification of dominant negative and soluble murine DR3. Agarose gel electrophoresis on 1% (v/v) TBE 
agarose gel. The original amplification of mDR3 is illustrated, a) Dominant negative mDR3 shown at 938bp. b) Soluble mDR3 without 
(1) and with (2 and 3) streptag sequence included.
3.6 Subcloning mDR3 into Eukaryotic expression vectors
Dominant negative mDR3 was cloned into the pEGFP-Nl vector. It was excised from 
the Topo vector using Xhol and BamHI restriction enzymes and subcloned into the 
corresponding sites in the pEGFP-Nl vector in frame with the GFP sequence (Figure 
3.8). It was re-sequenced to confirm that it still matched the published sequence.
Soluble mDR3 was excised from the Topo vector using Xhol and Xbal enzyme sites. 
It was ligated into the corresponding sites in the Signal Pigplus vector and was 
engineered to be in frame with both the CD33 signal sequence and the human IgGl 
Fc tail (Figure 3.8). The constructs were re-sequenced to ensure that mDR3 still 
matched the published sequence.
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3.7 In vitro expression of human and murine DR3 constructs
The soluble and dominant negative hDR3 constructs were expressed in eukaryotic 
cell lines for the purpose of soluble protein production and antibody generation. 
Both NIH-3T3 cells (murine fibroblast cells) and CHO cells (Chinese hamster ovary 
cells) were used due to their ease of handling. Initially the Effectene method of 
transfection was used. However, when this resulted in a low transfection efficiency, 
the calcium phosphate method was used instead. Following this protocol, 
transfected cells grew well under selective media. A table indicating the hDR3 
constructs that were transfected into mammalian cells is shown in table 3.1. 
Dominant negative hDR3 in the pDR26EFla was transfected into NIH-3T3 cells and 
protein expression via immunofluorescence against the streptag was achieved 
(Figure 3.9). However, the streptag protein was never detected via Western blot 
analysis. The soluble hDR3 constructs that were originally created were out of 
frame with the CD33 signal peptide and therefore no expression was detected. 
Following repair of these constructs, protein expression was detected via 
immunofluorescence against the streptag protein (Figure 3.9). Diffuse cytoplasmic 
staining was evident. The empty vector control also displayed a low level of 
background staining. However, Western blot detection of this protein was never 
achieved. Expression of soluble hDR3 in the pEGFP-Nl vector was also achieved 
(Figure 3.10) with transfected cells fluorescing green. From the cell lysate of these 
cells, both GFP and streptag could be detected by Western blot analysis (Figure 
3.11). However, the soluble protein was never detected in the supernatant from 
the cells.
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Figure 3.8
a
pEGFP-Nl
Dominant negative mDR3
Signal plgplus
Soluble mDR3
Figure 3.8 Subcloning of mDR3 into eukaryotic expression vectors.
Agarose gel electrophoresis on 1% (v/v) TBE agarose gel. The successful 
cloning of (a) dominant negative and (b) soluble mDR3 (containing 
either no streptag, n terminal streptag or c terminal streptag) into 
eukaryotic expression vectors is illustrated via restriction digest analysis. 
Upper bands show vectors and lower bands show mDR3 gene inserts. 
DN mDR3 was excised using Xhol/BamHI and soluble mDR3 was 
excised using Xhol/Xbal.
633bp 654bp 656bp
A summary of the transfected murine DR3 constructs is shown in table 3.2. Soluble 
mDR3 with either an n terminal or a c terminal streptag transfected into CHO cells 
could not be detected via Western blot analysis. Dominant negative mDR3 in the 
pEGFP-Nl vector was detected via both green fluorescence (Figure 3.10) and 
Western blot analysis (Figure 3.11) when transfected into CHO cells. However, 
when transfected into NIH-3T3 cells, the green fluorescence was lost after 5 days 
and GFP was never detected via Western blot analysis.
1 1 2
Dominant negative hDR3 Soluble hDR3 + streptag
Soluble hDR3 + streptag + Fc Empty vector control
Figure 3.9. Detection of hDR3 constructs in 3T3 cells via anti-streptag immunofluorescence.
3T3 cells transfected with hDR3 constructs exhibited positive staining for anti-streptage 
immunofluorescence. However, a low level of background fluorescence was also seen in the 
empty vector control.
Sol hDR3 + streptag + GFP in pEGFP-Nl DN mDR3 + GFP in pEGFP-Nl
Figure 3.10. GFP expression from soluble HDR3 and dominant negative mDR3 pEGFP-Nl vector 
constructs in CHO cells. CHO cells were transfected with pEGFP-Nl containing either sol hDR3 or DN 
mDR3. Transfected cells fluoresced green.
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Figure 3.11. Western blot detection of human and murine DR3. Proteins were resolved by SDS-PAGE and 
subsequently transferred to a PVDF membrane. Soluble human DR3 containing a streptag in pEGFP-Nl(49KDa) 
was detected with antibodies against both streptag (a) and GFP (b). Dominant negative murine DR3 in pEGFP- 
Nl(61KDa) could only be detected with antibodies against GFP. All cell lysates were generated from 3T3 cells as 
described in section 2.4.1.1.
Construct Vector Transfection Method Cell type Method of detection of expression Expression
Soluble hDR3 Signal plgplus Effectene CHO Anti-streptag western blot No*
Soluble hDR3 + streptag Signal plgplus Effectene CHO Anti-streptag western blot No*
Soluble hDR3 + streptag (stop) Signal plgplus Effectene CHO Anti-streptag western blot 
Anti-streptag western
No*
Soluble hDR3 Signal plgplus Calcium phosphate CHO blot/immunofluorescence 
Anti-streptag western
No
Soluble hDR3 + streptag Signal plgplus Calcium phosphate CHO blot/immunofluorescence 
Anti-streptag western
No
Soluble hDR3 + streptag (stop) Signal plgplus Calcium phosphate CHO blot/immunofluorescence No
Soluble hDR3 Signal plgplus Calcium phosphate 3T3 Anti-streptag western blot No
Soluble hDR3 + streptag Signal plgplus Calcium phosphate 3T3 Anti-streptag western blot No
Soluble hDR3 + streptag (stop) Signal plgplus Calcium phosphate 3T3 Anti-streptag western blot No
Soluble hDR3 Signal plgplus Calcium phosphate 3T3 Anti-streptag immunofluorescence Yes
Soluble hDR3 + streptag Signal plgplus Calcium phosphate 3T3 Anti-streptag immunofluorescence Yes
Soluble hDR3 + streptag (stop) Signal plgplus Calcium phosphate 3T3 Anti-streptag immunofluorescence Yes
Soluble hDR3 Signal plgplus Calcium phosphate 3T3 Anti-hDR3 polyclonal western blot No
Soluble hDR3 + streptag Signal plgplus Calcium phosphate 3T3 Anti-hDR3 polyclonal western blot No
Soluble hDR3 + streptag (stop) Signal plgplus Calcium phosphate 3T3 Anti-hDR3 polyclonal western blot No
Dominant negative hDR3 +
streptag pDR26EF1a Calcium phosphate 3T3 Anti-streptag western blot No
Dominant negative hDR3 +
streptag pDR25EF1a Calcium phosphate 3T3 Anti-streptag immunofluorescence Yes
Soluble hDR3 + streptag pEGFP-N1 Calcium phosphate CHO Anti-streptag western blot Yes**
Soluble hDR3 + streptag pEGFP-N1 Calcium phosphate CHO Anti-GFP western blot Yes**
Soluble hDR3 + streptag pEGFP-Nl Calcium phosphate CHO GFP fluorescence Yes
Table 3.1. Summary of transfected hDR3 constructs. The table indicates the constructs which were transfected, the method of transfection 
and the cell type used. The method for detecting expression is shown and whether or not expression is achieved is indicated. *Sequence not in 
frame. **Expression only seen in cell lysate. No soluble protein in supernatant detected.
Construct Vector Transfection Method Cell type Method of detection of expression Expression
Soluble mDR3 + nt streptag Signal plgplus Effectene CHO Anti-streptag western blot No
Soluble mDR3 + ct streptag Signal plgplus Effectene CHO Anti-streptag western blot No
Dominant negative mDR3 pEGFP-N1 Effectene 3T3 Anti-GFP western blot No
Dominant negative mDR3 pEGFP-N1 Effectene 3T3 GFP fluorescence Yes*
Dominant negative mDR3 pEGFP-N1 Calcium phosphate CHO Anti-GFP western blot Yes
Dominant negative mDR3 pEGFP-N1 Calcium phosphate CHO GFP fluorescence Yes
Soluble mDR3 +CD33+Fc pDR26EF1a Calcium phosphate CHO Anti-lgG1 Fc western blot No
Table 3.2. Summary of transfected mDR3 constructs. The table indicates the constructs which were transfected, the method of transfection 
and the cell type used. The method for detecting expression is shown and whether or not expression is achieved is indicated. *Green 
fluorescence was lost after 5 days.
3.8. Subcloning of human and murine soluble DR3 from the Signal Pigplus vector 
into pDR26EFla
Due to the difficulties in detecting expression of both human and murine DR3 in cell 
lines, soluble versions of the gene containing no streptag were re-amplified from 
the already generated genes in the Signal Pigplus vector. PCR primers were 
engineered to amplify the entire region in the Signal Pigplus vector that contained 
the CD33 signal sequence, the DR3 gene and the IgGl Fc tail. A summary of this is 
shown in Figure 3.12. Restriction enzyme sites were also engineered in the primer 
sequences to enable ligation of the human and murine PCR products into 
Xbal/EcoRV and Spel/EcoRV of pDR26EFla respectively. The EFla promoter in the 
pDR26EFla vector is a very powerful promoter which coupled with the CD33 signal 
sequence from the Signal Pigplus vector should drive high expression of the soluble 
DR3 genes. Retaining the IgGl Fc tail also permits the detection and purification of 
the protein. The PCR products containing soluble human (1523bp) or murine 
(1517bp) DR3 with the CD33 signal sequence and IgGl Fc tail are shown in Figure 
3.13.
The soluble murine DR3 containing the CD33 signal peptide and Fc tail in 
pDR26EFla was transfected into CHO cells and analysed for expression of the IgGl 
Fc tail via Western blot analysis. Protein expression was not detected.
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PCR products containing the CD33 
signal sequence, human or murine 
soluble DR3 and the IgGl Fc tail were 
amplified from the already generated 
Signal pigplus constructs containing 
soluble DR3 and subsequently Topo 
cloned into the pCR3.1 Topo vector
i
PCR product was excised from the 
Topo vector using Spel/Xbal and 
EcoRV and subcloned into the Spel 
and EcoRV sites in the pDR26EFla 
vector.
pDR2EF1 
7917 bp
Figure 3.12. Cloning of soluble human and murine DR3 from Signal pigplus to 
pDR26EFla. Both human and murine soluble DR3 were re-amplified from the Signal 
pigplus constructs using primers designed to include the CD33 signal sequence and 
IgGl Fc tail in the PCR product. These were subsequently Topo cloned into the 
pCR3.1 vector and then subcloned into pDR26EFla in an attempt to increase 
soluble protein production.
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1523bp 1517bp
Figure 3.13. PCR amplification of soluble human and murine DR3 
from signal pigplus. Agarose gel electrophoresis on 1% (v/v) TBE 
agarose gel. Human and murine soluble DR3 were re-amplified 
from the signal pigplus vector including the CD33 signal sequence 
and the IgGl Fc tail.
\ i * J a 1
122
4. Results -  Generation of Antibodies
4.1 Introduction
At the commencement of this PhD there were no antibodies available against 
murine DR3 and there was only one polyclonal antibody available against human 
DR3. Therefore, in order to progress research in the DR3 field, the ultimate goal of 
DR3 reagent generation was the production of antibodies.
Initially, the strategy employed to generate antibodies involved the production of 
vector constructs containing human or murine DR3 genes in both soluble and 
dominant negative forms. These were used to transfect mammalian cells either to 
produce stable cell lines containing the dominant negative gene constructs or cells 
lines which produced soluble proteins. Using this strategy, animals could be 
immunised with either cell suspensions or soluble proteins in order to generate 
antibodies. However, as was highlighted in the previous chapter, difficulties were 
encountered in detecting successful transfections. As such, neither stable cell lines 
nor soluble proteins were generated.
A second strategy was employed to generate antibodies against murine DR3. 
Synthetic peptides based on the murine DR3 sequence were designed and ordered 
from an in-house supplier and used to immunise DR37' mice, in which normal 
antibody responses are unimpaired. Spleen cells from immunised mice were 
subsequently removed and fused with mouse myeloma cells in order to generate a 
continuous culture of antibody producing cells. This is based on the method of 
Kohler and Milstein (1975) who described the production of a sheep red blood cell
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antibody producing cell line via the fusion of immunised mouse spleen cells and 
mouse myeloma cells (Kohler and Milstein, 2005). This method is now commonly 
employed in the process of antibody generation.
The aims of this chapter were:
1. To design immunoreactive peptides based on various regions of the murine 
DR3 protein sequence.
2. To immunise DR3'/_ mice with the peptides in order to generate an 
antibody response within those mice.
3. To generate continuous antibody secreting cell lines via the fusion of 
spleen cells from immunised mice and a mouse myeloma cell line.
4.2 Peptide Design
Peptide sequences which were predicted to be antigenic were selected with the 
assistance of the online Peptide Select Tool (http://peptideselect.invitrogen.com) 
(Invitrogen), which aids in identification of peptides with high solubility and 
antigenicity and those which are likely to produce antibodies capable of recognising 
native protein. Due to time and cost restraints only peptides for mDR3 were 
generated, as antibodies against murine DR3 are more valuable to our current 
research than those against human DR3 as human DR3 reagents are now more 
widely available. Four peptide sequences were identified. Peptide 1 
(casesqkrygpfccrgcpkghy) was located at amino acid position 40 -  61 in cysteine- 
rich domain 1. Using a structural analysis model, this region has previously been
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predicted to be located on an exposed face of the native receptor (Newman et al., 
2000) and thus represented a good sequence for generating antibodies capable of 
recognising native protein. Peptide 2 (gattpvheaptprpc) is located at position 147 -  
167 in cysteine-rich domain 3. Cystein-rich domain 3 is the region which differs 
most significantly from the same region of other TNFRSF members including TNFR1 
and FAS (Wang et al., 2001a) and is thus most likely to generate antibodies which 
are only specific for mDR3. Peptide 3 (Ipgfyirgndc) is located at position 162 -  172 in 
cysteine-rich domain 4. This domain is absent from mDR3 splice variant 3 (Newman 
et al., 2000) and thus should generate antibodies which only recognise the 
remaining 2 splice variants. Peptide 4 (qpaglgalyaalermgleg) is located at position 
380 -  398 in the death domain and thus should generate antibodies capable of 
detecting the full length receptor and variant 3 but not the soluble receptor. 
Peptides were generated by an in-house facility (Central Biotechnology Services, 
Cardiff University). The original synthesis of peptide 3 was not successful and 
therefore it was not used for immunisations. The selected peptide sequences are 
depicted in Figure 4.1. The peptides were generated on a poly-lysine core in order 
to avoid the use of a carrier protein and yet due to the high molecular weight of 
these molecules, still obtain a peptide with strong antigenic properties.
4.3 Immunisation of DR3_/' mice
DR37' mice were used for immunisation as they are devoid of DR3 and should 
generate immune responses against the peptides which shouldn't be recognised as 
self. DR3_/' mice received 2 initial sub-cutaneous injections containing a total of 
lOOpg peptide emulsified in complete Freund's adjuvant. For each peptide, 2
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separate mice were immunised. Mice received 2 booster immunisations of lOOpg 
peptide emulsified in incomplete Freund's adjuvant and were subsequently tested 
for antibody production via tail bleed and an enzyme-linked immunosorbent assay 
(ELISA) analysis was performed to detect the presence of antibodies. Figure 4.2 
illustrates the results of the first ELISA screen using blood plasma obtained from the 
tail bleed.
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Figure 4.2. Tail Bleed Screening 1.
Results of the first plasma screening are shown. Peptide antigens were coated onto 
ELISA plates at a concentration of 10 pig/ml and were used to screen serially diluted 
tail bleed plasma samples from the immunised mice. Plasma from each mouse was 
screened against both the immunising peptide and the other 2 non-immunising 
peptides. Plasma from mice 1 and 2 generated similar reactions against all 3 
peptides. Plasma from mice 3 and 4 appeared to react specifically with the 
immunising peptide. Plasma from mice 5 and 6 did not react with any of the 
peptides.
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The original peptides were coated onto ELISA plates and then serially diluted 
plasma samples were incubated with the peptides in order to assess if any 
antibodies that reacted with the peptides were present. All plasma samples were 
screened against all peptides to give an indication as to whether any positive results 
were specific for the immunising antigen or a non-specific response. Mice 1 and 2, 
which were immunised with peptide 1, produced a comparable O.D.405nm against 
all 3 peptides and did not appear to be specifically generating antibodies against 
peptide 1. Mice 3 and 4, which were immunised with peptide 2, generated a higher 
O.D.405nm against peptide 2 than they did against peptides 1 and 4 and thus 
appeared to be producing peptide specific antibodies. Mice 5 and 6, which were 
immunised with peptide 4, did not appear to be producing any DR3 antibodies. 
Consistently low O.D.405nm values when screened against all peptides were 
observed. All mice were given two further booster immunisations over a 4 week 
period and were reassessed for antibody generation. The results of the second 
ELISA screen are shown in Figure 4.3. Mice 1 and 2 continued to fail to produce 
specific antibodies against peptide 1. Mice 5 and 6 similarly failed to produce 
antibodies against peptide 4. Mice 3 and 4 however appeared to be generating 
antibodies specific for peptide 2 and received 1 single final booster injection prior 
to sacrifice and spleen removal.
4.4 Hybridoma Production
Spleen cells obtained from mouse number 3 were fused with murine myeloma cells 
and cultured in selective media. Once visible clones had appeared in the wells, 
supernatant was removed and analysed for the presence of antibody. The
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supernatants were screened against the immunising peptide (peptide 2) and also 
against a peptide which the mouse was not immunised with (peptide 1) to help 
determine specificity. Of the 720 wells in which the hybridomas cells were cultured, 
visible clones appeared in only 54.
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Figure 4.3. Tail Bleed Screening 2.
Results of the second plasma screening are shown. Peptide antigens were coated 
onto ELISA plates at a concentration of 10 pg/ml and were used to screen serially 
diluted tail bleed plasma samples from the immunised mice. Plasma from each 
mouse was screened against both the immunising peptide and the other 2 non­
immunising peptides. Plasma from mice 1, 5 and 6 failed to react with any of the
peptides. Plasma from mice 3 and 4 continued to react specifically with the
immunising peptide. Plasma from mouse 2 did not react specifically with the
immunising peptide.
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Supernatants from all 54 clones were screened via ELISA against the immunising 
peptide (Figure 4.4). Of these, only 6 clones gave a positive result. These clones 
were cultured up into larger flasks and subsequently re-screened against the 
immunising (peptide 2) and non-immunising (peptide 1) peptides (Figure 4.5). All 6 
clones displayed a non-specific affinity for the non-immunising peptide. 
Additionally, the O.D.405nm values were lower than had been seen before growing 
the clones up into larger cultures implying the presence of an over-growing non­
antibody producing cell within the cultures. All clones apart from number 13 were 
discarded. As clone number 13 displayed the greatest specificity for the immunising 
peptide, it was maintained in culture for further analysis. However, these cells 
subsequently died.
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Figure 4.4. Hybridoma Screen via ELISA. Supernatants from the hybridoma 
clones were screened against the immunising peptide (peptide 2). Samples in 
red were considered positive. Serum obtained from the immunised mouse 
was used as a positive control. Media from non-hybridoma cells was used as 
a negative control.
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1) peptides. Supernatants from all clones were reactive against both peptides.
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5. Characterisation of the susceptibility of DR3_/' mice to antigen-induced arthritis
5.1 Introduction
Rheumatoid Arthritis is a complex disease which, despite recent advances, is still 
poorly understood. Much focus and attention in the development of therapies for 
the treatment of RA has concentrated on blocking the TNFa/TNFRl pathway. TNFa, 
via its interaction with TNFR1, is widely accepted as a central mediator in the 
pathogenesis of RA. Drugs such as Etanercept, a TNFR2-lgG Fc fusion protein that 
binds soluble and cell bound TNFa, and Infliximab, an anti-TNFa monoclonal 
antibody, are classed as disease modifying antirheumatic drugs (DMARDs) and are 
currently available for treatment of patients with RA (Jobanputra et al., 2002). In 
the most successful clinical trials, only 79% and 75% of patients achieved an ACR20 
response with Infliximab and Etanercept respectively. Additionally, adverse 
reactions such as infections were also observed (Jobanputra et al., 2002). These 
studies indicate a need to develop novel therapies for Rheumatoid Arthritis which 
have a higher rate of success and lower incidence of infection.
The development of the aforementioned drugs was in large part permitted via the 
employment of in vivo models, which have been one of the most useful tools in 
enhancing our understanding of the disease. In 1992, a number of groups employed 
the CIA model for Rheumatoid Arthritis in order to support the rationale for anti- 
TNF therapy in treatm ent of the disease and to support already known in vitro data. 
In a study by Williams et al. (1992), the CIA model was induced in male DBA/1 mice 
to assess the effect of administering neutralizing antibodies against TNFa/p both 
before and after the onset of clinical disease. When treated weekly for four weeks
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prior to the development of disease, mice displayed significantly reduced paw 
swelling and only 19% of joints were considered to have severe histopathological 
features compared with 71% of joints from control mice. Severely affected joints 
were defined as having extensive synovial hyperplasia and bone erosions with 
disruption of the overall joint architecture. Similarly, when mice were treated with 
the anti-TNF antibody after arthritic disease was established, a significant reduction 
in paw swelling was again observed, as well as a significant reduction in severely 
affected joints. There were, however, significantly more mildly affected joints in the 
treatment group, displaying minimal evidence of synovial hyperplasia and cartilage 
and bone loss (Williams et al., 1992). This study in an animal model therefore 
highlighted the potential use of anti-TNF agents not only in reducing the symptoms 
of swelling but also in preserving overall joint architecture and preventing bone 
destruction. The same group again used the CIA model in 1994 to illustrate a 
synergy between TNFa and CD4+ T cells in the progression of disease. It was found 
that both paw swelling and erosions of the joint were significantly reduced when 
mice were treated after the onset of disease with a combination of an anti-TNFa/p 
antibody and an anti-CD4 antibody when compared to either of these agents 
administered alone. Joint erosions were evident in 70-80% of joints analysed from 
mice receiving sub-optimal anti-TNF alone or anti-CD4 alone compared to only 22% 
of joints from mice receiving a combination of sub-optimal anti-TNF and anti-CD4 
(Williams et al., 1994). This provided further important insight into the mechanisms 
of joint destruction during CIA and the possibility that this debilitating consequence 
of the disease might be treatable. The antigen-induced arthritis model has also 
been used to illustrate the role of TNF in Rheumatoid Arthritis. Lewthwaite et al.
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(1995) employed the rabbit AIA model to induce arthritis via the use of the antigen 
ovalbumin. Over the 21 day timecourse, TNFa was detected in the joint fluid on day 
1 post-arthritis induction and was detectable in the articular cartilage by day 3. 
Treatment of these animals with anti-TNFa neutralising antibodies over the first 3 
days post-arthritis induction resulted in a dose-dependent reduction in swelling and 
leukocyte infiltration. Reduction in cartilage proteoglycan depletion however was 
not achieved at any antibody dose examined (Lewthwaite et al., 1995). Thus animal 
models of Rheumatoid Arthritis have been instrumental in enhancing our 
understanding of the disease, allowing an insight into the mechanisms of joint 
destruction and the evaluation of anti-TNF therapies which now have human 
benefit.
The antigen-induced arthritis (AIA) model is a local model of disease, which was first 
described in rabbits (Dumonde and Glynn, 1962) and later in rodents (Brackertz et 
al., 1977). In the first rabbit model, animals were immunised with the antigen fibrin 
emulsified in complete Freund's adjuvant, prior to intra-articular injection of the 
antigen in order to initiate an inflammatory response. Description of the changes 
observed in the joint tissue over a sixteen week period revealed a chronic 
inflammatory process, initiating in the first 48 hours with an infiltration of 
inflammatory cells and the development of cellular exudate. This was proceeded by 
the thickening of synovial tissue, which developed into pannus and the appearance 
of bone erosions within four weeks. Evidence of inflammation continued to be 
present within the joint throughout the period of the study. This investigation 
highlighted the similarities between the model and the human disease in terms of
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chronicity, infiltration of immune cells and hyperplasia of the synovium (Dumonde 
and Glynn, 1962). The antigen-induced arthritis model in rabbits was further 
developed in 1971 using ovalbumin as the antigen, which was injected intra- 
articularly into pre-immunised rabbits. This study by Consden et al. (1971) sought to 
investigate the conditions necessary to generate a chronic experimental arthritis in 
terms of retention of antigen in the joint, the use of complete Freund's adjuvant 
during immunisations and the minimal dose of antigen required. Retention of 
antigen within the joint, as determined via radiolabelling, was greater in the 
immunised compared to the non-immunised animal. It took 7 days for the initial 
injection of 8mg ovalbumin to fall below lpg  in the non-immunised animal 
compared to over 100 days in the immunised animal. Antigen retention was also 
enhanced by the use of complete Freund's adjuvant compared to incomplete 
Freund's adjuvant corresponding with a greater degree of chronic arthritis. A 
minimal dose of lOpg of antigen injected intra-articularly was not sufficient for 
arthritis to develop (Consden et al., 1971). Using the evaluation of the ovalbumin 
model in rabbits, a similar model in rats and mice was developed.
The AIA model in mice was described in 1977. In this model the antigen methylated 
bovine serum albumin (mBSA) was used in mouse strains found to be susceptible 
(C57BI and Balb/c). Mice were immunised on days 0 and 7 with lOOpg mBSA in 
complete Freund's adjuvant prior to the induction of arthritis on day 21 via an intra- 
articular injection of lOOpg aqueous mBSA. Pertussis toxin was also administered 
on day 0. This protocol generated a chronic arthritis with characteristic infiltration 
of immune cells, synovial hyperplasia and cartilage and bone erosion. This persisted
141
for up to 3 months before gradually subsiding. The arthritic response was specific to 
the antigen used for immunisation as intra-articular injection with a different 
antigen, namely methylated human gabba globulin, to mBSA immunised mice only 
elicited a minor reaction (Brackertz et al., 1977). Unlike CIA, AIA is not a systemic 
model of inflammation and thus has more limited similarities with the human 
disease. However, many of its features are consistent with human RA. Experimental 
AIA joints display a chronic inflammatory disease with marked cellular infiltration, 
synovial hyperplasia and the destruction of both bone and cartilage (Dumonde and 
Glynn, 1962). The pathogenesis of AIA is also dependent on both T cell and B cell 
responses. Transfer of T cells from mBSA immunised mice to severe combined 
immunodeficient (SCID) mice rendered SCID mice susceptible to antigen-induced 
arthritis, implying a central role for T cells in the pathogenesis of the disease 
(Petrow et al 1996). Reduction in anti-mBSA titres are also correlated with a 
reduced severity of disease indicating an important role for B cells and antibody 
production. Since the development of this model in mice, it has been utilised in a 
number of studies to aid progression in the Rheumatoid Arthritis field.
The aim of this chapter was to evaluate the role of DR3 in RA using DR3_/' mice in 
the antigen-induced arthritis model. The availability of DR3 7 mice has provided a 
sound opportunity to investigate the role of DR3 signalling in a murine model of 
inflammatory joint disease. The susceptibility of DR3‘/_ mice and littermate controls 
to the AIA model is described, as assessed by routine methods. Animals were 
monitored for joint swelling and histopathological changes within the joint.
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Additionally, the effect of administering the ligand TL1A into the joint on day 0 of 
the model was analysed. Specifically the aims of this chapter were:
• To induce the AIA model for Rheumatoid Arthritis in DR3 deficient mice.
• To analyse the pathological changes resulting from this model in DR37' mice 
using histological techniques.
• To determine if the pathological response to the model in DR3_/' mice is DR3 
specific using the ligand TL1A.
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5.2 Results 
5.2.1 Anti-mBSA antibody responses were comparable between DR3+/+ and DR3'f' 
mice
A positive correlation between serum antibody titres and severity of arthritis in the 
AIA model has been reported (Cooke and Jasin, 1972). The anti-mBSA antibody 
titres were therefore analysed in both DR3+/+ and DR3 7 mice via ELISA. At day 21 
post-arthritis induction, serum anti-mBSA levels were not found to be significantly 
different between DR3+/+ and DR37' mice (p>0.05 Unpaired t-test) (Figure 5.1). It 
was therefore assumed that AIA could be successfully induced in both groups of 
mice.
5.2.2 AIA was induced in DR3+/+ and DR3'/- mice with 100% incidence but joint 
swelling decreased at a faster rate in DR3 deficient animals
To investigate the degree of joint swelling in DR3 sufficient and DR3 deficient mice, 
AIA was induced in the right knee joints of these animals. Prior to the induction of 
disease on day 0, baseline knee diameter measurements were taken using a 
micrometer. Average baseline knee joint diameters of DR3 sufficient mice 
measured 4.75mm and 4.72mm for right and left knee joints respectively. Those for 
DR3 deficient mice measured 4.89mm and 4.94mm and were not significantly 
different from DR3+/+ mice. DR3+/+ mice and DR3'/_ mice pre-immunised with mBSA 
in CFA, were given an intra-articular injection of mBSA into the hind right knee joint 
on day 0 of the experiment. Post-arthritis induction, joint swelling was measured 
(using a micrometer) as the difference between hind right and hind left knee joint
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diameters. Swelling of the AIA knee joint gave an indication of the successful 
induction of disease.
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Figure 5.1. Anti-mBSA antibody concentrations. Serum concentrations of 
anti-mBSA antibodies were analysed via ELISA using mice sacrificed on day 
21 post-arthritis induction. 5pg/ml mBSA was coated onto ELISA plates for 
24 hours. Sera was diluted as indicated in 5% (w/v) milk extract in PBS 
containing 0.1% Tween 20. Data are mean ± SEM, n = 6. Levels of antibodies 
in DR3'/' mice were found to be normal when compared to DR3+/+ mice 
when analysed using a t-test.
All DR3+/+ mice responded to intra-articular injection of antigen (mBSA) and 
exhibited joint swelling. A peak of inflammation was observed on day 1 post­
arthritis induction, with joint size increasing from average baseline diameters of 
4.7mm up to a maximum of 6.8mm. Mean peak joint swelling measured as the 
difference between right and left knee joints, was 1.72mm. Following this peak, 
inflammation subsequently decreased over the course of the experiment returning 
to baseline levels on day 14.
All DR37" mice similarly responded to AIA induction and reached a peak joint 
swelling on day 1 post-arthritis induction. The maximum joint diameter observed 
reached 6.9mm. Mean peak joint swelling in DR3 deficient animals was 1.67mm. 
Inflammation decreased over subsequent days returning to baseline levels on day 7 
post-arthritis induction.
The pattern of joint swelling over the 21 day experiment was comparable between 
DR3+/+and DR3-/' mice, both reaching a peak on day 1 and subsequently decreasing 
(Figure 5.2). Peak swelling was also comparable in DR3+/+ (1.72mm) and DR3_/ 
(1.67mm) mice. However, swelling decreased at a faster rate in the absence of DR3, 
returning to baseline levels on day 7 post-arthritis induction compared to day 14 in 
DR3 sufficient mice. Joint swelling over the 21 day time period was significantly 
lower in DR3_/~ mice compared with controls when analysed using a Two-Way 
Anova. Therefore, although DR3 /_ mice exhibited a similar pattern of joint swelling 
in response to AIA induction, swelling decreased at a faster rate than in control 
mice over the course of the experiment.
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Figure 5.2. Joint Swelling in Response to intra-articular mBSA injection.
Joint swelling, measured using a digital micrometer as a comparison 
between AIA joint (right knee) and normal joint (left knee), was measured 
over a 21 day time period in mice induced with AIA. Data are mean ± SEM, n 
= 6. Statistical analysis was performed using a two-way ANOVA. Joint 
swelling curves were significantly different between DR37' and DR3+/+mice 
over the 21 day timecourse, as indicated by the upper bar. * p<0.05.
5.2.3 Early joint pathology does not differ significantly between DR3'/_ and control 
mice
To assess the severity of disease occurring in the AIA model, joint sections were 
routinely analysed for histopathological changes relevant to RA pathogenesis. This 
was assessed via the employment of an in house published scoring system. H&E 
stained sections were scored by blinded independent observers as illustrated in 
Figure 5.3. The pathological features of the model, namely cellular exudate 
(observed within the joint space), synovial hyperplasia and bone erosions were 
scored from 0-3, and cellular infiltration of the adipose tissue was scored from 0-5, 
with 0 representing a normal joint. Total scores were summed to give the arthritis 
index (Al).
H&E stained sections taken from joints of mice sacrificed on day 3 post-arthritis 
induction were assessed for severity of arthritic disease according to the arthritis 
index. DR3+/+ mice displayed cellular exudate within the joint space and had 
significant infiltration of inflammatory cells into the adipose tissue (Figure 5.4a). At 
this time point, only minor synovial hyperplasia and bone erosions were evident.
Joint sections from DR37' mice on day 3 post-arthritis induction displayed cellular 
exudate within the joint space and infiltration of cells into the adipose tissue (Figure 
5.4b). There was only very minor synovial hyperplasia and no bone erosions. 
Comparison of the arthritis index between DR3 sufficient and deficient animals at 
this stage showed no significant difference using a Mann-Whitney U test (p>0.05)
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(Figure 5.5a). All individual parameters of the arthritis index were comparable and 
also showed no significant differences (p>0.05) (Figure 5.5b).
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Figure 5.3. The arthritis index. H&E stained joint sections illustrating the method of 
analysis of the arthritis index (Al). a) A normal non-diseased joint illustrating the overall 
anatomy of the murine knee joint (x4). b) A diseased joint illustrating the parameters 
that were assessed in determining the Al (x20). Individual features of arthritic disease 
were scored (cellular exudate (0-3), cellular infiltration (0-5), synovial hyperplasia (0-3), 
bone erosions (0-3)) and summed to give the arthritis index. This method of assessment 
was used routinely in analysis of joint pathology within AIA and control joints. Sections 
were assessed by 2 blinded independent observers.
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Figure 5.4. H&E Stained Joint Sections from Animals Sacrificed on Day 3. Joint sections were H&E stained and 
analysed for Al. Images were captured at x20 magnification. Cellular infiltration (black arrows) and cellular 
exudate (blue arrows) were evident in both DR3+/+ (a) and DR37' (b) mice. F = femur, T = tibia.
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Figure 5.5. Arthritis Index at Day 3 Post-arthritis Induction. Joint 
sections taken at day 3 post-arthritis induction were assessed for arthritis 
index, (a) A comparison of the Al between DR3+/+ and DR37' mice 
indicates no significant difference in disease severity. Horizontal lines 
depict means, (b) Comparison of the individual parameters of the Al. 
Data are mean ± SEM. Data was analysed using a Mann-Whitney U test, n 
= 6 .
5.2.4 DR3'/_ mice displayed resistance to the pathological features of arthritic 
disease at day 21
To ascertain if the pathological features of arthritic disease were more severe in 
DR3 sufficient and deficient mice at a later stage in the model, the arthritis index 
was also analysed in joint sections from mice culled on day 21 of the study. DR3+/+ 
mice displayed the characteristics of severe arthritis characterised by cellular 
infiltration and exudate within the joint space. Marked synovial hyperplasia, the 
development of thick pannus and extensive erosions of the bone were also evident 
(Figure 5.6a). DR37' mice however, only displayed very mild features of the disease 
with minimal evidence of cellular exudate and infiltration and minor synovial 
hyperplasia (Figure 5.6b). Additionally there was a complete absence of bone 
erosion.
The arthritis index was significantly lower in DR37' mice (Mann Whitney U Test; 
p<0.01) compared to controls (Figure 5.7a). All individual parameters of the arthritis 
index were significantly lower in DR37' mice compared with controls (cellular 
infiltration, exudate and bone erosion - Mann Whitney U Test; p<0.01; synovial 
hyperplasia - Mann Whitney U Test; p<0.05) (Figure 5.7b). DR3_/' mice were 
therefore resistant to the development of the histopathological hallmarks of AIA at 
day 21 of the model.
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Figure 5.6. H&E Stained Joint Sections from Animals Sacrificed on Day 21. Joint sections were H&E stained and 
analysed. Images were captured at x20 magnification. DR3+/+ mice (a) displayed features of cellular infiltration 
(black arrows), cellular exudate (blue arrows), synovial hyperplasia (red arrows) and bone erosion (green arrows). 
DR3_/' mice (b) showed only very mild features of disease with some minor synovial hyperplasia (red arrows). F = 
femur, T = tibia.
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Figure 5.7. Arthritis Index at Day 21 Post-arthritis Induction, (a) A
comparison of the Al between DR3+/+ and DR3'/' mice indicates a 
significant difference ( * *  p<0.01) in disease severity. Horizontal lines 
depict means, (b) Comparison of the individual parameters of the Al 
indicates a reduction in all features in DR3*/' mice. There is a significant 
difference between cellular exudate ( * *  p<0.01), infiltrate ( * *  p<0.01), 
synovial hyperplasia (* p<0.05) and bone erosion ( * *  p<0.01). Data are 
mean ± SEM. Statistical analysis was performed using a Mann-Whitney 
U test, n = 6.
5.2.5 Articular cartilage is preserved in the absence of the DR3 gene
Articular cartilage is a dynamic structure which functions to provide a protective 
low resistance tissue, covering the surface of diarthrodial joints (Saxne and Bengt, 
2000). Under normal conditions, it acts to withstand compression upon load 
bearing. However, during the course of diseases such as RA, it can become depleted 
and degenerative joint disease may occur. Articular cartilage is principally 
composed of water, collagen and proteoglycans. Its depletion can be determined 
histologically via the use of Safranin O staining. This is a sensitive method used to 
illustrate the concentration and distribution of cartilage proteoglycans, via its 
binding to glycosaminoglycans (Rosenberg, 1971). Fast green is used as a 
counterstain to aid visualisation and analysis of the red Safranin O staining, 
producing a visible tidemark. To assess the effect of DR3 on articular cartilage 
during AIA, articular cartilage depletion in the femoral head was analysed at both 
day 3 and day 21 post-arthritis induction, in both DR3 sufficient and deficient 
animals. This was achieved by measuring the depth of depletion and expressing it 
as a percentage of the total cartilage depth.
At day 3 post-arthritis induction, DR3+/+ mice displayed evidence of cartilage 
depletion with the presence of an obvious tidemark (Figure 5.8a), corresponding to 
approximately 40% depletion. In DR3'/_ mice however, cartilage was generally 
preserved (Figure 5.8b) with less than 20% depletion. Thus although the Al did not 
differ significantly between the 2 groups of mice at day 3, cartilage depletion was 
significantly affected, and was substantially greater in DR3+/+ mice (Figure 5.9) 
(Mann Whitney U test; p<0.01).
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Figure 5.8. Day 3 Cartilage Depletion in DR3+/+ and DR37' Mice. 
Representative Safranin 0 /  Fast Green stained sections (x40) are shown. 
Cartilage depletion was measured as a percentage of total cartilage 
using an eye piece with a line-graduated scale. Articular cartilage in the 
femoral head was significantly more depleted in DR3+/+ mice (a) than in 
DR3 7 mice (b) at day 3 post-arthritis induction. Depth of depletion is 
shown by the tidemark (black arrows).
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Figure 5.9. Cartilage Depletion on Day 3 Post-arthritis Induction.
Cartilage depletion in the femoral head, measured as a percentage of 
total cartilage, was significantly lower in DR3'/' mice (* p<0.05) as 
determined using a Mann-Whitney U test. Horizontal lines depict mean, 
n = 6.
At day 21 post-arthritis induction, cartilage continued to be depleted in the DR3+/+ 
mice, increasing to approximately 45% (Figure 5.10a). Depletion in the absence of 
DR3 however, did not increase and remained below 20% (Figure 5.10b). This 
corresponded with a significantly higher depletion of cartilage in DR3 control mice 
compared with DR3_/ mice at day 21 (p<0.05) (Figure 5.11) implying an important 
role for DR3 in the destruction of articular cartilage during AIA.
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aFigure 5.10. Day 21 Cartilage Depletion in DR3+/+ and DR37' Mice. 
Representative Safranin 0 /  Fast Green stained sections (x40) are shown. 
Cartilage depletion was measured as a percentage of total cartilage using 
an eye piece with a line-graduated scale. Articular cartilage in the femoral 
head was significantly more depleted in DR3+/+ mice (a) than in DR3_/ mice 
(b) at day 21 post-arthritis induction. Depth of depletion is shown by the 
tidemark (black arrows).
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Figure 5.11. Cartilage Depletion on Day 21 Post-arthritis Induction.
Cartilage depletion in the femoral head, measured as a percentage of total 
cartilage, is significantly higher in DR3+/+ mice than in DR3'/' mice 
(*p<0.05) as determined using a Mann-Whitney U test. Horizontal lines 
depict means, n =6.
5.2.6 Characterisation of DR3+/' mice in the AIA model
DR3+/‘ mice contain 1 copy of the DR3 gene and are bred in abundance within the 
colony due to the heterozygote breeding pattern employed. AIA was characterised 
in these mice to assess their potential use in the model and to assess whether a 
significant gene-dosage effect occurs.
5.2.7 AIA was induced in DR3+/' mice with 100% incidence and joint swelling 
followed a pattern similar to that of DR3+/+ mice
Pre-immunised animals were induced with AIA on day 0 of the experimental 
protocol in the same manner as used for both DR3+/+ mice and DR3‘/_ mice. As 
previously described, the pattern of joint swelling was assessed using a micrometer. 
DR3+/' mice exhibited a peak in joint swelling on day 1 post-arthritis induction, with 
joint diameters rising from an average of 4.9mm on day 0 (pre-arthritis induction) 
to 6.3mm on day 1. Joint swelling decreased over subsequent days returning to 
baseline levels on day 14 post-arthritis induction (Figure 5.12). This pattern in joint 
swelling was comparable to those of both DR3+/+ mice and DR37' mice and did not 
differ significantly from either at any individual time point. However, on days 2, 3, 5 
and 7, joint swelling in DR3+/‘ mice appeared to be intermediate of those of DR3+/+ 
and DR3'/_ mice. Similar to DR3+/+ mice however, baseline swelling did not return 
until day 14. Therefore, AIA can be induced in DR3+/" mice with 100% incidence with 
joint swelling following a similar pattern to DR3 sufficient mice.
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Figure 5.12. DR3+/' mice joint swelling post-AIA induction. Joint swelling 
was analysed in DR3+/’ mice for 21 days post-arthritis induction using a 
digital micrometer. Joint swelling of DR3+/‘ mice (solid line) follows the same 
pattern as that of DR3+/+ and DR37* mice (broken lines) and is not 
significantly different from either. Data are mean ± SEM, n = 6.
5.2.8 The Al of DR3+/‘ mice was less severe than that of DR3+/+ mice but did not 
differ significantly on either day 3 or day 21
To investigate whether DR3+/' mice displayed the histopathological hallmarks of 
arthritic disease, at days 3 and 21 post-arthritis induction, DR3+/‘ mice were 
analysed for the Al in the same manner as the analysis carried out on DR3+/+ and 
DR37' mice. At day 3 post-arthritis induction, DR3+/' mice showed evidence of joint 
pathology with infiltration of inflammatory cells into the adipose tissue and cellular 
exudate within the joint space. Synovial hyperplasia and bone erosion was minimal 
(Figure 5.13a). There was no significant difference in Al at day 3 between DR3+/‘ 
mice (mean Al 4.9) and either DR3+/+ (mean Al 5.2) or DR37' mice (mean Al 3.9) 
(Figure 5.13b). At day 21 post-arthritis induction, DR3+/' mice displayed 
degenerative joint pathologies with both bone erosions and pannus development 
and a mean Al of 2.3 (Figure 5.14a). This was not as severe as that seen within the 
joint of DR3+/+ mice (mean Al 4.1) however, there was not complete protection 
from bone erosion as seen in DR3 deficient animals (mean Al 0.3). There was no 
significant difference in Al between DR3+/‘ mice and DR3+/+, however Al in the DR3+/' 
mice was significantly greater than that seen in DR3 deficient animals (Mann- 
Whitney U test; p<0.01) (Figure 5.14b). Therefore, DR3+/' mice are susceptible to 
AIA displaying the characteristic histopathological features of disease at day 21 
post-arthritis induction, however, this is not as severe as that seen in DR3+/+ mice.
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Figure 5.13. Arthritis Index of DR3+/* Mice on Day 3 Post-Arthritis 
Induction, a) A representative H and E stained joint section (x40) from a 
DR3+/_ mouse on day 3 post-arthritis induction. DR3+/' mice display cellular 
exudate (blue arrows) and infiltration (black arrows) on day 3 post-arthritis 
induction, b) A comparison of the Al between DR3+/+, DR3+/ and DR37 . Al 
of DR3+/ mice does not differ significantly from either DR3+/+ or DR37 mice. 
Horizontal lines depict means, n = 6. Data was analysed using a Mann- 
Whitney U test.
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Figure 5.14. Arthritis Index of DR3+/‘ Mice on Day 21 Post-Arthritis 
Induction, a) A representative H and E stained joint section (x20) 
from a DR3+/' mouse on day 21 post-arthritis induction. DR3+/ mice 
display all features of the Al on day 21 post-arthritis induction. 
Cellular infiltration (black arrows), cellular exudate (blue arrows), 
synovial hyperplasia (red arrows), bone erosion (green arrows), b) Al 
of DR3+/* mice does not differ significantly from DR3+/+ but is 
significantly higher than DR3/ mice. * *  p<0.01 (Mann-Whitney U 
test). Horizontal lines depict means, n = 6.
one-way Anova (p>0.05) (Figure 5.15). Therefore, TL1A has no significant effect on 
joint swelling in DR3+/' mice when administered into the joint on day 0 of the AIA 
model at any of the concentrations that were assessed.
5.2.11 Administration of increasing concentrations of TL1A to the joints of DR3+/‘ 
mice results in an increase in Al in a dose-dependent manner
To discover if there was an effect of TL1A administration on joint pathology, the 
arthritis index of DR3+/‘ mice receiving TL1A was analysed at day 21 post-arthritis 
induction. Mice receiving no TL1A displayed all histopathological features of 
arthritic disease, namely cellular infiltration and exudate, synovial hyperplasia and 
bone erosions, as previously determined in DR3+/‘ mice. The addition of lng of TL1A 
into the joint resulted in a similar histopathological outcome with evidence of 
cellular exudate, infiltration, synovial hyperplasia and bone erosion. A mean Al of
3.3 was observed. Raising the concentration of TL1A to lOng resulted in an increase 
in Al to a mean value of 4.6 as a result of an increase in cellular exudate, synovial 
hyperplasia, cellular infiltration and bone erosion. Further increasing the 
concentration of TL1A to lOOng resulted in an increase in synovial hyperplasia and 
erosions of the bone. However, cellular exudate and infiltration did not increase 
(Figure 5.16). When comparing the significance of the Al at different concentrations 
of TL1A, it was found to increase in a dose-dependent manner with increasing 
concentration of TL1A (One-Way ANOVA; p<0.05) (Figure 5.17). When comparing 
the individual parameters of the Al at the different concentrations of TL1A, there 
was no significant difference in cellular infiltration or cellular exudate at any of the 
concentrations despite a dose-dependent increase in these parameters with TL1A
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administration. However, both synovial hyperplasia (One-Way ANOVA; p<0.05) and 
bone erosion (One-Way ANOVA; p<0.05) became significantly more severe with 
increasing concentration of TL1A (Figure 5.18). The increasing size of bone erosions 
was particularly striking.
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Figure 5.15. The Administration of Increasing Concentrations of TL1A to 
DR3+/' Mice has no Effect on Joint Swelling. TL1A was administered to 
DR3+/_ mice in increasing concentrations on day 0 of the AIA protocol. 
Joint swelling was analysed over 21 days post-arthritis induction using a 
digital micrometer. Data are mean ± SEM. 6 mice were analysed at each 
concentration of TL1A. Administering TL1A into the joints of DR3+/' mice 
did not effect joint swelling in response to mBSA injection across the 21 
day timecourse.
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Figure 5.16. Administration of Increasing Concentrations of TL1A to DR3+/_ 
Mice Results in a Dose-Dependent Increase in Al. H and E stained 
representative images (x20) of DR3+/ mouse knee joints on day 21 post­
arthritis induction are shown, (a) no TL1A (b), lng TL1A (c), lOng TL1A (d) 
and lOOng TL1A . Bone erosions are indicated with black arrows.
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Figure 5.17. Administration of TL1A to DR3+/' Mice Results in a Dose- 
Dependent Increase in Al. Al at day 21 post-arthritis induction increases 
with concentration of TL1A. *p<0.05 (One-Way ANOVA). Horizontal lines 
depict means. Each symbol represents one mouse.
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Figure 5.18. A Comparison of the Individual Features of the Al for DR3+/' 
Mice Receiving Increasing Concentrations of TL1A. Administration of 
increasing concentration of TL1A generally results in a dose-dependent 
increase in the individual features of the Al. Both synovial hyperplasia and 
bone erosion become significantly more severe with increasing 
concentration of TL1A as analysed using a one-way ANOVA (* p<0.05). Date 
are mean ± SEM.
5.2.12 TL1A administration to DR3+/' mice caused a trend towards exacerbation of 
cartilage depletion at lOOng
Cartilage depletion in the femoral head was analysed at day 21 post-arthritis 
induction in DR3+/' mice receiving TL1A. This was achieved via Safranin O/Fast 
Green staining as previously described. Depletion of cartilage occurred in DR3+/‘ 
mice which did not receive TL1A with approximately 30% depletion. Administration 
of lng of TL1A had no effect on cartilage depletion but the administration of lOng 
and lOOng TL1A increased cartilage depletion to 34% and 45% respectively (Figure
5.19). This effect was not significantly different as analysed using a t-test (Figure
5.20).
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Figure 5.19. Cartilage Depletion Increases in a Dose-Dependent Manner 
with Administration of TL1A to DR3+/" mice on day 21 post-arthritis 
induction. Representative Safranin 0 /  Fast Green stained sections (x40) are 
shown. Cartilage depletion was measured as a percentage of total cartilage 
using an eye piece with a line-graduated scale. Depletion of articular cartilage 
is illustrated by the visible tidemark (white arrows). Depth of depletion 
increases with increasing concentration of TL1A.
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Figure 5.20. Cartilage Depletion in DR3+/' Mice Receiving Increasing 
Concentrations of TL1A. Cartilage depletion in the femoral head, 
measured as a percentage of total cartilage was analysed. Safranin O/Fast 
Green staining of joint sections from DR3+/' mice receiving TL1A revealed a 
trend towards exacerbation of proteoglycan loss at lOOng TL1A. Horizontal 
lines depict means. Each individual symbol represents one mouse.
5.2.13 Administration of increasing concentrations of TL1A to the joints of DR3'/_ 
mice had no significant effect on swelling or Al
As TL1A is reported to be the only known specific ligand for DR3, the fact that it was 
able to exacerbate arthritic disease in a dose-dependent manner in DR3+/' mice 
implies that it is a DR3-dependent effect. To further clarify this, TL1A was 
administered to the joint of DR3 deficient mice where no effect should be 
observed. Concentrations of Ong, lng, lOng and lOOng of TL1A were examined. 
Joint swelling occurred at all concentrations of TL1A following the typical pattern of 
peaking on day 1 post-arthritis induction and subsequently decreasing, returning to 
baseline levels on day 7 post-arthritis induction. Peak swelling of joints on day 1 
reached 1.67mm with no TL1A, 1.17mm with lng TL1A, 1.6mm with lOng TL1A and 
1.7mm with lOOng TL1A. There was no significant difference in joint swelling at the 
different concentrations of TL1A (Figure 5.21). Al was also assessed at day 21 post­
arthritis induction. As previously determined, DR3'/_ mice did not show the 
histopathological features associated with arthritis, in particular, they have a 
complete absence of bone erosions. The addition of TL1A did not have a dose- 
dependent effect on Al (Figure 5.22). However, mean Al did increase from normal 
DR3_/ values (mean Al without TL1A = 0.3) to 1.5 with lng TL1A, 2.2 with lOng TL1A 
and 2.1 with lOOng TL1A (Figure 5.23). These increases were not significantly 
different from normal DR37' Al values when analysed via One-way ANOVA. When 
examining the individual parameters of the Al (Figure 5.24), administration of TL1A 
did result in an increase in these features although when statistically analysed, 
these did not reach significant levels. Cellular exudate rose from an average of 0.08 
without the administration of TL1A to 0.17 at lOng and 0.42 at lOOng TL1A.
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Increase in cellular infiltrate was quite uniform regardless of TL1A concentration 
administered. No infiltration was seen in the absence of TL1A but an average of 
0.58; 0.55 and 0.42 was observed at lng, lOng and lOOng TL1A respectively. 
Synovial hyperplasia appeared to increase in a dose-dependent manner with TL1A 
administration, rising from an average of 0.25 without TL1A to 0.83 with lOOng 
TL1A. The most notable effect was that of TL1A in DR3 7 mice on bone erosion. 
Previously it was noted that there was a complete absence of bone erosion in DR3 
deficient mice with antigen-induced arthritis. However, the administration of TL1A 
resulted in the emergence of bone erosions. An average score of 0 for bone erosion 
was observed without the administration of TL1A but this increased to 0.5, 0.92 and 
0.42 with the addition of lng, lOng and lOOng TL1A respectively. It must be noted 
that these increases in the individual features of the Al upon administration of TL1A 
to DR3 deficient mice, did not restore wildtype phenotype or achieve scores as high 
as those observed when administering TL1A to DR3+/" mice.
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Figure 5.21. The Administration of Increasing Concentrations of TL1A to 
DR3'/* Mice has no Effect on Joint Swelling. Joint swelling in DR3/_ mice 
which received TL1A on day 0 of the AIA protocol was assessed using a 
digital micrometer. Administering TL1A into the joints of DR3'/* mice did 
not effect joint swelling in response to mBSA injection. Data are mean ± 
SEM. n = 6.
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Figure 5.22. Arthritis Index of DR3'/’ Mice Receiving TL1A. Increasing 
concentrations of TL1A were administered to DR3/ mice on day 0 of the AIA 
protocol. Images show representative H and E stained sections from DR3'/' 
mice receiving a) no TL1A (xlO), b) lng TL1A (x20), c lOng TL1A (x20) and d) 
lOOng TL1A (x20). Administration of TL1A to DR3 / mice did not have a dose- 
dependent nor significant effect on Al. However, there was a greater 
emergence of features of the Al including bone erosion (green arrows).
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Figure 5.23. Administration of Increasing Concentrations of TL1A to 
DR3*/' Mice Has no Effect on Al Score. Al was analysed from DR3'/' 
mice receiving increasing concentrations of TL1A as shown, on day 0 of 
the AIA protocol and sacrificed on day 21 post-arthritis induction. 
There was no significant effect of administering increasing 
concentrations of TL1A to DR3 deficient mice in terms of Al. Horizontal 
lines depict means, n = 6.
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Figure 5.24. A Comparison of the Individual Features of the Al for DR37' 
Mice Receiving Increasing Concentrations of TL1A. Administration of 
increasing concentration of TL1A had no significant effect on any individual 
features of the Al (one-way ANOVA). However, there was an increased 
emergence of cellular exudate, infiltration, synovial hyperplasia and bone 
erosion. Data are mean ± SEM. n = 6.
5.2.14 Administration of increasing concentrations of TL1A to the joints of DRB '^ 
mice had no significant effect on cartilage depletion
Cartilage depletion in the femoral head was analysed at day 21 post-arthritis 
induction in DR37' mice receiving TL1A. This was achieved via Safranin O/Fast Green 
staining as previously described. Minimal cartilage depletion occurred in all DR3"/_ 
mice regardless of TL1A concentration administered (Figure 5.25). Average cartilage 
depletion in all groups was between 10-20% and did not differ significantly (Figure 
5.26).
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Figure 5.25. TL1A does not affect cartilage depletion when administered to DR3_/‘ 
mice. Representative Safranin 0 /  Fast Green stained sections (x40) are shown. 
Cartilage depletion was measured as a percentage of total cartilage using an eye 
piece with a line-graduated scale. Depth of depletion does not increase with 
increasing concentration of TL1A.
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Figure 5.26. Cartilage depletion on day 21 post-arthritis induction in 
DR37* mice receiving increasing doses of TL1A. Cartilage depletion in 
the femoral head, measured as a percentage of total cartilage was 
analysed. TL1A had no effect on cartilage depletion in DR3_/' mice. 
Horizontal lines depict means, n = 6.
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6. Adverse Joint Pathology is Reduced in DRS'  ^mice in the AIA Model
6.1 Introduction
One of the most debilitating consequences of RA is the eventual destruction of 
joints resulting in deformity and disability. This is a costly result of the disease both 
for the patient and for society, with approximately 50% lower work force 
participation amongst sufferers and increased medical costs from hospitalisation 
and drug treatments (March and Lapsley, 2001). Furthermore, the pain and 
suffering associated with the disease and the eventual mortality is highly distressing 
for all of those involved. It has become accepted that in order to prevent joint 
damage, RA must be treated early using DMARDs, such as those mentioned in the 
previous chapter, before joint destruction becomes established. The long-term goal 
of this sort of therapy is not only to control the symptoms associated with RA but 
also to slow or ideally stop the progression of disease, allowing joint architecture to 
be protected.
Anti-TNF therapy has proven successful to a certain extent in controlling joint 
destruction. In clinical trials, both Infliximab and Etanercept have been shown to 
halt or at least slow the progression of joint erosion. In a study by Lipsky et al 
(2000), the effect of administering Infliximab in a combined therapy with another 
DMARD, Methotrexate, was examined over a one year period in patients with 
persistently active arthritis. By evaluating joints for radiographic scores according to 
the degree of destruction, it was found that the combined therapy of Infliximab and 
Methotrexate resulted in significantly less progression of joint damage compared to 
treatment with Methotrexate alone. In fact, between 39% and 55% of those
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receiving the combined therapy actually resulted in improved radiographic scores 
compared with 14% of those receiving Methotrexate (Lipsky et al., 2000). In an 
Etanercept trial in patients with early arthritis, joints were again analysed for 
radiographic scores and it was found that twice weekly administration of 25mg of 
Etanercept resulted in a mean increase in erosion score of 0.47 at 12 months 
compared with 1.03 when treated with Methotrexate alone. Those in the 
Methotrexate group were also more likely to discontinue treatment due to adverse 
effects (Bathon et al., 2000). Adverse effects were experienced by a proportion of 
all experimental groups in both of the aforementioned trials and regardless of 
treatment group, a proportion of patients did not see any improvement in the 
progression of joint damage. Thus although these results provide promising data, 
Infliximab, Etanercept and Methotrexate cannot be described as a "cure" for the 
joint destruction associated with Rheumatoid Arthritis.
The mechanisms of normal bone turnover and the proposed processes of 
pathological bone resorption during RA have been discussed in setions 1.3 and 1.4. 
Why blocking TNFa results in a certain degree of protection from joint destruction 
is still a matter for debate. In a review article by Boyce et al (2005), a mechanism for 
TNFa mediated bone destruction is proposed. It is suggested that TNFa influences 
the formation of osteoclasts, the priniciple bone resorbing cells, by both RANK 
dependent and independent mechanisms. Independent of RANK, TNFa is suggested 
to promote the differentiation and proliferation of osteoclast precursors in the 
bone marrow by stimulating c-Fms expression. In this respect an increase in the 
osteoclast precursor pool size is achieved. In the later stages of osteoclast
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development, TNFa is suggested to work in concert with RANK/RANKL to enhance 
osteoclast maturation by both inducing RANKL expression on synovial cells, T cells 
and osteoblasts and also by binding directly to the osteoclast precursors in order to 
induce their differentiation (Boyce et al., 2005). Numerous conflicting studies have 
led to the proposal of this model, with authors producing conflicting arguments for 
the mechanism of TNFa induced osteoclastogenesis. Lam et al. (2000) suggested 
that "permissive" levels of RANKL are required for TNFa induced osteoclastogenesis 
and that TNFa induced osteoclastogenesis cannot be achieved independently of 
RANKL. In a population of osteoclast precursors, the authors were unable to induce 
osteoclastogenesis in the presence of TNFa and M-CSF. However, when treated 
with both TNFa and low doses of RANKL, TNFa was capable of increasing 
osteoclastogenesis in a dose-dependent manner. Interestingly, this effect was only 
seen when TNFa was administered 2-4 days after RANKL and not when 
administered at the same time (Lam et al., 2000). Nakao et al (2007) have also 
shown a synergistic effect of TNFa and RANK signalling on osteoclastogenesis. In co­
cultures of osteoclast precursor cells with osteoblasts from wildtype, TNFa or 
TNFR1 deficient mice, osteoclastogenesis was always reduced in the absence of TNF 
signalling. Furthermore, blockade of RANKL signalling via OPG administration in this 
system completely inhibited osteoclastogenesis thus implying that TNF promotes 
osteoclastogenesis in the presence of RANKL (Nakao et al., 2007). Additionally, 
when osteoclast precursor cells were cultured with RANKL itself in the presence of 
M-CSF and anti-TNFa or anti-TNFRl neutralising antibodies, osteoclastogenesis was 
inhibited in a dose-dependent manner. RANKL treatment of the osteoclast 
precursor cells was also shown to increase TNFa mRNA expression implying that
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TNFa may act as an autocrine agent in osteoclastogenesis (Nakao et al., 2007). In a 
conflicting study, using a murine bone marrow macrophage culture system, 
Kobayashi et al. (2000) demonstrated the generation of TRAP positive cells induced 
by TNFa during the blockade of RANK activity (Kobayashi et al., 2000). This implies a 
RANK independent mechanism for osteoclastogenesis in this system. However, 
when Boyce et al. (2000) crossed mice expressing chronic low levels of TNFa with 
RANK knockout mice they found that although the mice exhibited an increase in 
CDllb+ osteoclast precursor cells compared to control animals, they were unable 
to generate mature bone resorbing osteoclasts (Boyce et al., 2005). This data, taken 
together with the results from the clinical trials, confirms an important but complex 
role for the TNF signalling pathway in pathological bone resorption and that TNFa is 
capable of influencing osteoclastogenesis.
Like DR3 TNFR1, RANK and OPG are also members of the tumour necrosis factor 
receptor superfamily, and thus this family of receptors appears to play an important 
role in bone destruction due to their role in osteoclastogenesis. In the previous 
chapter, we identified that DR3'/_ mice which were induced to develop AIA had not 
developed erosions of the bone within the knee joint at the end point of the 
experiment. This was in stark comparison to the wildtype littermate controls which 
displayed extensive erosions. These results suggest that DR3 plays a role in bone 
degradation during the AIA model for Rheumatoid Arthritis and that its blockade 
may be an effective therapy for protecting joint architecture during the disease. For 
these reasons we decided to examine the numbers of osteoclasts evident at 
different sites within the AIA joints of experimental animals. Additionally, osteoclast
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precursor numbers within the joint were also examined via F4/80 staining to detect 
cells of the monocyte/macrophage lineage. These cells have been shown to have 
the potential to differentiate into osteoclasts and their accumulation within the 
joint is required for osteoclastogenesis. The specific aims of this chapter were:
• To assess the numbers of osteoclasts present within the AIA joints of DR3 
sufficient and deficient mice at day 3 post-arthritis induction at 3 distinct 
sites namely: growth plate; femoral head and sites of focal erosion.
• To assess the numbers of osteoclasts present within the AIA joints of DR3 
sufficient and deficient mice at day 21 post-arthritis induction at 3 distinct 
sites namely: growth plate; femoral head and sites of focal erosion.
• To assess the numbers of monocyte/macrophages within the AIA joints of 
DR3 sufficient and deficient mice at day 3 post-arthritis induction at 2 
distinct sites namely: growth plate and within the cellular infiltration.
• To assess the numbers of monocyte/macrophages within the AIA joints of 
DR3 sufficient and deficient mice at day 21 post-arthritis induction at 2 
distinct sites namely: growth plate and within the cellular infiltration.
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6.2 Results
6.2.1 Osteoclast expression at day 3 and day 21 post-arthritis induction
Osteoclast expression was assessed in knee joint sections from DR3+/+ and DR3_/" 
mice on day 3 and day 21 post-arthritis induction. This was achieved via tartrate 
resistant acid phosphatase (TRAP) staining which results in osteoclasts staining red. 
TRAP is a metallophosphoesterase which catalyses the hydrolysis of phosphate 
monoesters (Brehme et al., 1999). In histology, TRAP is used as a routine marker for 
osteoclasts, acting as an early differentiation marker for osteoclastogenesis (Schett, 
2007) and being secreted into the resorptive bone area during the resorptive phase 
of mature osteoclasts (Ek-Rylander et al., 1991). Osteoclast expression was 
examined at 3 separate sites. Under normal physiological conditions, osteoclasts 
are located within the growth plate, where they are involved in the normal 
turnover of chondrocytes within the maturation zone (Tsuboi et al., 2003). 
Additionally they are located within the cortical bone where remodeling occurs 
within microchannels (Schett, 2007). In RA, osteoclasts are additionally located at 
the bone:pannus interface resulting in local bone erosions (Schett, 2007). The 3 
sites within the joint that were selected for analysis at day 3 were the femoral head, 
the growth plate and in the absence of bone erosions at this early time-point, in the 
infiltrating cells of the adipose tissue. At day 21, sites of active bone erosion were 
additionally examined.
6.2.2 Osteoclast expression at day 3 post-arthritis induction in the growth plate
Multinucleated TRAP+ cells were evident in the growth plate of both DR3 sufficient 
and deficient mice on day 3 post-arthritis induction (Figure 6.1). The average TRAP+
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area in the growth plate of DR3 sufficient animals was 8.7%. In DR3_/~ mice this 
value was slightly lower at 6.5%. The reduction in TRAP+ staining in DR3 deficient 
animals compared with controls was not statistically significant (Figure 6.2).
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Figure 6.1 TRAP Expression in the Growth Plate at Day 3 Post-Arthritis Induction. Representative 
TRAP/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and sacrificed 
on day 3 post-arthritis induction. Sections were maintained in TRAP staining solution fo r 3 hours at 37°C as described in 
section 2.6.5. Osteoclasts (blue arrows) are expressed in the growth plate o f DR3+/+ and DR3'/_ mice at comparable 
levels. GP = growth plate.
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Figure 6.2. Osteoclast Expression in the Growth Plate at day 3 Post- 
Arthritis Induction. TRAP+ area was analysed in five randomly 
selected areas in the growth plate. In each area, the TRAP+ area in 
square pixels was determined using Adobe Photoshop CS3 and 
expressed as a percentage of the total area in view. TRAP+ area in the 
growth plate at day 3 post-arthritis induction is comparable in both 
DR3 sufficient and deficient mice. No statistical difference was 
observed (Mann-Whitney U test). Horizontal lines depict means. Each 
symbol represents one mouse.
6.2.3 Osteoclast expression at day 3 post-arthritis induction in the femoral head
TRAP+ staining was evident in the femoral head of both DR3 sufficient and deficient 
mice at day 3 post-arthritis induction (Figure 6.3). Control mice displayed an 
average TRAP+ area of 8.5% compared to 6.8% in DR3_/‘ animals. This was not a 
significant difference when assessed statistically (Figure 6.4).
6.2.4 Osteoclast expression at day 3 post-arthritis induction in the adipose tissue
As erosion of the bone is not typically evident at day 3 post-arthritis induction, this 
was not assessed. However, when analyzing the histological sections, TRAP+ cells 
were noted in the infiltrate of the adipose tissue of some of the mice (Figure 6.5). 
Therefore, TRAP expression in this area was instead examined. TRAP+ cells were 
generally only seen in DR3 sufficient animals within the adipose tissue. These cells 
did not display multinuclearity. Mean TRAP+ expression in this area in DR3+/+ 
animals was 0.08% whilst only an average area of 0.005% in DR3‘/_ mice was TRAP+. 
This difference was statistically different when analysed using a Mann Whitney-U 
test (p<0.05) (Figure 6.6).
6.2.5 Osteoclast Expression at Day 21 Post-Arthritis Induction in the Growth Plate
Osteoclast expression at day 21 post-arthritis induction was assessed in the same 
manner as those analysed on day 3 post-arthritis induction. Infiltrating cells of the 
adipose tissue were not assessed. Instead, points of focal erosion at the bone- 
pannus interface or equivalent anatomical areas were analysed. Multinucleated 
TRAP+ cells were evident in the growth plate of both DR3 sufficient and deficient 
mice on day 21 post-arthritis induction (Figure 6.7). When analysed for TRAP+
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percentage area as described in Materials and Methods, DR3+/+ mice had an 
average TRAP+ percentage area of 3% in the growth plate.
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Figure 6.3 TRAP Expression in the Femoral Head at Day 3 Post-Arthritis Induction. Representative 
TRAP/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and sacrificed 
on day 3 post-arthritis induction. Sections were maintained in TRAP staining solution fo r 3 hours at 37°C as described in 
section 2.6.5. Osteoclast expression is not significantly different in the femoral head o f DR3'/_ mice compared to DR3+/+ 
mice at day 3 post-arthritis induction. FH = femoral head.
Figure 6.4. TRAP Expression in the Femoral Head at Day 3 Post- 
Arthritis Induction. TRAP+ area was analysed In five randomly 
selected areas in the femoral head. In each area, the TRAP+ area in 
square pixels was determined using Adobe Photoshop CS3 and 
expressed as a percentage of the total area in view. Osteoclast 
expression in the femoral head, as visualised by TRAP+ staining, is not 
significantly altered in DR3 A mice at day 3 post-arthritis induction 
(Mann-Whitney U test). Horizontal lines depict means, n = 6.
DR3+/+
Figure 6.5 TRAP Expression in the Infiltrating cells of the Adipose Tissue at day 3 Post-Arthritis Induction.
Representative TRAP/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  
A IA  and sacrificed on day 3 post-arthritis induction. Sections were maintained in  TRAP staining solution fo r 3 hours at 
37°C as described in  section 2.6.5. TRAP positive cells (yellow  arrows) are clearly visib le w ith in  the adipose tissue in 
DR3+/+ mice but not in DR3_/* mice. Red staining is significantly greater in  DR3+/+ mice.
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Figure 6.6. TRAP Expression within the Infiltrating Cells in the 
Adipose Tissue at Day 3 Post-Arthritis Induction. TRAP+ area was 
analysed in five randomly selected areas in the infiltrate. In each area, 
the TRAP+ area in square pixels was determined using Adobe 
Photoshop CS3 and expressed as a percentage of the total area in view. 
TRAP expression in the adipose tissue is significantly greater in DR3+/+ 
mice at day 3 post-arthritis induction when analysed using a Mann- 
W hitney U test. * p = <0.05. Horizontal lines depict means. Each 
symbol represents one mouse.
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Figure 6.7 TRAP Expression in the Growth Plate at Day 21 Post-Arthritis Induction. Representative 
TRAP/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and sacrificed 
on day 21 post-arthritis induction. Sections were maintained in  TRAP staining solution fo r 3 hours at 37°C as described 
in  section 2.6.5. Osteoclasts (blue arrows) are expressed in  the growth plate o f DR3+/+ and DR3'A mice at comparable 
levels. GP = growth plate.
DR37' mice exhibited an average TRAP+ percentage area of 3.5%. When the average 
values were analysed statistically using a Mann-Whitney U test, no statistical 
significance was observed in TRAP+ area in the growth plate of DR3+/+ and DR37' 
mice (Figure 6.8).
6.2.6 Osteoclast Expression at Day 21 Post-Arthritis Induction in the Femoral Head
TRAP+ cells in the femoral head of DR3+/+ and DR37' mice were evident (Figure 6.9). 
DR3 sufficient mice had an average TRAP+ area of 0.6%. DR3 deficient mice had a 
lower TRAP+ area in the femoral head displaying an average of 0.4%. When 
compared statistically using a Mann-Whitney U test, the TRAP+ area in the femoral 
head of DR3+/+ and DR37' mice at day 21 post-arthritis induction did not differ 
significantly (Figure 6.10).
6.2.7 Osteoclast Expression at day 21 Post-Arthritis Induction at sites of Erosion
Sites of bone erosion adjacent to areas of pannus development were not evident in 
DR37' mice. However, in order to statistically compare the areas of bone erosion in 
DR3+/+ mice and DR37' mice, it was necessary to analyse those areas in the DR3 
sufficient mice for TRAP+ cells and compare them to equivalent areas in the DR3 
deficient mice. Thus, bone erosions in the DR3 sufficient animals were viewed 
under high magnification and anatomically equivalent areas in the DR37' mice were 
located and both were analysed forTRAP+ percentage area. In DR3+/+ mice, areas of 
focal erosion were clearly evident adjacent to a thick layer of pannus development. 
TRAP+ multinucleated cells were present at these sites of erosion (Figure 6.11). 
Equivalent areas in the DR3 deficient mice did not display any evidence of TRAP+
204
staining. The mean TRAP+ area at sites of focal erosion in DR3+/+ mice was 0.7%. 
The corresponding average value in the DR3 deficient mice was 0.2% (Figure 6.12). 
When analysed statistically using a Mann Whitney U test, a significant difference 
was identified between TRAP expression at sites of focal erosion between DR3 
sufficient and deficient mice (p<0.05).
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Figure 6.8. Osteoclast Expression in the Growth Plate at day 21 Post- 
Arthritis Induction. TRAP+ area was analysed in five randomly 
selected areas in the growth plate. In each area, the TRAP+ area in 
square pixels was determined using Adobe Photoshop CS3 and 
expressed as a percentage of the total area in view. TRAP+ osteoclast 
numbers in the growth plate at day 21 post-arthritis induction are 
comparable in both DR3 sufficient and deficient mice. No statistical 
difference was observed (Mann-Whitney U test). Horizontal lines 
depict means, n = 5.
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Figure 6.9 TRAP Expression in the Femoral Head at Day 21 Post-Arthritis Induction. Representative 
TRAP/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and sacrificed 
on day 21 post-arthritis induction. Sections were maintained in TRAP staining solution fo r 3 hours at 37°C as described 
in section 2.6.5. Osteoclast expression is reduced in  the femoral head o f DR3'A mice compared to DR3+/+ mice, however, 
this reduction in expression is not significant.
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Figure 6.10. TRAP Expression in the Femoral Head at Day 21 Post- 
Arthritis Induction. TRAP+ area was analysed in five randomly selected 
areas in the femoral head. In each area, the TRAP+ area in square pixels 
was determined using Adobe Photoshop CS3 and expressed as a 
percentage of the total area in view. Osteoclast expression in the femoral 
head, as visualised by TRAP staining, is reduced in DR3_/‘ mice at day 21 
post-arthritis induction although not significantly so (Mann-Whitney U 
test). Horizontal lines depict means, n = 5.
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Figure 6.11 TRAP Expression in Areas of Focal Bone Erosion at Day 21 Post-Arthritis Induction. Representative 
TRAP/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and sacrificed 
on day 21 post-arthritis induction. Sections were maintained in TRAP staining solution fo r 3 hours at 37°C as described 
in  section 2.6.5. M ultinucleated osteoclasts (blue arrows) are clearly visible adjacent to pannus form ation at areas o f 
focal bone erosion in  DR3+/+ mice. Comparable areas in  DR3V' mice do not display positive staining fo r osteoclasts nor 
pannus formation. P = pannus.
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Figure 6.12. TRAP Expression in Areas of Focal Bone Erosion at Day 
21 Post-Arthritis Induction. TRAP+ area was analysed at sites of active 
bone erosion. In each area, the TRAP+ area in square pixels was 
determined using Adobe Photoshop CS3 and expressed as a percentage 
of the total area in view. Areas o f focal bone erosion in DR3+/+ mice 
displayed significantly more TRAP+ expression than anatomically 
equivalent areas in DR3 /_ mice. * p = <0.05 (Mann-Whitney U test). 
Horizontal lines depict means, n = 4.
6.2.8 Expression of F4/80+ cells in the AIA joint at day 3 post-arthritis induction
Osteoclast precursors are derived from cells of the monocyte/macrophage lineage, 
as discussed in section 1.3.6. Thus, in order for bone resorbing osteoclasts to be 
present within the joint, it is necessary for osteoclast precursor cells to first be 
recruited to the joint before they can differentiate into mature functional 
osteoclasts. In order to assess whether DR3'/_ mice displayed dysfunctional 
recruitment of cells of the monocyte/macrophage lineage into the joint, the 
expression of F4/80 at both day 3 and day 21 post-arthritis induction was analysed. 
F4/80 is a monoclonal antibody that recognises a mouse macrophage-restricted 
glycoprotein which is routinely used in macrophage research (McKnight et al.,
1996). Although macrophages are not necessarily destined to become osteoclasts, 
they do share a common progenitor cell. As such, the recruitment of the precursor 
cells of both macrophages and osteoclasts to the joint likely share common 
mobilisation and recruitment processes. Thus, in the absence of a specific marker 
for osteoclast precursor cells, F4/80 expression was studied instead. F4/80+ cells 
residing within the growth plate, where physiological bone remodeling occurs, and 
those which entered the joint in the inflammatory cell infiltrate were both 
examined.
At day 3 post-arthritis induction, F4/80+ cells are clearly visible in the growth plate 
of both DR3 sufficient and deficient mice (Figure 6.13). DR3+/+ mice had a mean 
F4/80 positive area in the growth plate of 0.07%. The corresponding mean F4/80+ 
percentage area in the growth plate of DR3 deficient mice was 0.11%. When 
compared statistically using a Mann-Whitney U test, no significant difference was
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found between the F4/80+ area in the growth plate of DR3+/+ and DR37' mice at day 
3 post-arthritis induction (Figure 6.14).
Infiltration of F4/80+ cells into the adipose tissue of the joint was examined. Both 
DR3+/+ and DR37" mice displayed very little F4/80+ staining within the adipose tissue 
at day 3 post-arthritis induction (Figure 6.15). DR3+/+ mice had a mean F4/80+ area 
of 0.002% compared to a corresponding value of 0.002% in the DR37' animals. 
There was no significant difference when compared statistically (Figure 6.16).
6.2.9 Expression of F4/80+ cells in the AIA joint at day 21 post-arthritis induction
At day 21 post-arthritis induction, F4/80+ cells were present in the growth plate of 
both DR3 sufficient and deficient mice (Figure 6.17). DR3+/+ mice displayed an 
average F4/80+ area within the growth plate of 0.22%. DR37' mice displayed a 
mean F4/80+ area of 0.21%. When analysed statistically using a Mann Whitney U 
test, there was no significant difference in F4/80+ area within the growth plate of 
DR3+/+ and DR37' at day 21 post-arthritis induction (Figure 6.18).
Within the cell infiltrate in the adipose tissue, F4/80+ cells were quite abundant in 
both DR3+/+ and DR37' mice by day 21 post-arthritis induction (Figure 6.19). DR3 
sufficient animals had an average F4/80+ area of 0.07%. The corresponding mean 
value in DR37‘ mice was 0.03%. These values did not differ significantly when 
testing statistically (Figure 6.20).
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Figure 6.13 F4/80 Expression in the Growth Plate at Day 3 Post-Arthritis Induction. Representative 
F4/80/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and sacrificed 
on day 3 post-arthritis induction. Sections were incubated w ith  anti-mouse F4/80 monoclonal antibody overnight at 4°C, 
as described in section 2.6.7. F4/80+ mononuclear cell expression (yellow  arrows) in the growth plate, as indicated by 
positive F4/80 staining, was comparable between DR3+/+ and DR3'A mice at day 3 post-arthritis induction. GP = growth 
plate.
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Figure 6.14. F4/80 Expression in the Growth Plate at day 3 Post- 
Arthritis Induction. F4/80+ area was analysed in five randomly selected 
areas in the growth plate. In each area, the F4/80+ area in square pixels 
was determined using Adobe Photoshop CS3 and expressed as a 
percentage of the total area in view. Comparable levels o f F4/80+ 
staining was evident in the growth plate on day 3 post-arthritis induction 
(Mann-Whitney U test). Horizontal lines depict means, n = 6.
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Figure 6.15. F4/80 Expression in Adipose Tissue on Day 3 Post-arthritis Induction. Representative 
F4/80/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and 
sacrificed on day 3 post-arthritis induction. Sections were incubated w ith  anti-mouse F4/80 monoclonal 
antibody overnight at 4°C, as described in  section 2.6.7. F4/80+ mononuclear cell in filtra tio n  into the adipose 
tissue was comparable between DR3+/+ and DR3'A mice at day 3 post-arthritis induction.
0.02
5  0.01
L i-
0.00- •  f  ■
DR3+/+ DR3-/
Figure 6.16. Statistical Analysis of F4/80+ Mononuclear Cell 
Infiltration into the Adipose Tissue on Day 3 Post-Arthritis 
Induction. F4/80+ area was analysed in five randomly selected areas in 
the infiltration. In each area, the F4/80+ area in square pixels was 
determined using Adobe Photoshop CS3 and expressed as a percentage 
of the total area in view. No statistical difference was observed in 
mononuclear cell infiltration into the adipose tissue o f the joint on day 3 
post-arthritis induction when analysed using a Mann-Whitney U test. 
Horizontal lines depict means, n = 6.
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Figure 6.17. F4/80 Expression in the Growth Plate at Day 21 Post-Arthritis Induction. Representative 
F4/80/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and sacrificed 
on day 21 post-arthritis induction. Sections were incubated w ith  anti-mouse F4/80 monoclonal antibody overnight at 
4°C, as described in section 2.6.7. F4/80+ mononuclear cell expression (yellow  arrows) in  the growth plate, as indicated 
by positive F4/80 staining, was comparable between DR3+/+ and DR3‘/_ mice at day 21 post-arthritis induction. GP = 
growth plate.
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Figure 6.18. F4/80 Expression in the Growth Plate at day 21 Post- 
Arthritis Induction. F4/80+ area was analysed in five randomly selected 
areas in the growth plate. In each area, the F4/80+ area in square pixels 
was determined using Adobe Photoshop CS3 and expressed as a 
percentage of the total area in view. Comparable levels o f F4/80+ cells 
were present in the growth plate at day 21 post-arthritis induction (Mann- 
Whitney U test). Horizontal lines depict means, n = 6.
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Figure 6.19. F4/80 Expression in Adipose Tissue on Day 21 Post-arthritis Induction. Representative 
F4/80/Haemotoxylin stained knee jo in t sections from  DR3 sufficient and deficient mice induced w ith  A IA  and 
sacrificed on day 21 post-arthritis induction. Sections were incubated w ith  anti-mouse F4/80 monoclonal 
antibody overnight at 4°C, as described in  section 2.6.7. F4/80+ mononuclear cell in filtra tio n  (yellow  arrows) 
into the adipose tissue, as indicated by positive F4/80 staining, was comparable between DR3+/+ and DR3‘A 
mice at day 21 post-arthritis induction.
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Figure 6.20. Statistical Analysis of F4/80+ Mononuclear Cell 
Infiltration into the Adipose Tissue on Day 21 Post-Arthritis Induction.
F4/80+ area was analysed in five randomly selected areas in the infiltrate. 
In each area, the F4/80+ area in square pixels was determined using 
Adobe Photoshop CS3 and expressed as a percentage of the total area in 
view. No statistical difference was observed in mononuclear cell 
infiltration into the adipose tissue o f the joint on day 21 post-arthritis 
induction when analysed using a Mann-Whitney U test. Horizontal lines 
depict means. Each symbol represents one mouse.
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7. Discussion
7.1 DR3 Reagent Generation
A general lack of DR3 reagents, including antibodies and soluble proteins, has 
hampered progression in the DR3 field. As such, an aim of this project was to 
attempt to generate a number of reagents for use in DR3 research and particularly 
to help confirm any of our in vivo observations in the AIA model.
7.1.1 Summary of Findings from Chapter 3
• Soluble and dominant negative hDR3 genes with and without streptag 
sequences were PCR amplified from plasmid DNA and sub-cloned into 
eukaryotic expression vectors.
• The full length mDR3 gene was amplified via RT-PCR reaction from murine 
thymus tissue.
• The mDR3 splice variant missing exons 5 and 6 was also generated via RT- 
PCR reaction.
• Dominant negative mDR3 was PCR amplified from the full length gene and 
sub-cloned into a eukaryotic expression vector.
• The soluble mDR3 splice variant, which is devoid of exon 6, was 
commercially manufactured and PCR amplified to insert streptag sequences 
if required. It was sub-cloned into a eukaryotic expression vector.
• All of the generated gene constructs were transfected into eukaryotic cell 
lines in order to facilitate soluble protein and stable cell line production. 
Detection of protein expression was difficult to achieve and very few of the
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transfected constructs produced detectable levels of protein despite 
growing in selective media.
• However, the streptag protein included in the hDR3 constructs was 
successfully detected via immunofluorescence.
• Furthermore, the GFP tag included in the pEGFP-Nl vector enabled the 
detection of dominant negative mDR3 and soluble + streptag hDR3 via 
Western blot and fluorescence.
• Soluble protein was never detected in the supernatant of the cells. Attempts 
to increase expression of soluble protein via new cloning strategies did not 
rectify this problem.
7.1.2 Chapter 3 Discussion
7.1.2.1 DR3 Gene Cloning
Prior to this work, both the human and murine DR3 genes had been previously 
cloned. Human DR3 was originally cloned in 1996 by multiple research groups 
(Bodmer et al., 1997, Chinnaiyan et al., 1996, Marsters et al., 1996, Screaton et al., 
1997) and the full length gene comprised 1665 bps made up of 10 exons. Murine 
DR3 was cloned in 2001 by Wang and co-workers and was shown to contain 1619 
bps and like the human gene, was made up of 10 exons (Wang et al., 2001a). We 
obtained the full length human DR3 gene for use as a template for further PCR 
amplification from Stuart Farrow (Glaxo Wellcome, Herts, UK). Full length mDR3 
was isolated by RT-PCR from thymus tissue and matched the published sequence of 
full length murine DR3. Additionally, one of the published murine DR3 splice 
variants which is devoid of exons 5 and 6 was also cloned by RT-PCR. Murine DR3
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transfected constructs produced detectable levels of protein despite 
growing in selective media.
• However, the streptag protein included in the hDR3 constructs was 
successfully detected via immunofluorescence.
• Furthermore, the GFP tag included in the pEGFP-Nl vector enabled the 
detection of dominant negative mDR3 and soluble + streptag hDR3 via 
Western blot and fluorescence.
• Soluble protein was never detected in the supernatant of the cells. Attempts 
to increase expression of soluble protein via new cloning strategies did not 
rectify this problem.
7.1.2 Chapter 3 Discussion
7.1.2.1 DR3 Gene Cloning
Prior to this work, both the human and murine DR3 genes had been previously 
cloned. Human DR3 was originally cloned in 1996 by multiple research groups 
(Bodmer et al., 1997, Chinnaiyan et al., 1996, Marsters et al., 1996, Screaton et al.,
1997) and the full length gene comprised 1665 bps made up of 10 exons. Murine 
DR3 was cloned in 2001 by Wang and co-workers and was shown to contain 1619 
bps and like the human gene, was made up of 10 exons (Wang et al., 2001a). We 
obtained the full length human DR3 gene for use as a template for further PCR 
amplification from Stuart Farrow (Glaxo Wellcome, Herts, UK). Full length mDR3 
was isolated by RT-PCR from thymus tissue and matched the published sequence of 
full length murine DR3. Additionally, one of the published murine DR3 splice 
variants which is devoid of exons 5 and 6 was also cloned by RT-PCR. Murine DR3
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proved difficult to amplify by conventional RT-PCR methods from thymus tissue. 
This may reflect the guanosine/cytosine (GC) -rich nature of the gene, as sequences 
which are high in GC content are notoriously difficult to amplify due to their ability 
to form secondary structures (Henke et al., 1997). This difficulty in amplification 
may also reflect the level of DR3 expression within normal tissues. Wang et al. have 
reported the expression of all 3 murine DR3 splice variants in thymus tissue (Wang 
et al., 2001a). However, the activation of T cells has been associated with an 
increase in the ratio of trans-membrane DR3 mRNA to total DR3 mRNA compared 
to the levels seen in resting T cells (Bamias et al., 2006). Thus it appears that full 
length DR3 may not be expressed at high levels in normal tissues making its 
amplification by RT-PCR difficult. The full length mDR3 gene was eventually 
amplified using a technique modified from a method which has been described to 
successfully amplify GC-rich products (Bachmann et al., 2003). In this respect, the 
difficulties associated with cloning the mDR3 gene may just reflect the composition 
of the gene.
In order to facilitate the expression of DR3 in an eukaryotic system, dominant 
negative forms of both human and murine DR3 genes were PCR amplified from the 
full length DR3 gene templates. It was essential to use dominant negative genes 
which did not contain a death domain because the over-expression of DR3 in 
eukaryotic cells results in apoptosis (Bodmer et al., 1997, Chinnaiyan et al., 1996, 
Marsters et al., 1996, Screaton et al., 1997, Kitson et al., 1996). A further truncated 
version of human DR3 was also cloned from the full length template which was 
devoid of both transmembrane and death domain regions in order to generate a
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soluble protein. The published soluble splice variant of murine DR3 in which exon 6 
is absent and an early stop codon occurs prior to the transmembrane domain was 
obtained commercially. Dominant negative and soluble versions of human and 
murine DR3 genes were cloned into appropriate eukaryotic expression vectors. 
Dominant negative gene sequences were cloned into the vector pDR26EFla. This 
vector contains a powerful EFla promoter which drives high levels of protein 
expression (personal communication with Claire Harris, Medical Biochemistry and 
Immunology, Cardiff University). Soluble gene sequences were cloned into the 
vector Signal pigplus which contains a CD33 signal sequence and a human IgGl Fc 
sequence which serve to facilitate high levels of secretion of the fusion protein 
(Bose et al., 2006). Not all of the soluble constructs were engineered to include the 
human IgGl Fc tail. They were designed to contain the Fc tail or the streptag 
sequence or both. The streptag II sequence has previously been used successfully 
within our lab for protein detection via both fluorescence and Western blot. It was 
hoped that adopting a cloning strategy which generated constructs with multiple 
options for detecting the expressed protein might overcome the obvious difficulties 
associated with the absence of a commercially available DR3 antibody.
7.1.2.2 DR3 Protein Expression
Protein expression from transfected cell lines was assessed by both fluorescence 
and Western blot methods. The streptag protein was only detectable by 
immunofluorescence methods whilst Western blots for either streptag or IgGl Fc 
for those constructs which were tested were consistently unsuccessful. However, 
when attempts to overcome this protein detection difficulty were undertaken by
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cloning the genes into GFP expressing vectors, positive Western blots for both GFP 
and the streptag protein in the cell lysate were achieved. Soluble proteins were 
never detected in the cell supernatant. It is possible that the GFP expressing vector 
is capable of achieving higher levels of protein expression than both Signal pigplus 
and pDR26EFla and that the ability to obtain positive expression by Western blot 
analysis was a reflection of the higher expression levels. As the production of 
soluble DR3 protein was of particular interest, we adopted a new cloning strategy 
for the soluble genes to attempt to boost protein expression. The murine and 
human soluble genes were amplified from the Signal pigplus vectors with primers 
engineered to amplify the CD33 signal sequence and the IgGl Fc tail in addition to 
the gene of interest. The products of this amplification were subsequently 
subcloned into the pDR26EFla vector which we had been advised would increase 
soluble protein production by 10 fold. Following transfection of the soluble mDR3 
construct however, protein was not detected in the cell lysate via anti-lgGl Fc 
Western blot analysis.
7.1.3 Summary of Findings from Chapter 4
• Four peptides based on the sequence of murine DR3 were designed and 
purchased.
• DR37 mice were immunised with the peptides.
• Only mice immunised with peptide 2 generated specific antibodies and were 
selected for hybridoma production.
• Hybridoma clones were generated and screened for antibody production 
against the original peptide.
2 2 6
• Although antibody secreting hybridoma clones were produced, only 1 clone 
secreted a peptide specific antibody. However, this clone subsequently died.
7.1.4 Chapter 4 Discussion
The Kohler and Milstein protocol for antibody generation is a widely employed 
method which has successfully enabled the generation of antibodies against 
numerous different antigens. The aim of this chapter was to exploit this method in 
order to generate antibodies against human and murine DR3. A pre-requisite of this 
protocol is the availability of pure antigen with which to immunise animals. Initially 
it was the intention to use cells which stably expressed dominant negative DR3 or 
soluble DR3 proteins tagged with either streptag or human IgGl Fc as the antigens. 
However, difficulty in generating stable cell lines and soluble proteins precluded 
this work. Thus a second method was employed to generate antibodies against 
mDR3 which used synthetic peptides as the immunogen. Peptides represent only a 
small portion of the complete protein and thus run the risk of generating antibodies 
which cannot recognise the native protein due to masking during protein folding. 
However, antibodies generated in this manner should be able to recognise linear 
protein during procedures such as Western blot analysis when proteins are 
denatured. Even anti-DR3 antibodies which are only suitable for Western blot 
techniques were of importance to us, thus the peptide method of antibody 
generation was considered appropriate. As peptides are very small molecules and 
unable to generate effective memory immune responses, mDR3 peptides were 
constructed as MAPs which contain multiple copies of the antigen on a lysine core. 
MAP peptides have been shown to generate an effective immune response whilst
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removing the need for coupling the antigens to carrier proteins, which themselves 
are immunogenic (Tam, 1988). Four peptides based on the mDR3 sequence, which 
according to an online peptide design tool (http://peptideselect.invitrogen.com) 
were predicted to be capable of generating antibodies with the ability to recognise 
native protein, were designed and synthesised. By selecting 4 different peptides, 
the chances of generating a panel of antibodies which were DR3 specific, capable of 
recognising native protein and with the potential to recognise only specific splice 
variants of the gene were increased. Following immunisation of DR3 deficient mice 
with 3 of these peptides, immune responses were only developed against peptide 
number 2 which fell within cysteine-rich domain 3 of DR3. Thus it would appear 
that the remaining 2 peptides did not display the immunogenic properties which 
would be expected of a MAP peptide. Hybridoma cells were generated from the 
spleen cells of one of the mice immunised with peptide 2. The efficiency of 
hybridoma cell production proved extremely poor with only 54 out of 720 wells 
containing clones for analysis. Using this technique, it would not be unexpected to 
have at least 500 wells to test for antibody production (personal communication 
with Mrs Sian Llewellyn-Lacey, MRC Tissue Culture Technician, Cellular and Viral 
Immunology Resource, Cardiff University). Following fusion, cells were seeded into 
96 well plates and were grown in the presence of a hybridoma feeding supplement 
in order to enhance growth. However, if the cells had initially been grown at higher 
densities in fewer wells, growth factors released from the surrounding cells may 
have further enhanced the growth of hybridoma cells enabling a greater proportion 
of cells to reach the densities required for analysis. This would, however, have 
increased the likelihood of non-antibody secreting cells over-growing those that
228
were secreting antibodies. Supernatant from only 6 of the clones tested reacted 
with the immunising peptide and of these 6, only one was specifically reactive with 
the peptide. Supernatant from 5 of the clones also reacted with a non-immunising 
peptide indicating that the lysine core which the MAPs were generated on was not 
entirely inert. Screening the supernatants against poly-L-lysine itself would confirm 
this. The one clone which appeared to be specifically reactive against the 
immunising peptide did not survive in culture. Thus despite attempts to generate 
anti-mDR3 peptide antibodies, poor immunogenicity of the peptides and poor 
efficiency of hybridoma generation in addition to a lack of specificity for the 
immunising peptide of the hybridomas produced, meant that the successful 
production of anti-DR3 antibodies was not achieved. The spleen from the second 
mouse that was immunised with peptide 2 and reacted positively with the 
immunising peptide in test bleeds, was frozen and remains available for hybridoma 
production. Following fusion of these spleen cells, they could be seeded at a higher 
density to encourage growth and survival and hopefully increase the number of 
clones available for analysis. In this manner, an anti-mDR3 antibody may still be 
produced from this set of experiments.
7.1.5 Concluding Remarks
The availability of antibodies against both human and murine DR3 was very limited 
prior to the commencement of this work. However, despite the limited success in 
generating antibodies and proteins in this study, DR3 reagents have now become 
more widely available. Multiple companies are now providing polyclonal human 
and murine anti-DR3 antibodies and a human anti-DR3 monoclonal antibody is also
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available. Additionally, soluble proteins for both human and murine DR3 have been 
generated. There is still a distinct lack of murine monoclonal anti-DR3 antibodies 
available on the market although one has been generated by an independent 
research group (Fang et al., 2008). However, with the generation of a soluble mDR3 
protein, there is potential to use this as an antigen in order to generate monoclonal 
antibodies. As previously mentioned, there is also still scope to generate antibodies 
against mDR3 using the remaining spleen from the second peptide immunised 
mouse that displayed a positive antibody response in chapter 4. With an improved 
efficiency of hybridoma production this may yield mDR3 specific antibodies. It is 
likely that as research in the DR3 field develops with the publication of articles, 
more commercially available reagents will be manufactured and DR3 research 
should develop at a much faster pace.
7.2 The Role of DR3 in the mAIA Model for RA
An important role for members of the TNFRSF in the inflammatory joint disease RA 
has been well documented. TNFR1 for example, via its interaction with TNFa, has 
been shown to significantly contribute to disease pathology in animal models of RA 
(Mori et al., 1996) and blockade of this receptor/ligand system has proven highly 
successful in clinical trials in the treatment of the disease (Bathon et al., 2000, 
Lipsky et al., 2000). Additionally, anti-TNF therapies are currently licensed for 
treatment of RA. RANK, another TNFRSF member, is also tightly linked with the 
destructive joint pathology associated with RA. Via interaction with its ligand 
RANKL, it is an essential component of the cellular differentiation pathway which 
results in the production of the sole bone resorbing cell type, osteoclasts (Hsu et al.,
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1999). Prior to the initiation of this project, the association between the relatively 
newly identified member of the TNFRSF, DR3, had been specutively linked with RA 
in published material. Since then, DR3 has been identified as a candidate gene for 
association with RA and a duplication of the gene has been noted in a greater 
proportion of RA patients (Osawa et al., 2004). Additionally, expression of the DR3 
ligand TL1A has been reported in rheumatoid synovium (Cassatella et al., 2007). 
DR3 also has reported roles in other inflammatory diseases including inflammatory 
bowel disease (Bamias et al., 2003) and atherosclerosis (Kang et al., 2005). 
However, no studies had been carried out in vivo in order to define the functional 
role of the DR3/TL1A pathway in inflammatory arthritis either in man or in an 
animal model. In order to address this issue, an important aim of this project was to 
evaluate the role of DR3 in a local model of RA, namely AIA. This model was 
induced in DR37' mice and in age-matched littermate controls. Indices of arthritis 
severity were compared between the groups.
7.2.1 Summary of Findings from Chapter 5
• DR3'/_ mice exhibit the initial joint swelling associated with induction of AIA.
• Joint swelling in response to AIA decreased at a faster rate in DR3 deficient 
mice.
• Joint pathology on day 3 post-arthritis induction did not differ between DR3~ 
/_ and DR3+/+ mice.
• DR3'/_ mice are resistant to joint destruction at day 21 post-arthritis
induction, with a complete absence of bone erosion.
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• Articular cartilage is preserved in DR37' mice at both day 3 and day 21 post­
arthritis induction.
• DR3+/' mice are susceptible to AIA with joint swelling following a similar 
pattern to that of DR3+/+ mice.
• Joint pathology in DR3+/~ mice was not as severe as that seen in DR3
sufficient mice at day 21 post-arthritis induction.
• Administration of the DR3 ligand TL1A to the joints of DR3+/' mice on the day
of AIA induction did not affect joint swelling.
• However, joint destruction was significantly exacerbated according to the
arthritis index.
• TL1A administration in DR3+/' mice also exacerbated cartilage depletion in a 
dose-dependent manner but had no effect in DR37' mice.
• Administration of TL1A to DR3_/' mice had no effect on joint swelling.
• However, although Al was not significantly affected, DR3‘/- mice were no 
longer completely protected from AIA with the emergence of occasional 
bone erosions.
7.2.2 Chapter 5 Discussion
This investigation into the role of DR3 in murine AIA is the first study to be 
conducted investigating the pathological role that DR3 might play in vivo in an 
inflammatory model of arthritic disease. Due to the similarities seen between 
human RA and the AIA model, inducing DR3 deficient animals to develop AIA is a 
sound model for assessing the contribution that DR3 makes to the pathological 
processes occurring during the disease. Since DR37' mice are capable of generating
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an effective antibody response, as illustrated in the assessment of serum anti-mBSA 
titres, they are suitable for the induction of AIA. DR3 deficient animals display a 
high degree of protection from AIA in terms of resolution of joint swelling and the 
pathological degenerative alterations occurring within the joint. This is similar to 
animals deficient in other TNF superfamily members, such as TNFR1 (Mori et al., 
1996) and RANKL (Pettit et al., 2001), which have also been shown to display 
protection from such models of arthritic disease. Similar to the effects seen in 
TNFR1 deficient mice in the CIA model (Mori et al., 1996), DR3 knockout resulted in 
reduced severity of disease associated with AIA. As blockade of the TNFa/TNFRl 
system is already being used as a successful treatment of the human disease in 
many patients, DR3 may therefore represent an alternative target for the future 
treatment of RA.
7.2.2.1 The effect of DR3 knockout on joint swelling and cellular infiltration 
following AIA induction
In the absence of DR3, inflammation of the joint did arise following AIA induction. 
The inflammatory reaction which occurred in DR3 deficient mice displayed a 
comparable peak of joint swelling to wildtype littermate controls at day 1 post­
arthritis induction. However, joint swelling resolved at a faster rate in the absence 
of DR3 implicating a pro-inflammatory role for the DR3 pathway. This is in 
agreement with the published role of DR3 in other inflammatory disease states 
such as atherosclerosis (Kang et al., 2005) and inflammatory bowel disease (Bamias 
et al., 2003). By day 21 post-arthritis induction, a striking reduction in cellular 
infiltration was evident in DR3_/ mice compared with controls. However, at day 3
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there was no difference in cellular infiltration nor was there a significant dose- 
dependent effect on cellular infiltration following administration of TL1A. The lack 
of difference at day 3 compared to day 21 may be explained by the cell types 
recruited at these different stages. During the acute inflammatory phase of early 
AIA neutrophil infiltration predominates (McLoughlin et al., 2003) which is later 
taken over by monocytes/macrophages and small numbers of B cells and T cells. 
Neutrophils are specifically trafficked to the inflammatory joint through the action 
of the C-X-C chemokines such as IL-8 and growth related gene protein (GRO) 
(Badolato and Oppenheim, 1996). The C-C chemokines on the other hand are 
responsible for monocyte and T cell recruitment and these include monocyte 
chemotactic protein 1 (MCP-1), monocyte interacting protein la  (M IP-la) and 
regulated on activation normal T expressed and secreted (RANTES). All of these are 
upregulated in the synovial joint of RA patients (Badolato and Oppenheim, 1996). 
DR3 has been reported to induce the expression of a variety of these chemokines. 
For example, the activation of DR3 on THP-1 cells in concert with IFNy stimulation 
has been shown to induce both the chemokines MCP-1 and IL-8 (Kang et al., 2005). 
However, Su et al. (2006) demonstrated that TL1A addition to primary human 
monocytes, only resulted in the secretion of IL-8 as they differentiated into 
macrophages but that MCP-1 secretion could not be detected (Su et al., 2006). Thus 
DR3 has the potential to affect cellular recruitment via influencing chemokine 
expression but the regulation of recruitment of different cell types by DR3 may be 
complex. In chapter 6 it was determined that the infiltration of F4/80+ cells into the 
joints of DR3 sufficient and deficient mice was comparable and that 
monocyte/macrophage cell recruitment appeared intact in the absence of DR3.
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Thus the reduced cellular infiltrate evident in the joints of DR37" mice at day 21 
post-arthritis induction cannot be attributed to a reduced ability to recruit 
monocytes/macrophages. When TL1A was added to the joints of DR3+/' mice on day 
0 of the AIA model, no dose-dependent effect on cellular infiltration was noted. 
This may reflect the complex nature of the role of DR3 signalling in cellular 
recruitment according to time of TL1A expression during the inflammatory process. 
This would be in agreement with the data of Su et al. (2006) who noted differing 
effects of TL1A stimulated IL-8 secretion throughout the monocyte-macrophage 
differentiation process (Su et al., 2006). Additionally, although Kang et al. (2005) 
reported the induction of both MCP-1 and IL-8 from DR3 activated THP-1 cells, 
treatment of the same cell line with recombinant human TL1A and IFNy resulted in 
IL-8 but not MCP-1 induction (Kang et al., 2005). In order to dissect the role of DR3 
in cellular infiltration during models of inflammatory arthritis, it is necessary to stain 
for other cell types within the AIA joint such as T cells and neutrophils. The effect of 
DR3 on T cells in this model is a particularly interesting area of future work. Meylan 
et al. (2008) have demonstrated that DR3 plays an important role in two other T cell 
dependent animal models of autoimmune and allergic inflammation. Using the 
Ova-induced lung inflammation and EAE models, the authors reported reduced 
accumulation of T cells in the target organs of these models, namely the lungs and 
the spinal cord respectively (Meylan et al., 2008). Furthermore, DR3 has recently 
been linked with Thl7 cell proliferation, as discussed in section 7.2.4, and therefore 
a detailed investigation into the effects of DR3 on T cell recruitment and 
proliferation in the AIA model might provide some interesting results. It would also 
be interesting to culture blood and bone marrow leukocytes from DR3 sufficient
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and deficient mice and measure chemokine expression following stimulation with a 
panel of RA associated cytokines such as TNFa, IL-1 and TL1A. Measurement of 
chemokine expression within the joints of AIA mice would also provide invaluable 
data. Such experiments would help to generate a clearer picture of the infiltrating 
cells into the AIA joint which are affected by DR3/TL1A interaction and the 
expression of the chemokines which facilitate this recruitment.
7.2.2.2 The effect of DR3 knockout on joint destruction following AIA induction
Similar to the reduction in cellular infiltration seen in DR3 deficient mice at day 21- 
post-arthritis induction, the increased rate of resolution of joint swelling in DR3_/' 
mice also corresponded to an improved pathological outcome within the joint, as 
assessed by the other disease parameters of the arthritis index including synovial 
hyperplasia and bone and cartilage destruction. However, again no such association 
was seen during the acute inflammatory phase of the disease model, with joints 
from DR3_/‘ mice and control mice displaying similar degrees of pathology at day 3 
post-arthritis induction. Thus it appears that AIA develops in DR3'/_ mice similar to 
controls during the early phase of the model, however, at a time point when 
maximal structural damage would be expected, DR3 deficiency confers resistance 
to the joint degeneration associated with AIA. When the individual features of the 
arthritis index were examined at day 21 post-arthritis induction, a significant 
reduction in all histopathological parameters was apparent. It was most intriguing 
that DR3 deficient mice did not develop the histopathological joint changes 
associated with AIA despite reaching comparable peaks in joint swelling to control 
mice on day 1 post-arthritis induction. This is because when TNFR1 deficient
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animals were induced to develop CIA, when joint swelling did occur, albeit at a 
reduced incidence compared to controls, the afflicted joints went on to develop 
severe features of arthritic disease (Mori et al., 1996). It is possible therefore, that 
the role of DR3 in inflammatory joint disease might be different to that of TNFR1 
with a potentially distinct role in the destruction of joint architecture, separate to 
any role the receptor might play in joint inflammation. In order to assess the 
structural damage occurring within the joint both bone erosion and cartilage 
depletion were analysed according to both the arthritis index and histological 
analysis of femoral head cartilage depletion.
One of the most interesting findings of this study was the complete absence of 
bone erosions in the DR3 deficient mice at day 21 following AIA induction. The 
destruction of bone represents one of the most debilitating consequences of 
inflammatory arthritis. Therefore, the apparent protection from this effect via DR3 
deletion was a very exciting observation. In order to attempt to elucidate a 
mechanism for this effect, an investigation of osteoclast expression and potential 
precursors within the AIA joint was undertaken in chapter 6. As such, a discussion 
of the role of DR3 in bone destruction will be discussed later.
At both day 3 and day 21 post-arthritis induction, a significantly greater amount of 
cartilage degradation was observed in wild type animals compared to DR3 deficient 
mice. Thus although the Al was not different between the 2 groups at day 3 post­
arthritis induction, DR37' mice were protected from the early cartilage depletion 
occurring within the joint and this protection was maintained at day 21.
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Additionally, the administration of TL1A to DR3+/' mice on day 0 of the AIA model 
resulted in a trend towards exacerbating the depletion of cartilage when lOOng of 
TL1A was used. Conversely the administration of TL1A to DR3 deficient mice had no 
effect on cartilage degradation. Cartilage destruction can be uncoupled from bone 
erosion in certain models of arthritis as mice which are deficient in RANKL, a factor 
critical for osteoclastogenesis, do not develop bone erosions in the serum transfer 
model of arthritis which is generated through the transfer of serum containing anti- 
glucose-6-phoshate isomerase antibody from transgenic mice with a spontaneous T 
cell dependent arthritis. However cartilage degradation is still apparent (Pettit et 
al.; 2001). DR3 may therefore play a specific role in cartilage destruction in AIA that 
could be distinct from its role in bone erosion or at least distinct from its potential 
effects on the activity of RANKL. The mechanisms for this however are unclear. The 
principle cell types thought to be responsible for cartilage destruction in the 
rheumatoid joint are synovial fibroblasts (Abeles and Pillinger, 2006). During RA 
pathogenesis, synovial fibroblasts become invasive and proliferative, contributing 
to the destruction of the joint. Thus synovial hyperplasia and cartilage degradation 
are intrinsically linked. It is therefore of particular interest that DR3 deficient mice 
display protection from cartilage depletion at both day 3 and day 21 post-arthritis 
induction in addition to displaying significantly reduced synovial hyperplasia at day 
21 post-arthritis induction. Furthermore, administration of the DR3 ligand TL1A into 
the joints of DR3+/' mice resulted in a significant dose-dependent increase in 
synovial hyperplasia and a dose-dependent increase in cartilage degradation. This 
provides compelling evidence that DR3 contributes to cartilage degradation during 
AIA pathology. There is no published evidence regarding the expression of DR3 on
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synovial fibroblasts. However, synovial fibroblasts are able to respond to a variety 
of stimuli such as the cytokines and growth factors produced in abundance in the 
rheumatoid joint (Konttinen et al., 2000). For example, TNFa stimulated synovial 
fibroblast cell lines derived from human knee joints display enhanced proliferation 
(Gitter et al., 1989) and incubation of cultured synovial fibroblasts with TNFa has 
been demonstrated to induce the conversion of the cartilage degrading enzyme 
MMP-2 from its latent to its active form (Migita et al., 1996). It is therefore possible 
that TL1A, via signalling through DR3, is also capable of activating synovial 
fibroblasts, enhancing their proliferation and migration and increasing their 
production of MMPs. There is published evidence to suggest that DR3 activation 
can result in MMP production in other cell types. Stimulation of THP-1 cells with 
recombinant human TL1A is reported to induce the release of MMP-9 in a dose- 
dependent manner (Brand et al., 2003). Activation of DR3 on the same cell line was 
also found to induce MMPs -1, -9 and -13 (Kim et al., 2001). All of these MMPs have 
been associated with the rheumatoid joint (Burrage et al., 2006) and are 
responsible for the degradation of cartilage. In order to fully elucidate the role of 
DR3/TL1A in MMP production from synovial fibroblasts, DR3 expression on this cell 
type requires investigation and the effect of TL1A addition to the cells on MMP 
expression needs to be measured. Additionally, expression of MMPs from 
monocytes derived from DR3 deficient mice could be examined. This has already 
been undertaken in IL-1 deficient mice revealing impaired production of MMPs -3 
and -13 (Zwerina et al., 2007). Synovial fibroblasts are not the only cell type capable 
of producing MMPs involved in cartilage degradation in the rheumatoid joint. 
Additionally, macrophage-like synoviocytes, chondrocytes and TRAP positive cells
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are also capable of proteinase secretion (Tsuboi et al., 2003). Thus should DR3 not 
be expressed on synovial fibroblasts, it may exert its effects on cartilage 
degradation via MMP induction from other cell types. Indeed, 
immunohistochemical analysis of the synovium from RA patients has revealed 
positive TL1A staining in cells with monocyte-macrophage morphology located 
particularly beneath the synovium. These cells also stained positively for the 
macrophage markers CD68 and CD14 (Cassatella et al., 2007). This positive TL1A 
staining was closely associated with the synoviocytes at areas of significant 
inflammation. Thus macrophage derived TL1A may act in an autocrine manner to 
induce MMP release from macrophage-like synovial fibroblasts thus contributing to 
cartilage degradation. Of particular note are the findings of Prehn et al. (2007) who 
determined that monocytes and dendritic cells could be induced by immune 
complex stimulation via FcyR to produce TL1A (Prehn et al., 2007). FcyR stimulation 
by immune complexes is also considered to play a prominent role in cartilage 
depletion during arthritic disease which is highlighted by reduced cartilage 
degradation in FcyR7' mice (van Lent et al., 2006). These mice display an absence of 
severe cartilage depletion on day 7 post AIA induction and a complete absence of 
VDIPEN staining, the latter being used to illustrate the expression of MMP-induced 
aggrecan cleavage sites and give an indication of MMP activity within the joint (van 
Lent et al., 2000). Thus immune complex activation of FcyR receptors on cells in the 
rheumatoid joint may increase TL1A expression which can then interact with DR3 to 
increase MMP production, thus contributing to cartilage depletion. Another 
interesting observation in chapter 6, and relevant to the discussion of cartilage 
depletion, was the increase in TRAP+ mononuclear cells within the cellular infiltrate
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of the adipose tissue and at sites of focal erosion in DR3 sufficient mice compared 
with DR3 deficient mice with AIA. TRAP+ cells within the human rheumatoid 
synovium have been reported to express MMPs -2 and -9 (Tsuboi et al., 2003) thus 
these TRAP+ cells may represent an additional source of MMPs within the AIA joint 
of DR3 sufficient animals. MMP expression within the AIA DR3 deficient mouse 
knee joint requires examination for example via northern blot analysis from total 
RNA isolated from the complete knee joint as has been previously executed in 
another transgenic mouse model (Salminen et al., 2002). This would provide data 
on the in vivo production of MMPs in the presence and absence of DR3 which might 
explain the protection from cartilage depletion noted in the DR3 deficient mice.
7.2.2.3 TL1A exacerbates disease in a DR3-dependent fashion
Our results suggest that the protection from AIA seen in DR3_/ mice is as a result of 
DR3 deficiency as opposed to an effect resulting from the generation of the 
knockout animal. This was concluded via studying the effect of TL1A administration 
on the joints of animals on day 0 of the AIA protocol. This data is extremely 
interesting because it is widely considered that TNFa is the central cytokine sitting 
at the top of an inflammatory cytokine cascade, which is responsible for many of 
the pathological effects of RA (Feldmann and Maini, 2001). This work therefore 
implicates the potential importance of a novel cytokine-receptor system in the 
pathogenesis of RA. In the absence of an mDR3 blocking antibody, which could have 
been used to confirm the effect of DR3 blockade in AIA, this conclusion was reached 
through the use of the DR3-specific ligand TL1A. TL1A is reported to be the only
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ligand for DR3 and in mouse, DR3 is the only published receptor for TL1A (Bossen et 
al., 2006).
The effect of TL1A administration in AIA was assessed in DR3+/" mice as opposed to 
wildtype mice in order to observe potential exacerbations of the disease within the 
realms of the Home Office project license. This is because DR3+/" mice did not 
develop as severe disease as DR3 sufficient mice but joint swelling and the 
underlying histopathology did arise and there was a significant gene dosage effect. 
Whilst increasing concentrations of TL1A had no significant effect on joint swelling, 
a dose-dependent increase in Al was seen within the joints. A significant dose- 
dependent increase in synovial hyperplasia and bone erosion rather than cellular 
infiltration and exudate accounted for this effect on the Al. The increase in the size 
of the bone erosions seen with increasing concentrations of TL1A was particularly 
striking. Thus DR3 appears to specifically effect the destructive phase of arthritic 
disease in terms of contributing to invasive synovial hyperplasia and the 
subsequent destruction of bone. When the same experiment was carried out in 
DR3 deficient animals, no significant effects were seen in terms of joint swelling or 
Al. These data suggest that DR3 via its interaction with TL1A is specifically involved 
in the pathological processes associated with AIA thus conferring protection from 
these pathological changes to the DR37' mice.
7.2.2.4 DR3 deficiency does not confer complete resistance to AIA
Although when TL1A was administered to DR3 deficient animals there were no 
significant effects on either joint swelling or Al, as would be expected in the
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absence of the only known receptor for the ligand, Al did increase from the scores 
seen at day 21 of DR3~/_ mice not receiving TL1A. This was an unusual finding as 
there are no other known receptors for murine TL1A and an extensive investigation 
of the binding capabilities of the known TNF receptors and ligands revealed that 
only TL1A can bind mDR3 (Bossen et al., 2006). There are 2 possible reasons for this 
effect. Firstly, it is feasible that another receptor for TL1A exists. A decoy receptor 
(DcR3) which binds TL1A has been identified in humans thus the presence of 
another receptor for TL1A in the mouse would not be totally unexpected. Secondly, 
the increase in Al may just be an artifact of the TL1A preparation used which may 
contain impurities which are capable of exacerbating the inflammatory response.
7.2.3 Summary of Findings from Chapter 6
• At day 3 post-arthritis induction, osteoclast expression in the joints of DR3+/+ 
and DR3'/_ mice was comparable both in the femoral head and in the growth 
plate.
• At day 3 post-arthritis induction, significantly increased osteoclast 
expression was observed in the adipose tissue of wildtype mice.
• At day 21 post-arthritis induction, osteoclast expression in the joints of 
DR3+/+ and DR37' mice was comparable both in the femoral head and in the 
growth plate.
• At sites of active focal bone erosion, osteoclast expression was significantly 
increased in DR3+/+ mice.
• At day 3 post-arthritis induction, only low levels of F4/80+ cells were present 
in both the growth plate and infiltrate of DR3+/+ and DR37' mice.
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• At day 21 post-arthritis induction, there were greater numbers of F4/80+ 
cells in the growth plate and infiltrate of DR3+/+ and DR3_/" mice and these 
levels were comparable.
7.2.4 Chapter 6 Discussion
In Chapter 5, the striking absence of bone erosions in the joints of DR3 deficient 
animals at day 21 post-arthritis induction and the ability of TL1A to increase bone 
erosion in a dose-dependent manner in DR3+/' mice, suggested that DR3 might play 
a role in the mechanisms responsible for bone destruction during arthritic disease. 
In order to address this point, we decided to assess the number of osteoclasts 
within the joints of DR3 sufficient and deficient mice at days 3 and 21 post-arthritis 
induction. Analysis was carried out by staining sections for TRAP, which is an 
osteoclast specific marker expressed both by mature osteoclasts during bone 
resorption (Ek-Rylander et al., 1991) and by early osteoclast precursors (Schett, 
2007). TRAP staining methodology requires that joints are decalcified in EDTA for 
high levels of staining to be achieved. When joints are decalcified in formic acid, 
TRAP staining is only weak and not very reproducible. Unfortunately as formic acid 
was the routine method of decalcification used in this study, only those 
experiments that were carried out specifically to decalcify joints in EDTA were 
available for analysis. Thus only day 3 and day 21 experiments were assessed, and 
those in which TL1A was administered could not be analysed.
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7.2.4.1 The role of DR3 in the expression of TRAP+ cells in the AIA joint
Due to the normal physiological processes of bone turnover, TRAP expression is 
expected within the growth plates and cortical bone of non-diseased joints. As 
such, the growth plate and femoral head were analysed for TRAP expression during 
AIA in DR3 deficient and sufficient mice at both day 3 and day 21. No statistically 
significant differences in TRAP expression were evident at these locations at either 
timepoint. This suggests that osteoclast expression at sites distant from 
inflammation is unaffected by DR3 expression and that normal bone turnover is not 
DR3 dependent. TRAP expression in both the growth plate and femoral head in all 
animals is greater at day 3 to that seen at day 21. However, the TRAP staining 
protocol is very temperature dependent and sections from day 3 and day 21 were 
stained on different days when the ambient temperature would not have been the 
same, thus potentially affecting the degree of TRAP staining. Therefore caution 
must be taken in comparing the results from separate experiments and conclusions 
should only be drawn from sections from each individual experiment which were 
stained together.
TRAP expression was evident at sites of active bone erosion at day 21 post-arthritis 
induction in DR3 sufficient animals. As bone erosion and pannus formation were 
not evident in the absence of DR3, similar areas of TRAP positive expression were 
not seen in DR3 deficient animals. This data implicates a role for DR3 in 
osteoclastogenesis at sites of inflammation within the joint where cells are in direct 
contact with the bone surface.
245
A particularly interesting finding was the observation that significantly more TRAP+ 
cells were located within the cellular infiltrate of the adipose tissue in DR3 sufficient 
mice compared with DR3'/_ mice at day 3 post-arthritis induction. These cells did not 
display the phenotypic multinuclearity of osteoclasts and thus may represent a 
precursor cell. It is unknown within the osteoclast field whether osteoclasts develop 
from monocytic precursors infiltrating into the joint or if they already display 
commitment to osteoclastogenesis upon entering the joint. Thus there are 3 
possible explanations for our observation: DR3 may affect the recruitment of 
predisposed TRAP positive osteoclast precursor cells into the inflamed joint which 
are already some way down the osteoclast differentiation pathway; DR3 may affect 
the recruitment of monocytic osteoclast precursor cells into the joint increasing the 
available pool of cells capable of undergoing osteoclastogenesis; or recruitment of 
precursor cells may be unaffected but the process of osteoclastogenesis from 
precursor cells within the joint may be DR3 dependent leading to an increase in 
TRAP+ cells. Early osteoclastogenesis does not require direct contact with bone and 
thus TRAP+ cells are capable of accumulation at sites distant from the bone within 
the joint (Schett, 2007).
7.2.4.2 Infiltration of F4/80+ cells into the joints is unaffected by DR3
To address the issue of impaired cellular infiltration into the joint, potential 
osteoclast precursor cells which were positive for the monocyte/macrophage 
marker F4/80 were analysed. Although multiple cell types have been shown to 
differentiate into osteoclasts in vitro, accumulation of macrophages within the RA 
joint have been shown to correlate with the severity of joint damage in the human
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disease (Mulherin et al., 1996). Thus F4/80+ osteoclast precursors were selected for 
analysis. In order to assess whether the infiltration of these osteoclast precursor 
cells into the AIA joint was impaired in the absence of DR3, we stained day 3 and 
day 21 joint sections for F4/80. No differences were observed in F4/80+ cell staining 
between DR3 sufficient and deficient mice at either day 3 or day 21 post-arthritis 
induction, either in the growth plate, where normal physiological bone remodelling 
occurs or in the inflammatory infiltrate of the adipose tissue. Taken together this 
suggests that the infiltration of F4/80+ osteoclast precursor cells is unaffected by 
DR3 and that the accumulation of TRAP+ cells in the adipose tissue of DR3 sufficient 
mice either represent cells which are predestined to become osteoclasts prior to 
infiltration into the joint or that it is not the F4/80+ osteoclast precursor pool that is 
the important cell type involved in osteoclastogenesis in this model.
DR3 deficiency confers resistance to AIA induced bone destruction but this cannot 
be attributed to a reduction in basal osteoclast numbers or to the recruitment of 
their F4/80+ precursor cells. Data from this chapter suggests, however, that DR3 
may play a role in the differentiation of osteoclasts at sites of inflammation which 
may or may not be derived from F4/80+ cells. The recruitment of cells which may 
be predestined to become osteoclasts in DR3 sufficient mice could also represent 
an explanation for the protection from bone erosion in DR3 deficient animals.
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7.2.4.3 Potential mechanisms for the protection from bone erosion in the absence 
of DR3
As the sole bone resorbing cell, osteoclast expression within the joint was examined 
and an accumulation of osteoclasts at the bone/pannus interface was revealed in 
addition to an accumulation of TRAP+ cells in the adipose tissue in DR3+/+ mice. We 
have also recently shown in an in vitro study that TL1A can promote 
osteoclastogenesis from bone marrow macrophages derived from DR3+/+ mice but 
not DR3_/' mice in the presence of RANKL and M-CSF and also from human PBMC- 
derived monocytes (Bull et al., 2008). This data is particularly interesting as 
preservation of joint architecture is the ultimate goal of RA therapy and, as 
discussed in chapter 6, current anti-TNF therapies are falling short in this aim. 
However, this data raises a lot of questions. For example, is the reduction in bone 
erosion seen in DR37' mice just coupled to the overall reduction in inflammation 
associated with these animals during AIA? Is the increased accumulation of 
osteoclasts within the joints of wildtype mice compared with DR3'/_ mice a 
consequence of reduced infiltration of osteoclast precursor cells or impaired 
osteoclastogenesis in the latter? These issues all require addressing.
In animal models for RA such as AIA and CIA, the degree of inflammation is 
intrinsically linked to the level of joint destruction occurring and it is not easy to 
distinguish between them experimentally. For example using FcyR knockout mice in 
the AIA model, van Lent et al. (2006) noted a direct correlation between the 
severity of bone destruction and the degree of cellular infiltration (van Lent et al., 
2006). Thus the reduction in bone erosion in DR3 deficient mice may be regulated
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by the reduction in inflammatory cells within the joints of these mice rather than 
due to the effect of DR3 on osteoclastogenesis. However, administration of the 
DR3-specific ligand into the joints of DR3+/' mice on day 0 of the experimental 
protocol resulted in a significant dose-dependent increase in bone erosion but no 
dose-dependent or significant effect on cellular infiltration was noted. This implies 
that TL1A exacerbates bone erosion in AIA via a mechanism which is uncoupled 
from cellular infiltration.
The accumulation of TRAP+ mononuclear cells in the adipose tissue of DR3 
sufficient mice either indicates the initiation of osteoclastogenesis at this site 
distant from the bony surface or recruitment of osteoclast precursor cells which are 
already TRAP+ and predestined to differentiate into osteoclasts prior to infiltration 
into the joint. Osteoclast precursor cells can enter osteoclastogenesis and express 
TRAP independent of contact with mineralised tissue (Schett, 2007) and it is likely 
that it is these cells that are seen accumulating in the adipose tissue of DR3 
sufficient animals which have the potential to undergo final differentiation into 
osteoclasts. It is entirely unknown whether or not cells are partially committed to 
osteoclast differentiation prior to entry into the inflamed joint, thus it is difficult to 
comment on whether the accumulation of these cells is due to recruitment. 
However, the effect of the DR3/TL1A pathway on chemokine production indicates 
that there is potential for this system to affect the recruitment of a "predestined" 
osteoclast precursor cell. However, as no difference was observed in F4/80+ cell 
numbers within the AIA joints of DR3 sufficient and deficient mice, the recruitment 
of at least this osteoclast precursor cell appears unaffected by DR3 signalling.
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The process of osteoclastogenesis from osteoclast precursor cells to fully functional 
bone resorbing osteoclasts is well defined. The absence of TRAP positive cells within 
the joints of DR3 deficient mice may be explained via the effect of DR3/TL1A on this 
process. Other members of the TNFRSF have confirmed, although often 
incompletely defined roles in the process of osteoclast differentiation. RANKL for 
example, in concert with M-CSF, is essential for the production of mature 
osteoclasts (Lacey et al., 1998). TNFa, via TNFR1 engagement, is also reported to 
enhance osteoclastogenesis by increasing the size of the osteoclast precursor pool 
via the stimulation of c-fms expression (Boyce et al., 2005), through the induction of 
RANKL on synovial cells, osteoblasts and T cells, and also by directly binding to 
osteoclasts to enhance the effect of RANKL (Schett, 2007). DR3 is not known to be 
expressed on osteoclasts (Borysenko et al., 2006) and the effect of the DR3/TL1A 
pathway on osteoclastogenesis is unknown. We have demonstrated that TL1A can 
enhance osteoclastogenesis from murine bone marrow macrophages and human 
PBMC in the presence of M-CSF and RANKL. However, in the absence of RANKL and 
M-CSF, TL1A could not directly induce osteoclast differentiation (Bull et al., 2008). 
Thus, it seems that TL1A is not an essential factor for osteoclastogenesis but can 
promote it in the presence of RANKL and M-CSF in a DR3-dependent fashion. This is 
similar to the effects of TNFa on osteoclastogenesis. Although reports suggest that 
TNFa can directly drive osteoclastogenesis from precursor cells (Azuma et al., 
2000), such studies have utilised protocols in which the precursor cells would have 
been exposed to RANKL in culture prior to purification. In studies where isolated 
myeloid cells were not previously exposed to RANKL, TNFa was unable to induce 
osteoclastogenesis. However, the addition of subosteoclastogenic levels of RANKL
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(lng/ml) 2-4 days prior to TNFa treatment enhanced osteoclastogenesis (Lam et al.,
2000). This did not occur when RANKL and TNFa were added at the same time. In 
our system, RANKL (50ng/ml) and TL1A were added to the cultures at the same 
time and osteoclastogenesis was promoted which may imply a different effect of 
TL1A and TNFa in the timing of osteoclastogenesis. However, in our system, whole 
bone marrow cell cultures were used and thus osteoclast precursor cells may have 
already been exposed to RANKL resulting in a priming effect. Comparable assays 
would need to be performed in order to assess if TL1A and TNFa enhance 
osteoclastogenesis at different timepoints. The effects of osteoclastogenic factors 
such as TNFa are usually attributed to their ability to enhance RANKL expression on 
stromal cells and osteoblasts (Ross, 2000). The effect of DR3 signalling on RANKL 
expression in these cells has not been examined. However, DR3 is expressed on 
osteoblasts (Borysenko et al., 2006) raising the possibility that its signalling could 
induce RANKL expression on this cell type.
DR3 signalling has recently been linked with Thl7 cell activity, an IL-17 secreting 
helper T cell subset that has published links with bone destruction. It has in fact 
been reported that the presence of either Thl or Th2 cells in in vitro 
osteoclastogenesis assays has no effect on osteoclast differentiation but that Thl7 
cells are the only helper T cell subset capable of enhancing osteoclastogenesis (Sato 
et al., 2006). Using an in vivo model of inflammatory bone destruction, the authors 
have also reported a reduction in bone destruction and osteoclast formation in IL- 
17 deficient mice (Sato et al., 2006). It has been proposed that IL-17 is capable of 
promoting osteoclastogenesis through upregulating the expression of RANKL on
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osteoblasts (Kotake et al., 1999). Thus IL-17 production by Thl7 cells may be 
important in the destructive phase of inflammatory arthritis. DR3 expression on 
Thl7 cells is reported to be greater than that seen on either Thl or Th2 subsets and 
expression of the full length receptor in particular is highly upregulated (Pappu et 
al., 2008). In naive T cells where IL-2 signalling was blocked, TL1A was shown to 
enhance Thl7 cell differentiation and in differentiated Thl7 cell populations, TL1A 
enhanced cellular proliferation. This was confirmed through the use of TL1A 
deficient dendritic cells (DCs) which caused reduced differentiation of naive T cells 
into Thl7 cells and reduced proliferation of Thl7 cells compared with wildtype DCs 
(Pappu et al., 2008). Pappu et al. (2008) further explored the role of TL1A in the 
control of Thl7 cells via the employment of the Thl7 mediated myelin 
oligodendrocyte glycoprotein-induced experimental autoimmune 
encephalomyelitis model in TL1A deficient mice (TLIA^). TL1A_/' mice displayed 
consistently reduced disease severity and reduced T cell infiltration throughout the 
course of the experiment, hypothesised to result from both reduced priming of 
autoreactive T cells and the reduced proliferation of Thl7 cells (Pappu et al., 2008). 
Similarly another research group demonstrated the ability of TL1A to enhance IL-17 
production with and without IL-23 stimulation from mucosal CD4 T cells and 
illustrated a reduction in the clinical outcome of a Thl/Th l7  mediated model of 
colitis following anti-TLlA treatment in which CD4 T cell accumulation was again 
reduced (Takedatsu et al., 2008). However, more recently, Meylan et al 
demonstrated that DR3/TL1A interaction was not required for the differentiation of 
naive T cells into any of the T helper subsets and in the absence of DR3 signalling, T 
cell priming was normal (Meylan et al., 2008). Thus it is possible that DR3/TL1A
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interactions play an important role in the differentiation of Thl7 cells in 
inflammatory arthritis, which in turn cause the upregulation of RANKL on 
osteoblasts leading to increased osteoclastogenesis and bone erosion. However, 
the role of DR3 in the differentiation of Thl7 cells continues to be debated. A first 
step in investigating this hypothesis would be to examine the T cell numbers within 
the AIA joints, examining each of the individual subsets. Additionally, IL-17 
expression could be evaluated in order to indicate whether the DR3/TL1A pathway 
plays an important role in Thl7 cell production and IL-17 mediated bone erosion.
In addition to its potential role in osteoclast formation and function, DR3 has a 
reported role in the control of osteoblast function. Both nontransformed and 
transformed (MG63 cells) human osteoblasts express the full length and soluble 
hDR3 receptor (Borysenko et al., 2006). Activation of DR3 on MG63 cells via cross- 
linking of the receptor is reported to result in apoptosis of cells when seeded at a 
low cell density with minimal cell contact. Addition of TL1A to these cells mediated 
similar effects (Borysenko et al., 2006). Thus DR3 may have a dual role in 
pathological bone turnover in terms of enhancing bone resorption via its effects on 
osteoclasts and through inhibiting bone generation via its effects on osteoblast 
function. By tipping the balance in favour of bone destruction, through an action on 
both osteoclasts and osteoblasts, DR3 may have the potential to significantly 
influence bone destruction during pathological inflammatory states.
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7.2.5 DR3/TL1A expression in the rheumatoid joint
One of the most pertinent questions arising as a result of our data is where and 
when are DR3 and TL1A expressed in the rheumatoid joint and are they related to 
the expression of TNFa? Immunohistochemical staining for DR3 and TL1A in the 
murine AIA joints has not been possible due to both the unavailability of antibodies 
against these proteins and the difficulties associated with immunological staining in 
paraffin-embedded tissues. The construct used to generate the DR3'/_ mice 
contained a LacZ cassette which enables (3-galactosidase expression in those cells 
which normally express DR3 (Wang et al., 2001a). This could be exploited in an 
enzymatic reaction in order to determine DR3 expression in the AIA joint sections of 
DR3 deficient mice. However, enzymatic reactions can also be impaired as a result 
of the paraffin-embedding process and other work within this laboratory has been 
unable to detect (3-galactosidase in these sections to date.
DR3 is expressed on many of the cells which are involved in RA pathogenesis 
including T cells, B cells (Screaton et al., 1997), monocytes, macrophages (Kang et 
al., 2005) and osteoblasts (Borysenko et al., 2006). Additionally analysis of human 
synovial RA tissue by Cassatella et al. (2007) revealed strong expression of TL1A on 
cells with monocyte-macrophage morphology but not on neutrophils, endothelial 
cells or lymphocytes (Cassatella et al., 2007). Thus there is a confirmed presence of 
TL1A within rheumatoid joints and due to the expression of DR3 on multiple 
immune cells, it seems reasonable to assume that DR3 will also be expressed within 
the rheumatoid joint. Whether or not DR3 activation occurs downstream from 
TNFa expression is a matter for debate. A particularly notable finding by Cassatella
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et al. (2007), was that human monocytes released TL1A in response to insoluble 
immune complexes which are also present within rheumatoid synovial fluid but 
that TNFa was unable to stimulate this effect (Cassatella et al., 2007). Additionally, 
the production of TL1A in response to immune complexes occurred with slower 
kinetics than that of TNFa and was unaffected via the administration of anti-TNF 
antibodies (Cassatella et al., 2007). This suggests that TL1A expression may be 
independent of TNFa upregulation. However, Migone et al. (2002) reported the 
upregulation of TL1A mRNA in HUVEC cells following TNFa stimulation (Migone et 
al., 2002). Kang et al. (2005) also reported the upregulation of DR3 expression on 
monocytes when incubated with TNFa but conversely noted the induction of TNFa 
by THP-1 monocytic cells upon stimulation both via DR3 activation and IFNy 
treatment together (Kang et al., 2005). Thus DR3/TL1A and TNFRl/TNFa may have 
a complex relationship in RA which requires further investigation. However, due to 
the presence of DR3 on multiple immune cells and the confirmed expression of 
TL1A within the RA joint, there is scope for involvement of DR3 signalling in multiple 
aspects of the disease process.
7.2.6 Other effects of DR3
Other published effects of DR3/TL1A interaction further complicate the role of this 
ligand/receptor system in models of inflammatory arthritis. Previous DR3 research 
has principally concentrated on its role in T cell function. Due to the original 
observations which suggested that DR3 might have lymphoid restricted expression 
this is hardly suprising. TL1A/DR3 interaction is widely reported to induce IFNy 
secretion from T cells (Bamias et al., 2003, Bamias et al., 2006, Papadakis et al.,
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2005) and TL1A functions as a T cell co-stimulator, increasing T cell responsiveness 
to IL-2 (Migone et al., 2002). In inflammatory arthritis T cells act as an additional 
source of RANKL and supernatant from activated CD4+ T cells can initiate 
osteoclastogenesis (Kong et al., 1999). This may represent a mechanism for 
increased osteoclastogenesis during AIA in DR3 sufficient mice compared with 
DR37 mice. Analysis of the ability of activated DR37' T cells to induce 
osteoclastogenesis would help to elucidate this issue. A published outcome of T cell 
costimulation by TL1A is an increased expression of IFNy. In Crohn's disease for 
example, increased expression of both TL1A and DR3 has been illustrated and it has 
been hypothesised that their increased interaction augments IFNy secretion thus 
sustaining the inflammatory response (Bamias et al., 2003). In models of 
inflammatory arthritis however, IFNy is reported to have anti-inflammatory effects, 
with IFNy deficient mice (IFNy/_) displaying increased susceptibility to CIA 
(Manoury-Schwartz et al., 1997). Additionally, IFNy7' mice display more severe 
degenerative joint changes in response to AIA compared with wildtype controls 
(Williams et al., 2007). Thus the phenotype of DR3 deficient mice during AIA cannot 
be explained by the published role of DR3 and TL1A in the upregulation of IFNy 
expression within the joint.
A further complicating factor in DR3 signalling is its ability to be expressed as 
multiple splice variants. There are 3 DR3 splice variants in mice (Wang et al., 2001a) 
and at least 13 in man (Kitson et al., 1996, Screaton et al., 1997). Bamias et al. 
(2006) have reported differential expression of the murine DR3 splice variants 
throughout lymphocyte activation. In resting T cells, full length transmembrane DR3
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was expressed at a low level compared to total DR3 expression. However, upon 
activation, the ratio of transmembrane to total DR3 expression increased 
significantly (Bamias et al., 2006). Thus DR3 activity in inflammatory arthritis may be 
extremely complicated with expression of the full length signalling receptor being 
upregulated under certain conditions. However, this would be in contrast to the 
work of Shiozawa et al (2000) who revealed an increase in mRNA in RA patients for 
the transmembrane portion of DR3 compared with controls but not in mRNA for 
the death domain portion of DR3, suggesting a complex role for DR3 in RA 
(Shiozawa et al., 2000). RT-PCR analysis of murine knee joints following AIA 
induction may give some indication of the relative expression of the different DR3 
splice variants as a result of this inflammatory disease.
7.2.7 DR3/TL1A as a therapeutic target for RA
The DR3/TL1A pathway is potentially a very attractive target for the treatment of 
RA. Should further studies support our work to suggest that blocking DR3/TL1A 
specifically prevents the joint degeneration associated with RA including erosion of 
the bone and cartilage degradation, then anti-DR3/TLlA therapy may represent a 
breakthrough in the treatment of the disease achieving the ultimate aim of 
preserving joint architecture. However, before such bold statements can be made, 
far more extensive studies need to be carried out in order to assess the in vivo 
effects of blocking this pathway. It has after all taken in excess of 20 years for anti- 
TNF treatment in RA to progress from bench to bedside. Recent work from this 
laboratory has provided the first evidence that inhibiting signalling through DR3 
might prove an effective therapy in the treatment of RA. Using the CIA mouse
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model for RA, which is currently used as the industry standard for assessing 
potential therapies for RA and was used in the discovery of anti-TNF treatment, Bull 
et al. (2008) illustrated that neutralisation of TL1A in wildtype mice through the 
prophylactic administration of a blocking antibody during the CIA protocol resulted 
in reduced disease activity. Paw scores which were clinically assessed on the basis 
of the degree of redness, swelling and the number of joints involved were 
consistently lower in the anti-TLlA treatment groups compared with both isotype 
and PBS treatment controls. When analysed histologically, joints from the anti-TLlA 
treatment group displayed a significantly reduced arthritis index (Bull et al., 2008). 
This data gives the first indication that blocking the DR3/TL1A pathway might be an 
effective treatment in RA and supports our data in the AIA model.
Considering the similarities seen between DR3 and TNFR1 function in models of RA, 
how likely is it that countering the DR3/TL1A pathway might provide a more 
effective therapy than anti-TNF treatment of RA, which is already licensed for use 
with a high degree of success? In the most successful clinical trials of anti-TNF 
therapy during RA, a maximum of 79% of patients achieved an ACR20 response. 
Thus despite the success of anti-TNF treatment, there is scope for improving on it. 
The ultimate aim is to preserve joint architecture by preventing bone and cartilage 
degradation. Although TNFa has reported effects on osteoclast differentiation and 
function, its effects on osteoblasts are unclear. Generally however, human non- 
tranformed and transformed osteoblasts do not respond to TNFa-induced 
apoptosis (Robinson et al., 2007). DR3 on the other hand, according to our data, has 
a potential role in osteoclastogenesis as well as being reported to cause apoptosis 
of osteoblasts under tightly regulated conditions (Borysenko et al., 2006). Thus DR3
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may have a more important role than TNFR1 in pathological bone loss with the 
ability to both enhance osteoclast activity whilst causing osteoblast apoptosis. This 
could result in DR3 blockade being the more effective therapy choice.
Anti-TNF treatment is associated with the onset of infections, most notably 
tuberculosis. Use of all of the currently available anti-TNF agents has a positive 
association with TB incidence. Those using Infliximab for example can be up to 20 
times more likely to develop TB typically from the reactivation of a latent infection 
(Theis and Rhodes, 2008). This reactivation of latent infection following TNFa 
blockade is thought to be caused by reduced recruitment of immune cells in 
response to TB infection, reduced macrophage activation, dysregulation of the 
inflammatory response and a reduction in CD4 cell activity (Ehlers, 2005). Due to 
the ability of DR3 to influence chemokine expression, macrophage activation and to 
initiate both apoptosis and cellular proliferation, it might be reasonable to assume 
that blockade of the DR3/TL1A pathway might confer susceptibility to certain 
bacterial infections. Few studies have been carried out to assess the role of DR3 in 
various infections. However, Meylan et al have shown that DR3 deficient mice 
respond normally to infection with the parasite Toxoplasma gondii in which host 
survival depends upon production of IFNy-producing Thl cells (Meylan et al., 2008). 
Thus at least in this infection, control of the pathogen is not dependent on DR3. 
However, further investigation regarding the effect of DR3/TL1A blockade on 
infection occurrence is required to determine if this potential therapy for RA might 
not be associated with increased occurrence of serious infections.
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Before DR3/TL1A blockade can be considered an effective therapy in the treatment 
of human RA, far more extensive work is required to assess whether this therapy 
would prove more effective than those already available and what the potential 
side effects are of blocking this system. Generation of murine DR3 blocking 
antibodies would greatly enhance this research and could be tested in the CIA 
model for efficacy. An assessment of the responses of DR3 deficient mice to a host 
of infectious agents would also provide a better understanding of the potential 
complications of this therapy. Additionally, translation from murine models to 
human therapies is further complicated by the existence of decoy receptor 3 in 
humans but not in mice, which binds and sequesters TL1A inhibiting its signalling. 
Should this therapy get this far, anti-DR3/TLlA treatment would have to be fully 
evaluated in clinical trials, as occurred during the development of anti-TNF therapy. 
On the basis of current data, the DR3/TL1A axis represents a promising novel target 
in the treatment of RA.
7.6 Final conclusions
This work has shown for the first time an important role of the DR3/TL1A pathway 
in the AIA model of Rheumatoid Arthritis. Blockade of this pathway through gene 
knockout reduces the severity of all of the histopathological changes associated 
with the model, in particular protecting from bone and cartilage erosion. Although 
further investigation is required to fully elucidate the role of DR3 in this and other 
models of RA, our data firmly supports the DR3/TL1A pathway as a potential target 
in the treatment of inflammatory joint disorders.
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Autoimmunity fought in the cortex
In  the best-case scenario, self-attacking T  cells are ousted before they have a chance to  leave the 
thym us. That essential process, w h ich  elim inates autoreactive thym ocytes fro m  the get-go, is kno w n 
to  occur in  the thym ic  m edulla. N o w , on  page 2575, M cC augh try  et al. p rov ide solid evidence that 
this e lim inauon also occurs in  the thym ic  cortex.
A lthough im m unologists have reported T  cell de le tion in  the cortex before, th e ir results were 
made ambiguous by the transgenic m ice models they used. These m ice expressed T  cell receptors 
specific fo r a self-peptide earlier in  developm ent than they are norm ally expressed. O ne  fear was that 
those T  cells were be ing deleted before they had a chance to  m igrate in to  the medulla. T o  quell that 
concern, M cC au gh try ’s team generated a transgenic mouse in  w h ich  the receptors are turned on at 
the appropriate tune. Tu rns ou t, the earlier models were correct.
T  cells reacting to  ub iqu itous self-antigens were deleted in  the cortex alone, before entering the 
medulla. Furtherm ore, the medulla-based transcription factor A IR E , w h ich  mediates T  cell deletion, 
d id  no t seem to  be required in  the cortica l deletions. Local dendritic  cells, however, were needed. 
W ith o u t them , a large fraction o f  autoreactive T  cell clones survived.
The  locale o f  T  cell de le tion may depend on the antigen involved. Tissue-specific self-antigens 
are produced on ly  in  the medulla, whereas ub iquitous self-antigens, such as house-keeping peptides 
and the antigen recognized in  the authors’ mouse m odel, are widespread and can be handled in  the 
cortex, at the site o f  first encounter. N o w  that the question o f  location has been settled, future studies 
can focus on learning ho w  cortica l dendritic  cells con tro l T  cells gone awry.
Death receptor chews up bone
A rth ritis  sufferers m igh t fin d  some re lie f in  a new com pound found to  ease bone damage in  m ice. 
B u ll et al. (page 2457) prevented jo in t  erosion w hen they cripp led a m em ber o f  the T N F  receptor 
supcrfam ily. Death R ecep tor 3 (D R 3 ), by b lock in g  its ligand, T L 1 A .
P atie n ts  w ith  rheumatoid arthritis arc m ore like ly to  have extra copies o f  the gene that codes fo r D R 3 . 
A  causative role for D R 3  u i disease pathology, however, had not been shown. Bull et al. now  find that 
mice lacking D R 3  are freed from  the bone damage usually caused by antigen-induced arthritis. A nd 
blocking T L 1 A  curtailed the bone erosion typical o f  collagen-induced arthritis in mice.
Back m the dish, the team investigated how  this reccptor-ligand pair m ight induce bone destruction 
in  humans. They found that the addiuon o f  T L 1 A  to  ordinary monocytes from  human blood enhanced 
the generation ofbone-resorbing osteoclasts. A lthough how  T L 1 A  leads to osteoclast differentiation is not 
yet clear, its D R 3  receptor s  know n to  activate N F k B, w hich is required for osteoclast formation.
A  few  stones remain un turned in  the hun t fo r vandals, as obstructing T L 1A  d idn t e lim inate bone 
destruction altogether. Soil, the researchers p o in t ou t that the a n t i-T L lA  antibody d id  ameliorate 
m uch o f  the damage.
Pain in the brain
A severe and unusual disorder o ften confused w ith  m u ltip le  sclerosis (M S) has no w  become a litt le  
less mysterious. O n  page 2473. H inson and colleagues demonstrate how  the disease’s distinguishing 
autoantibody disrupts glutamate regulation.
N eu rom ye litis  op tica (N M O ),  also k n o w n  as D e v ic ’s disease, results in  M S -lik e  lesions in  the 
op tic  nerves and along the spine. Y e t u n like  M S. N M O  is associated w ith  p ro d u c tio n  o f  a specific 
au toantibody kn o w n  as N M O - Ig G . C lin ic ians use N M O - Ig G  to  diagnose the disease, bu t they 
d o n ’t  kn o w  h o w  the an tibody contributes to  its symptoms— sight im pa irm en t, paraplegia, and loss
o f  lim b , bladder, and bo w e l sensation.
In  2<X)5, the same g ro u p  id e n tif ie d  N M O - lg G ’s target as a q u apo rin -4 , a w a te r channel 
p ro te in  concentra ted  in  astrocyte mem branes a long the b lo o d -b ra in  ba rrie r. H o w e ve r, the 
f in d in g  was som ew hat p e rp le x in g  because m ye lin  damage occurs on  nerve cells, n o t . o n  
astrocytes. N o w  the team  co n firm s  tha t astrocytes are indeed the re levan t target and show 
h o w  au toan tibod y  b in d in g  can lead to  de m ye lin a tio n . C lu e : w hen  astrocytes h u rt, th e ir  duties
P W hen N M O - Ig G  binds to  aquaponn-4, they show, the levels o f  the astrocyte glutamate 
transporter E A A T 2  drop. A nd  no transporter, no  glutamate regulation. Astrocytes themse ves aren t 
sensitive to  changes in  glutamate levels, bu t neurons and oligodendrocytes are. These cells re ly on
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EAAT2 to mop up excess glutamate from extracellular space. Accumulation o f the neurotransmitter 
can be toxic to myelin-making oligodendrocytes.
After spelling out the pathway in astrocyte in vitro assays, the team examined human tissue. Sure 
enough, N M O  lesions along cadaver spines lacked both aquaporin-4 and EAAT2. Lesions from MS 
patients show no such deficiencies, highlighting another way in which the demyelinating disorders differ.
I f  the groups’ results are confirmed in vivo, drug development could be straightforward. 
Therapeutic trials for glutamate antagonists, created to treat other neurodegenerative diseases like 
Lou Gehrig’s disease (or ALS), are already underway.
Friend to the brain, foe to the spine
Shouting dunng a World Cup match and shouting during a funeral w ill be met with different reactions. 
Context is equally important in a cytokine outburst, find Lees et al. on page 2633. Regional responses to 
interferon-y (IFNy) dictated whether the spinal cord or cerebellum came under fire in mice with EAE, a 
mouse model o f human multiple sclerosis (MS). In other words, both outburst and audience matter.
IFNy, the signature T  helper (Th)-l cytokine, contributes to CNS inflammation during EAE. But 
not all forms o f EAE are alike. In classical EAE, the T  cell attack is focused on the spinal cord. But in 
atypical disease, the cerebellum and brain stem are the primary victims. A  prior study suggested that the 
ratio o f interleukin (IL)-17 to IFNy determines whether disease pathology occurs in the spine or brain, 
w ith increasing levels o f IL-17 associated with disease in the brain. But the data from Lees et al. instead 
show that lesion location is mainly controlled by the brain’s response to IFNy.
When transferred into wild-type mice, the authors show, myelin-specific T h l cells attacked the 
spinal cord. But when transferred into mice lacking the IFN y receptor, the cells instead attacked 
the cerebellum and brain stem, sparing the spinal cord. The production o f IL-17 by the transferred 
T  cells was comparable in both settings. However, the production o f IL-17 by non-T cells 
predominated in the cerebellum, suggesting that IL-17-producing cells contribute to atypical disease 
but do not determine its location.
In agreement w ith past reports, however, transferring mixed populations o f IFNy- and IL -17- 
producing cells resulted in a mixed disease phenotype, w ith increasing numbers o f IFNy producers 
causing progressively more spinal cord disease.
Why IFNy induces inflammation in one tissue and not another remains unknown— particularly 
because no obvious regional differences in the expression o f the receptor were detected. The authors 
suspect that IFNy triggers a localized production o f T  cell—attracting chemoltines in the spine.
Giving imatinib a hand
Researchers have discovered a new a way to make the anticancer drug imatinib more effective. 
By suppressing the oncogene A H l- i , Zhou and colleagues were able to hold chronic myeloid 
leukemia (CM L) in check (page 2657).
Imatinib is currently the most popular targeted therapy for CM L. The leukemia is associated with the 
abnormal fusion o f BCR  with a kinase gene, ABL, which results in a perpetually active kinase known as 
BCR-ABL. Imatinib, a tyrosine kinase inhibitor, slows down the spread o f cancer by blocking BCR-ABL 
activity. But die drug doesn’t work in everyone and patients often relapse, most likely because the drug 
only targets mature cells, leaving C M L stem cells behind. Scientists have therefore been hunting for 
complementary therapies that act on pathways left undeterred by kinase inhibitors.
Mutated versions o f the recently identified protein AHI-1, whose function is unknown, have been 
shown to be highly expressed in leukemic stem cells— the same cells that express BCR-ABL in patients 
with CM L. Here, Zhou et al. show that expressing AHI-1 in stem cells turns the cells cancerous in vitro, 
and these cells caused lethal leukemia when transferred into mice. When expressed in B C R -A B L- 
positive cells, AH  1-1 exacerbated the growth-promoting effects o f the fusion protein.
A H I - l ’s growth-promoting activity was attributed to the ability o f  AHI-1 to bind to BCR -ABL, 
along w ith an activated version o f the downstream signaling protein JAK2. Cells expressing this 
complex were resistant to the kinase-blocking action o f imatinib. Indeed, blocking AH I-1  in cells 
from imatinib-resistant C M L patients restored the cells’ sensitivity to the drug.
W ith  this finding, the race is on to find a drug to block A H I-1 . As other studies have recently 
suggested, the cure for C M L and other leukemias may not he in a miracle drug, but rather in a 
carefully concocted cocktail o f targeted therapies.
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an AHI-1 blocker (red) killed more 
cells from imatinib-resistant CML 
patients than did imatinib alone 
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The Death R eceptor 3—TNF-like protein 
1A pathway drives adverse bone pathology 
in inflammatory arthritis
M elanie Jane B u ll,1 Anw en Sian W illiam s ,2 Zarabeth M ecklenburgh ,1 
Claudia Jane Calder,1 Jason Peter Tw ohig ,1 Carole E lford ,3 
Bronwen Alice James Evans,3 Tania F. R ow ley ,4 Tomasz J. Slebioda,4 
Vadim Y. Taraban ,4 Aymen A l-Sham khani,4 and Eddie Chung Yern W ang 1
'Department o f Medical Biochemistry and Immunology, ‘ Department o f Rheumatology, and ’Department o f Child Health, 
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Rheumatoid arthritis (RA) is a chronic inflammatory disease of synovial joints that is asso­
ciated with cartilage and bone destruction. Death Receptor 3 (DR3), a tumor necrosis 
factor CTNF) receptor superfamily member, has recently been associated with the patho­
genesis o f RA. We demonstrate that absence o f DR3 confers resistance to the development 
of adverse bone pathology in experimental antigen-induced arthritis (AIA). DR3ko mice 
exhibited a reduction in all histopathological hallmarks o f AIA but, in particular, failed to 
develop subchondral bone erosions and were completely protected from this characteristic 
of A IA  In contrast, TNF-like protein 1A (TL1A), the ligand for DR3, exacerbated disease in 
a dose- and DR3-dependent fashion. Analysis o f osteoclast number within AIA joint re­
vealed a reduction in areas susceptible to bone erosion in DR3ko mice, whereas in vitro 
osteoclastogenesis assays showed that TL1A could directly promote osteoclastogenesis in 
mouse and man. Treatment with antagonistic a n ti-T H A  mAb protected animals in a sys­
temic model of RA disease collagen-induced arthritis. We therefore conclude that the 
DR3-TL1A pathway regulates jo int destruction in two murine models o f arthritis and 
represents a potential novel target for therapeutic intervention in inflammatory joint 
disease.
Rheumatoid arthritis (RA) is a chronic inflam­
matory disease affecting ~ 1% of the global pop­
ulation (1). R A  is characterized by infiltration 
o f synovial joints by immune cells, principally 
macrophages, T  cells, plasma cells, and hyper­
plasia o f the synovial lining. This eventually re­
sults in the destructive phase o f disease causing 
damage to cartilage and bone. It is w idely ac­
cepted that cytokines and their receptors play a 
central role in the pathogenesis of R A , thus 
T N F a , IL— 1. and IL - 6  have been identified as 
key mediators o f the disease (2-4). The role 
played by members o f the T N F  receptor super­
family (TNFRSF) in pathological bone resorp­
tion has also become widely accepted, w ith 
R A N K  and R A N K L  acting as crucial factors in 
diff erentiation o f osteoclasts (5), the primary cell 
type involved in bone degradation.
M .| .  Hull and A .S  W illiam s  con tribu ted  equally to  this paper.
D R 3 (TR A M P , LA R D , Apo3, W s ll, and 
TNFRSF25) is a member o f  the TNFR SF and 
shows closest homology to TNFR 1 (6 ). Like 
T N F R 1, D R 3 contains four extracellular cys­
teine-rich repeats and is capable o f signaling 
both apoptosis via caspase 8  activation and cell 
survival via the activation o f N FkB  (7-9). The 
biological function o f D R 3 is an area o f g row ­
ing interest. In the immune system, D R 3  has 
been shown to affect negative selection during 
thymocyte development ( 1 0 ) and can m odu­
late T  cell (11-13) and N K T  cell function (14). 
It has also been associated w ith  inflammatory 
diseases such as irritable bowel disease (15, 16) 
and atherosclerosis (17). Interestingly, I)R 3 ,
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along w ith  its only know n ligand, T N F -like  protein 1A 
(TL1A) (18), has been linked w ith  R A . Duplication o f  the 
D R 3 gene is more prevalent in R A  patients compared w ith 
controls (19), whereas TL1 A* mononuclear phagocytes have 
been identified in rheumatoid synovium and soluble TL1A 
has been detected in synovial fluid o f patients (20). However, 
functional analysis o f the in vivo role o f the D R 3-T L1A  
pathway in R A  has not yet been reported.
To  address this, we have generated mice lacking the DR3 
gene (D R 3 ko) on a C 57B L/6  background (10) and used a 
salient model o f  experimental arthritis to elucidate functional 
aspects o f D R 3  activity. Antigen-induced arthritis (AIA) is a 
local model o f disease which displays many pathological fea­
tures o f R A  including cellular infiltration, synovial hyperpla­
sia, pannus formation, cartilage depletion, and bone destruction 
(21). We show that D R 3 is essential for the development o f 
adverse jo in t pathology in A IA  and that an ti-TL l A treatment 
can protect from  the systemic model o f  disease, collagen- 
induced arthritis (C IA ). These results im ply an important 
in vivo function for D R 3 in the pathogenesis o f inflammatory 
arthritis and provide proof o f principle that countering this 
pathway may represent a novel therapy for RA.
RESULTS AND DISCUSSION
DR3ko mice show reduced inflammatory response to AIA 
compared with DR3"’ controls
To investigate the in vivo role o f D R 3 in inflammatory ar­
thritis, we induced A IA  in D R 3ko mice and D R 3wt controls. 
A ll mice developed an inflammatory reaction in response to 
intraarticular injection o f methylated BSA, w ith both D R 3ko 
and D R 3 wt mice exhib iting a similar pattern o f  jo in t  swell­
ing over a 21-d time course. Comparable knee jo in t swell­
ing measurements were noted in D R 3ko and D R 3wt mice 
at the peak o f  response, 1 d after mBSA injection. There­
after, swelling resolved in both but faster in the absence o f 
D R 3 (Fig. 1 A).
We next assessed whether more rapid resolution o f jo in t 
swelling was translated to improved pathological outcome in 
D R 3ko mice. Examination o f histopathological severity was 
performed on jo in t sections taken during the acute inflamma­
tory phase when T N F a , IL - lf$ , and IL - 6  reach a peak and 
destructive pathology first becomes detectable (3 d after in ­
duction) and when there is maximal evidence o f structural 
damage w ith in  the jo in t (21 d after induction) (21). The se­
verity o f  arthritis (arthritis index [A l]) was quantified in he­
m atoxylin  and eosin (H&E)-stained sections by grading 
parameters as described in Materials and methods. O n day 3 
after arthritis induction, D R3wt (Fig. 1 B) and D R 3ko mice 
(Fig. 1 C) did not differ histopathologically. By day 21, D R 3wt 
mice had developed arthritis characterized by extensive cellu­
lar infiltration, synovial hyperplasia, formation o f a thick pan­
nus, and bone erosions (Fig. 1 D). In contrast, D R 3ko mice 
displayed m ild pathological features o f arthritis, showing gen­
eral absence o f synovial hyperplasia, lack o f  pannus formation, 
and no evidence o f  bone erosion (Fig. 1 E). Indeed, all scor­
ing parameters were either absent or significandy milder in
D R 3ko compared w ith D R 3wt mice (Fig. 1 F). This translated 
into a significant reduction in the A l (Fig. 1 G).
As a second outcome measure o f structural damage to the 
jo in t, we assessed proteoglycan depletion from articular carti­
lage on the femoral head using Safranin O/Fast Green stain­
ing 21 d after arthritis induction. In D R 3wt mice, cartilage 
was severely depleted, as illustrated by lack o f red Safranin O  
staining resulting in an obvious tidemark (Fig. 1 H). D R 3ko 
mice did not display much cartilage depletion (Fig.l I), re­
taining similar levels o f Safranin O  staining as nonarthritic 
control left knees (not depicted). Collectively, this data ind i­
cate that there is considerable protection against degenerative 
A IA  disease pathology in D R 3ko mice.
TL1A exacerbates disease in a DR3-dependent fashion
To confirm  that resistance to A IA  was D R 3 specific, TL1A  
was injected with mBSA on day 0 o f die A IA model at escalating
Figure 1. Protection against AIA in DR3to mice. (A) Joint swelling after 
intraarticular injection of mBSA Data are mean ± SEM from n -  6 DR3*'
(A) or DR3to (■) mice. Two-way analysis of variance (ANOVA) shows signifi­
cance at P < 0.02 (*). One representative experiment of three is shown.
(B—E) Representative images from DR3"' (B) and DR3to (C) mice, 3 d after 
arthritis induction, and DR3*rt (D) and DR3to (E) mice. 21 d after arthritis 
induction. Bars, 200 pm. Inflammatory tissue (black arrowheads) and erosions 
(blue arrowheads) are shown. (F) Breakdown of each component of the Al. *, 
P < 0.05; **, P < 0.01. (6) Al scores from DR3*rt and DR3to mice." ,  P < 0.01. 
Lines mark means of graphed points. (H and I) Representative images of 
collagen around knee joints from DR3"" (H) and DR3to (I) mice. Sections 
were stained with Safranin 0/Fast Green to visualize collagen in red. Tidemark 
of cartilage depletion (arrows) is shown. Bars, 50 pm. (J) Estimated cartilage 
depletion from DR3"* and DR3to mice. *, P < 0.05. Each point in the sum­
mary graphs represents a single 6 DR3,rt (A) or DR3*° (■) animal.
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quantities up to 100 ng. D R 3bc' mice were chosen as they 
showed intermediate A l scores compared w ith D R 3wt mice 
(Figs. 1 G and 2 A). Consequendy, exacerbation or ameliora­
tion o f disease after T L1A  in jection could be quantified, 
irrespective o f the inherent variability in the model. Coad­
ministration o f TL1A  resulted in significant dose-dependent 
exacerbation o f  disease in D R 3h*t mice (Fig. 2 A). This was 
strikingly illustrated by the effect on size o f bone erosions and 
severity o f  bone destruction, which increased in a dose- 
dependent fashion after TL1A  in jection (Fig. 2, B and C). 
In contrast, T L 1 A  had no significant effect on arthritis 
progression in D R 3 ko mice over the concentration range 
studied (Fig. 2 D). Representative images o f D R 3ko mice re­
ceiving 1 and 100 ng TL1A  show the continued absence o f  
bone erosions (Fig. 2, E and F). TL1A therefore exacerbates 
A IA  and, in particular, adverse bone pathology in a D R 3- 
dependent manner.
DR3 expression promotes osteoclastogenesis in AIA
Because D R 3ko mice were protected from the development 
o f  subchondral bone erosions in A IA , we elected to quantify 
the number o f  bone-resorbing osteoclasts w ith in  the jo in t at 
two distinct sites o f epiphyseal bone. Osteoclasts are clearly 
visualized as large red multinucleated cells w ith tartrate-resis­
tant acid phosphatase (TRAP). TR A P  expression in D R 3wt 
and D R 3ko mice was comparable in the femoral head (Fig. 3, 
A -C ) and growth plate (not depicted). However, in the peri­
osteum at areas adjacent to pannus formation, where focal 
bone erosions could be visualized at high magnification, 
T R A P  staining was significandy greater in D R 3wl mice than 
at equivalent areas in D IO 110 mice (Fig. 3, D -F). These data 
implicate a role for D R 3 in generation o f osteoclasts at sites 
o f bone pathology but not in influencing osteoclastogenesis 
in areas away from the pannus.
Figure 2. TL1A promotes adverse bone pathology of AIA in a DR3- 
dependent manner. (A) Al with increasing administration of TL1A in 
DR3'*’ mice. Horizontal lines mark means of graphed points. Open 
symbols represent DR3'*’ mice; filled symbols represent DR3to mice.
(B and C) Representative images from DR3hrt mice with no (B) or 100 ng 
(C) TI1A added. Bone erosions (arrowheads) are shown. (D) Al with 
increasing administration of TL1A to DR3‘° mice. (E and F) Representative 
images from DR3to mice with 1 (E) or 100 (F) ng TL1A added. Bars, 200 
pm. One-way AN0VA showed significance of TL1A addition to DR3hrt but 
not DR3“  mice. *. P < 0.05. Each point in the summary graphs represents 
a single animal. One representative experiment of two is shown.
DR3ko mice show normal myeloid infiltration within 
joints in AIA
Recruitment o f mononuclear cells to the subintimal synovial 
lin ing layer and to periarticular adipose tissue adjacent to the 
meniscus is a process characteristic o f the A IA  model and R A  
patient joints. Indeed, the degree o f macrophage (osteoclast 
precursor) infiltration w ith in rheumatoid jo in t has been cor­
related w ith severity o f structural damage in human disease. 
T o  assess whether reduction in osteoclast number was caused 
by impaired recruitment o f these cells to the jo in t, we per­
formed immunohistochemical analysis o f  F4/80 expression 
in sections from D R 3ko and D R 3wt mice on days 3 and 21 
after arthritis induction. O n day 3, some F4/80 expression 
was detected in the periarticular adipose tissue, which did not 
differ significantly between D R 3wt and D R 3ko mice (Fig. 3, 
G -I). By day 21, F4/80 staining was markedly increased w ith 
strong F4/80 expression visualized microscopically in both
DR3wt DR3ko
Figure 3. TRAP and F4/80 expression in joints of DRS’'’ and DR3ko 
mice. Sections were stained for TRAP or F4/80 as described in Materials 
and methods. Horizontal lines mark means of graphed points.
(A and B) Representative images of TRAP staining at day 21 after arthritic 
induction from DR3,rt (A) and DR3to (B) mice. Red TRAP* staining (arrows) 
is shown. (C) Summary of TRAP staining in femoral head at day 21.
(D and E) Representative images of TRAP staining around areas of bone 
erosion at day 21 after arthritic induction from DR3"* mice (D) and 
equivalent areas from DR3to mice (E). Red TRAP* staining (arrows) is 
shown; js, joint space; p. pannus; c, cartilage. (F) DR3to mice show signifi­
cantly reduced TRAP* staining compared with DR3wt mice. *, P < 0.05.
(6 and H) Representative images of F4/80 staining from DR3'" (G) and 
DR3to (H) mice, 3 d after arthritis induction. (I) Summary of day-3 data.
(J and K) Representative images of F4/80 staining from DR3"1 (J) and 
DR3to (K) mice, 21 d after induction of arthritis. F4/80-positive cells 
(arrows) are shown. (L) Summary of day-21 data. Each point in the 
summary graphs represents a single DR3"1 (A) or DR3k0 (■) animal.
Bars, 50 pm. One representative experiment of two is shown.
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D R 3ko and D R 3wt niice. Quantification o f F4/80+ cells again 
revealed no significant difference in expression between D R3WI 
and D R 3ko mice (Fig. 3, J—L). Overall, these data suggest that 
absence o f D R 3 does not impair recruitment o f myeloid cells 
to the jo in t, nor does it affect overall numbers o f basal mature 
osteoclasts in the femoral head. Neither hypothesis can ex­
plain the reduction in osteoclast numbers in areas o f bone pa­
thology in D R 3 ko mice.
TL1A promotes osteoclastogenesis in vitro in a DR3- 
dependent fashion
We therefore tested the possibility that TL1A  could directly 
prom ote d iff erentiation o f osteoclasts. T o  achieve this, we 
used an in v itro  system o f osteoclastogenesis from adherent 
BM-derived cells (BMC). BM macrophages (BM M ) from 
D R 3wt mice were confirmed to express D R 3 (Fig. 4 A). BM C 
from D R 3"* and L)R3ko mice did not differ in their ability to 
generate osteoclasts in the presence o f soluble R A N K -L  and 
M-CSF as measured by the formation o f multinucleated TRAP" 
cells (Fig. 4 B). However, TL1A addition significandy en­
hanced development o f  osteoclasts from  D R 3 W* but not 
D R 3ko B M C  (Fig. 4, B -D ). TL1A in the absence o f R A N K - 
L and M-CSF could not generate osteoclasts (Fig. 4 E). The 
functional capacity o f in vitro-generated osteoclasts to de­
stroy bone was visualized by toluidine blue staining o f pits in 
the ivory discs (Fig. 4 F). This data indicates that TL1A is not 
necessary for osteoclastogenesis per se, but promotes it in the 
presence o f R A N K -L  and M-CSF and in a DR3-dependent 
fashion. In support o f  our murine data and highlighting the 
significance o f these results for humans, TL1A significandy 
promoted osteoclastogenesis from monocytes derived from 
human peripheral blood (Fig. 4 G).
Anti-TLl A neutralizing antibody ameliorates AIA and CIA
To test the therapeutic potential o f countering the D R 3-TL1A  
pathway, we generated an antagonistic rat inAb to murine 
TL1A (Fig. 5, A and B) and applied it in A IA  and the systemic 
model o f disease. C IA  is the industry standard for testing poten­
tial therapeutic agents against RA. A  single treatment o f anti- 
TL1A at the point o f arthritic induction in A IA  resulted in 
more rapid resolution o f swelling that mirrored our observa­
tions in DR3ko mice (Fig. 5 C). In CIA, clinical signs o f arthritis 
became apparent in control mice on day 25 (Fig. 5 D). Disease 
activity was assessed by assigning scores to each paw according 
to degree o f redness, swelling, and jo in t involvement. Paw 
scores in anti-TL l A-treated mice were consistently lower than 
in control IgG2a-treated mice, reaching significance on days 27 
and 28 (Fig. 5 E). Disease activity in control IgG2a-treated 
mice was characterized by leukocyte infiltration o f synovial tis­
sues and variable degrees o f bone erosion (Fig. 5 F). Specimens 
from anti-TL l A-treated mice demonstrated mild changes by 
comparison (Fig. 5 G). The A l in an ti-TL l A-treated mice was 
significandy less than in IgG2a-treated controls (Fig. 5 H). 
These data are consistent with the protection against A IA  ob­
served in D R 3ko mice and suggest that countering the D R 3 - 
TL1A pathway may be therapeutic against R A  in man.
The role of the DR3-TL1A axis in driving adverse bone 
pathology in inflammatory arthritis
O ur findings show that D R 3ko mice are resistant to the ad­
verse jo in t pathology that is typical in A IA  and are consistent 
w ith an essential role for the D R 3—TL1A pathway in devel­
opment o f inflammatory arthritis. DR3ko mice elicited an 
initial inflammatory reaction in response to A IA  induction, 
such that at day 3 after arthritis induction, there was no dif­
ference in histopathologjcal scoring or level o f inflammatory 
cell infiltrate between control and D R 3ko mice. Resolution 
o f inflammation, however, occurred at a faster rate in D R 3ko 
mice, as indicated by reduction in jo in t swelling over the 
course o f  the study and reduction in all histopathological pa­
rameters measured at day 21 after arthritic induction. O f par­
ticular note was the absence o f bone erosion and marked 
reduction in cell infiltrate in D R 3ko mice in later stages o f 
disease. Comparable numbers o f infiltrating F4/80+ macro­
phages were present in joints o f  D R 3wl and D R 3ko mice, de­
spite the observed differences in jo in t pathology. Therefore, 
the mechanisms involved in  initiating the inflammatory reac­
tion and in recruitment o f  myeloid cells into the jo in t appear
■
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Figure 4. TL1A promotes DR3-dependent in vitro osteodastogen-
esis. (A) RT-PCR of DR3 in BMM. In vitro osteoclastogenesis assays were 
performed as described in Materials and methods. Osteoclast numbers 
were estimated by counting multinucleated TRAP* cells. (B) Effect of TL1A 
on proportion of osteoclasts generated in presence of RANKL and M-CSF. *, 
P -  0.0003. Each point represents a single ivory disc from experiments on 
DR3"rt (open symbols) or DR3*10 (filled symbols) mice. Four discs from four 
mice were counted for each treatment Lines mark means of graphed 
points. One representative experiment of two is shown. (C-E) TRAP stain­
ing of BM cells from DR3*rt mice on discs with RANK-L + M-CSF and no 
TLlA (C) or 10 ng/ml TLlA (D) and TL1A (E). but no RANKL and M-CSF 
Bars, 50 pm. (F) Toluidine blue staining of ivory discs showing pit-forming 
ability of osteoclasts generated in vitro. Bar, 150 pm. (G) Effect of TLl A on 
osteoclastogenesis from adherent human peripheral blood mononuclear 
cells and proportion of osteoclasts in cultures shown with (V) or without 
(▲) exogenous TLl A added. P -  0.0013. One representative experiment 
of two is shown.
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Figure 5. Early therapeutic intervention with anti-TLl A antibody 
arrests development of arthritis. (A) Binding of rat anti-THA mAb (TAN 
2-2} to J558L cells transfected with plasmid encoding membrane-bound 
TL1A. Shaded histogram and dotted line represent binding of isotype con­
trol and TAN 2-2 to plasmid only transfected cell* respectively. Binding of 
isotype control and TAN 2-2 to TLl A-expressing cells is represented by a 
thin and thick line, respectively. (B) Titration of TAN 2-2 binding to J558L 
cells expressing membrane-bound TL1A (C) Time course of swelling in AIA 
after anti-TL1A mAb treatment Data are mean ± SEM from mice treated 
with control lgG2A (A) or anti-TLIA (V) mAb. One representative experi­
ment of two is shown. *, P < 0.02 by two-way ANOVA. CIA was induced as 
described in Materials and methods All data were derived from six mice 
for each treatment (D) Arthritis incidence tabulated over 28-d time 
course. (E) Arthritis severity as a mean paw score from day 20 when dos­
ing schedule for anti-TLl A and control lgG2a was started. Data are mean ± 
SEM. Timing of injections are shown (arrows). (F and G) Representative 
images of H&E-stamed sections from control lgG2a (F) and anti-TLl A
(G). /. intense synovial infiltration; e. aggressive bone erosion. Bar* 200 pm.
(H) Analysis of Al of CIA in control lgG2a and anti-TLIA-treated mice. 
Dotted horizontal line depicts mean for each group. \  P < 0.05; **. P -  
0.01;***. P - 0.006.
intact in the absence o f DR3. Because o f this, we chose to 
investigate differentiation o f osteoclasts, discovering that os­
teoclast differentiation in vitro and bone erosion in vivo was 
exacerbated by exogenous T L l A in control but not D R 3ko 
mice. These DR3-dependent effects confirm that T L l A  is a 
specific functional ligand for D R3 and identifies the control 
o f  osteoclasts as a novel function for DR3. The potential o f 
countering the D R 3-T L1A  pathway as a therapy was proven 
by amelioration o f C IA  and A IA  using a neutralizing anti- 
T L IA  mAb. Interestingly, an ti-T L IA  therapy was not totally 
protective. The possibility remains that there may be second­
ary ligands for D R3 and T L l A  as implicated for T L l A by re­
cent data in renal inflammation (2 2 ), but detailed studies have 
shown no other TNFSF/TNFRSF family members that bind 
murine D R 3 or murine TL1A (18), whereas human TL1A 
binds Decoy Receptor 3 (11), a mouse homologue o f which 
has not been found.
This is the first paper reporting that signaling through 
D R 3 on myeloid cells promotes osteoclastogenesis, although 
it is clear from our data that it is not a prerequisite for, nor can 
it induce, this differentiation in the absence o f R A N K -L  and 
M-CSF. In this respect, it mirrors functions that have been 
reported for T N F a  (23). However, a function independent o f 
TN F a  is suggested by a recent paper showing that macro­
phages produce T L l A independent o f  T N F  activity (20). 
T L l A expression, including release o f active soluble forms o f 
the protein, can be induced on human monocytes by FcyR 
stimulation through soluble (24) and insoluble immune com­
plexes purified from R A  synovial fluid (20). The majority o f 
stromal macrophages in R A synovial tissue express T L l A, and 
in vitro stimulation o f monocytes w ith PEG precipitates from 
R A  samples results in production o f nanogram quantities o f 
soluble TL1A (20). This suggests very high levels in localized 
R A  jo in t akin to the levels we used to exacerbate AIA (Fig. 2 A). 
The implication is that in inflammatory arthritis, myeloid 
cells may exhibit a positive feedback loop whereby T L l A  is 
triggered through ICs and can drive differentiation o f bone- 
destroying cells i f  the right cytokine milieu is provided. In- 
triguingly, T L l A also has varied effects on human osteoblast 
cell lines in vitro, inhibiting differentiation and promoting 
quiescence at low  densities but inducing death at high den­
sities (25). We therefore propose that the D R 3-T L1A  path­
way may act as a switch that is capable o f direcdy activating 
osteoclast but also inhibiting osteoblast differentiation and, in 
so doing, disregulate the homeostatic balance o f degradation 
and formation in normal bone into the detrimental situation 
observed in destructive bone pathologies such as RA. Although 
our in vitro data supports this proposal, some caution is neces­
sary in interpreting the contribution o f direct TL lA -driven 
osteoclastogenesis to arthritic bone damage in vivo, as inflam­
mation and bone erosion cannot be dissociated in A IA  or CIA. 
The possibility remains that the resistance o f D R3ko mice to 
bone erosion is secondary to D R3—TLlA-dependent control 
o f other parts o f the inflammatory process.
In this respect, our data also show that cartilage depletion is 
significandy reduced in DR3ko mice (Fig. 1). Cartilage depletion
-♦ -A n ti-T L IA  
“ ♦ -C o n tro l lgG2a 
V  Lp. Treatment
20 22 24 26 28
Days Post 1st l.d. Collagen Injection
Control lgG2A
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is attributed to the efforts ot matrix metalloprotemases (MMPs), 
levels ot which are raised in R A  jo in t. In v itro  experiments 
on human cell lines have shown that 1)R3 activation can in ­
duce the production o t'M M P -1 , 9, and -13 in T H P -ls  (17).
I hese MM Ps have all been associated w ith  R A  jo in t pathol­
ogy (26). In addition, it is also established that T L l A plays an 
important role in T  cell function. T L l A has been shown to 
costimulate IL. 2  responsiveness ( 1 1 ) and synergize w ith  the 
I C R and 1L 12/ IL 18 pathways to induce IF N 7  release (15, 
27, 28) I I 1A also amplifies cytokine release by N K T  cells 
(14) and I cells (13) and regulates the development o fp ro in - 
tlamniatory Ih l7  cells (12, 16), which are reported to aid os 
teoclastogenesis in autoinunune arthntis (29). The action o f 
T L l  A 011 T  cells mav also be regulated by differentia l ex 
pression of splice variants o f l)R 3  (27). The exact role o fT L l A 
and D R 3 on lymphocytes 111 inflammatory arthntis remains 
to be elucidated, but it is interesting to note that we find nor 
mal anti-niBSA Ab levels 111 serum, unchanged T  cell prolifer 
ation to 111BSA 111 draining lymph nodes ot D R 3 k'° mice after 
A IA  induction, and normal 111 v itro  generation o f T i l l  7 cells 
from I)R 3 L" splenocytes (unpublished data).
In summary, we have induced inflammatory arthntis in 
I )R 3 k” mice and found that they exhibit strong resistance to 
the adverse pathology observed 111 A IA . We show D R 3-de- 
pendent T L lA -d n v e n  exacerbation o f bone damage in vivo 
and prom otion ot osteoclastogenesis 111 vitro. We also show 
that a n ti-T L l A therapy ameliorates disease. O ur data suggest 
that the D R 3-TL . 1A pathway is an important component o f  
inflammatory responses 111 jo in t disease and, as such, identifies 
a potential therapeutic target for treatment ot diseases like 
R A  but w ith  potential impact 111 other diseases involving dis­
rupted bone physiology.
MATERIALS AND METHODS
Animals. I he D R 3  m o u s e  c o lo n s  was fo u n d e d  fro m  an im a ls  s u p p lie d  bv  
t  j m e r  R e se a rch  L 'K .  I o n d o n  A l! e x p e rim e n t-, ssere u n d e rta k e n  in  m a le  
W  I if ) R  3 “ ') .  h e te ro z y g o u s  i D R  V"1), and  K O  ( I ) R 3 k ’) m ic e , w h ic h  h a ve  
K een describes! p re v io u s ly  (l<>). I )U A  l |  m ic e  w e re  a c q u ire d  fr o m  H a r la n .  
L 'K  A n im a ls  w e re  used at (>-S w k  o f  age. A ll p ro c ed u re s  w e re  a p p ro v e d  bs 
th e  I oval R e s e a rc h  E th ics  C o m m it t e e  and  p e r fo rm e d  in  s trict a cc o rd a n ce  
w ith  H o m e  C )t fu  e -a p p ro x  ed licenses P P E  3 d  l l>‘D  and 3<l 2 3 < il.
In d u c tio n  o f  m u r in e  A IA . A I A  was in d u c e d  as p re v io u s ly  described  ( 3 0 .  
In  b n e t, m ice  w e re  s c im m u n iz e d  on  tw o  occasions, 1 w k  apart, w ith  1 m g  m l 
m B S A  w ith  an eq u al v o lu m e  o f  C E A  A n  a d d itio n a l 1 p  in je c t io n  o t 1 <KI p i 
o f  h e a t - in a c t iv a te d  K'rJtU 'ILi perilous to x in  was a d m in is te re d  w ith  the  first 
im m u n iz a t io n  A I A  w as in d u c e d  in  th e  h in d  r ig h t k n e e  jo in t  v ia  an m tra a r -  
tic u lar m ie c t io n  o t In  m g  m l m B S A  d> ph. a d m in is te re d  21 d afte r th e  in it ia l  
im m u n iz a t io n  Eo assess th e  e tle c t o f  I I  1A  o r an ti I I IA  a d m in is tra tio n . 
A IA  was in d u c e d  v ia  111 U S A  in je c t io n  111 c o n ju n c t io n  w ith  1. In .  o r 1UU ng  
o f  so lu b le  I f  1 A  ( R A  I ) Ss stems 1 o r  1« H) ng  o t a n ti-  I I I A  m A h
G en era tio n  o f  a rat an ti m ouse T L l  A  m ono clona l a n tib o d y . R a ts  
w e re  im m u n iz e d  w ith  a s o lu b le  re c o m b in a n t I M A  p ro te in  consis ting  o t a 
h u m a n  Ig G  I lc  d o m a in , w ith  an a d d itio n a l h in g e  lik e  re g io n  at the  C  ter  
m in u s , l in k e d  to  th e  e x tra c e llu la r  d o m a in  o t m ouse  I L I A  ( 1 7 7  I 2 3 2 ) 1 fie  
p ro te in  was p ro d u c e d  m  C h in e s e  ham ster ovary  cells and was p u r if ie d  bs 
l im iu m o a lf im ts  c h ro m a to g ra p h s  us ing  an a n ti h u m a n  Ec m A h  A n t i I I  I A  
m A h  was g e n e ra te d  bs standard h x b r id o m a  te c h n o lo g y  and h v b r id o m a  su- 
[K-rnatants w e re  sc re en e d  tor b in d in g  to  re c o m b in a n t so luble and m e m b ra n e -
expressed T L l  A . T o  ge n era te  cells express ing  m e m b ra n e -a n c h o re d  11.1 A . 
P C R  fra g m en ts  e n c o d in g  th e  e n tire  c o d in g  sequence o f  m ouse  I ’L l  A  w e re  
c lo n e d  in to  th e  m a m m a lia n  expression vectors pE .El 'V 5 - H is  A  and  p c D N A 3 . 1 
( In v it r o g e n ) ,  and  p lasm ids w e re  th e n  transfected in to  J 3 5 8 L  o r  2 9 3 1  cells. 
S tab le  J 5 3 8 L  cell lines express ing  m e m b ra n e -a n c h o re d  T L .l A  w e re  selected  
111 G e n e tic in  (4<XJ p g  m l)-c o n ta in in g  m ed ia . S p len ic  c D N A  o r  IM A G E  c lon e  
3<)74<>8()2 w as used as a te m p la te  fo r  l * C R  reactions to  g enera te  E L I A - e n -  
c o d in g  D N A  frag m en ts , f u r t h e r  se lectio n  o f  n e u tra liz in g  a n t i - T L I A  in A b s  
w as based 011 th e  a b ility  to  b lo c k  b in d in g  o f  so lub le  re c o m b in a n t E L IA -E c  
to  a n t i - C I ) 3  'C l  )2 8 -s t i in u la te d  I cells.
A n t i - T L IA  therapy in  C IA . C I A  was in d u c ed  as p re v io u s ly  described  
(3 1 ) .  In  b r ie t , 2  m g  m l o t c h ic k e n  ty p e  I I  co llagen  ( t i l l ;  S ig m a -A ld n c h ) was  
e m u ls if ie d  w ith  an equal v o lu m e  o f  c o m p le te  E reu n d  s a d ju va n t and 1(H) pi 
o t c o lla g e n  a d ju v a n t m ix tu re  in je c te d  ln tra d e rm a llv  in to  several sites near the  
base o f th e  ta il o t 7 -v v k -o ld  m a le  D B A  '1 |  m ice . A  second id en tica l booster  
was a d m in is te re d  to  eac h m ouse  21 d a lte r the first in je c tio n . I he day o t the  
first im m u n iz a t io n  w as designated  as day 0 . M ic e  w e re  ra n d o m ly  assigned to  
o n e  o t th re e  tre a tm e n t g roups 011 day 2 0 . A n im a ls  re ce ive d  n in e  da ily  l(M )-p ] 
in je c tio n s  c o n ta in in g  e ith e r  2 5 m g /k g  of a n t i - T L I A  o r  L E A L  p u n f ic d  c o n ­
tro l rat lg G 2 a  (C a m b r id g e  B iosciences) dissolved 111 s terile  BBS o r  P B S  alone  
a d m in is te re d  by  th e  i.p . ro u te  fro m  day 2 0 . T h e re a fte r , a rth n tis  in c id e n c e  
a nd  seven ty  was assessed da ily  u n til te n m n a tio n  011 day 2 8  w h e n  th e  disease 
seven ty  lim its  w e re  a tta in e d  111 IgC>2a and  PB S  contro ls . T he in c id e n c e  o f  
C I A  w as assessed as th e  p e rce n ta g e  o t m ic e  d e v e lo p in g  a rth n tis  a m o n g  all 
m ic e  T h e  seven ty  o f  a rth n tis  111 each p a w  (p a w  score) was e va lu a ted  by using  
an established 111-h o u s e  s co n n g  system it. n o n n a l. 1, m ild  b u t d e fin ite  s w e ll­
in g  111 th e  a n k le  o r  w n s t jo in t  o r  redness and s w e llin g  lim ite d  to  in d iv id u a l 
d ig its  regardless o t th e  n u m b e r  o t d ig its  a ffected; 2 . m o d e ra te  s w e llin g  o f  an­
k le  o r  w n s t; 3 , severe  redness and  s w e llin g  o t th e  an kle  o r  w n s t and  p ro x im a l 
ph a lan g ea l Jesuits, a nd  4 , m a x im a lly  in fla m e d  lim b  w ith  in v o lv e m e n t o t m u l­
t ip le  jo in ts , n o  ankylosis .
Assessment o f  arth ritis . J o in t s w e llin g  was assessed on  days 1, 2 . 3 . 5 , 7 , 
14. and  21 a lte r  a n im u s  in d u c tio n  bv  m c as u n iig  the d iffe re n ce  b e tw e e n  h in d  
n g h t  ( A IA )  and  h in d  left (c o n tro l)  k n ee  jo in t  d iam eters  using an an alo g u e  
in n  r o m e te r  A n im a ls  w e re  k il le d  on  day 3 o r 21 to r  assessment of in f la m m a ­
to ry  and  p a th o lo g ic a l changes w ith in  th e  jo in t .  H is to lo g ic a l assessment w as 
p e rfo rm e d  as p re v io u s ly  d esenbed  (3 0 ) A ll |om is  w e re  fix e d  111 n e u tra l b u f f ­
e red  to rm a l saline a nd  d e ca lc ifie d  w ith  K f  u to n n ic  acid  to r  2  w k  at 4 ° C  b e ­
fo re  e m b e d d in g  111 pa rathn  w a x . S ena l sections o t 7 -p n i  th ickness w e re  taken  
and sta ined  ro u tin e ly  w ith  H A L  fo r  analysis. Esso b lin d e d  in d e p e n d e n t o b ­
servers scored  the  sections tor cellu lar in filtra tio n  ( 0 -3 ) ,  ce llu lar e xu d a te  ( 0 - 3 ) .  
s yn o v ia l hyperp las ia  ( 0 - 3 ) ,  and  b o n e  e rosion  ( 0 - 3 ) ,  w ith  0  re p re s e n tin g  a 
n o rm a l jo in t .  T h e  sum  o t all param eters  gave the  A L  S ections w e re  a d d it io n ­
a lly  s ta ined  w ith  S afran in  O  and East G re e n  to  assess cartilage  d e p le tio n .
R T -P C R . B M M  w e re  ge n era te d  as p re v io u s ly  dese n b e d  (3 2 ) . R1S .A  was  
e xtrac ted  fro m  B M M  cultures using R N e a s y  ( Q I A G E N )  after m a n u fa ctu rer's  
in s tru c t io n s , w h e re a s  c D N ’A  was g e n e ra te d  a nd  R T - P C R  p e r fo r m e d  a c ­
c o rd in g  to  standard In v itro g en  protocols. I * C R  prim ers w ere  as fo llow s: (4-actin , 
fo rw a rd  5 ' - C G G C C A G G T C A T C A C T A T T G - 3 '  and  reverse 3 ' - C  E C A G -  
E A A C C C G C C  T A G - 3 ’ g iv in g  a 4 1 0 -b p  p ro d u c t;  a n d  1 ) R 3 .  fo r w a r d  
5 ’ - C ' I  A A G G C T T G C A C T G C E G T C T - . V  and reverse 3 ' G A G C A T C I  
C A  E A C  E G C  E G G  E C -3 '  g iv in g  a 4 5 7 -b p  p ro d u c t. Ehe P C R  consisted ot 
3 3  cycles w ith  a 5 9 ° C  a n n e a lin g  te m p e ra tu re .
T R A P  staining fo r osteoclasts, l o r  E R A P  s ta in in g , jo in ts  w ere decalci 
n ed  m  E D E A  (7"u), r r h v d r a tr d .  and  in c u b a te d  w ith  I R A P  s ta in in g  s o lu tio n  
1 o n ta m m g  "  1 M  ace tate  b u tle r , 0  5 M  s o d iu m  ta rtra te , 10 m g  m l n a p h th o l 
A S - M X  p h o s p h a te , 1(H) 1 r ito n  X  1(H), and 0 .3  m g  m l la s t  R e d  V io le t
I B salt to r  3 h at 3 7 ° C .  S ections w e re  th e n  io u n te rs ta m e d  w ith  h e m a to x y lin  
b e fo re  m o u n t in g  111 D P X .  Im a g e s  w e r e  c a p tu re d  u s in g  a d ig ita l  c am e ra  
( N 4 5 7 ;  O lv m p u s ) .  and  E R A P  p o s itiv e  cells w e re  a n aly zed  us ing  P h o to s h o p  
(  S 3 5 (A d o b e ) R a n d o m ly  chosen selected  areas w e re  used to r  analysis
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Im m u n o h is to c h e m is try  fo r F 4 /8 0  expression. P4 80 express ion  was  
d e te c te d  us in g  an a n t i - r a t  H R P - D A B  s ta in in g  k it  ( R A D  System s) a cc o rd in g  
to  th e  m anutas  H ire r's  in s tru c tio n s . In  b n e f. sections ssere re h v d ra te d  and  e n ­
d o g e n o u s  p e ro x id a se  a c t iv ity  ssas b lo c k e d  A n t ig e n  u n n ia s k in g  was achieves! 
bs i iK i ib a tm g  th e  sections in  o . | " „  press a rm e d  I r s jn in  h i )  I A  in P B S  fo r  
.V) n u n  at d ’ M  A f te r  b lo c k in g  steps, sections ssere incu bates ! o v e rn ig h t  
ss ith  4 j.ig m l s>t rat a n ti 1 4  8 0  antibosls ( In v it r o g e n )  o r  iso tvpe  c o n tro l d i-  
lutes! in  I ’ BS tollsisscs! bs scssmslarx a n tib sx lv  as pe r th e  m a n u fa c tu re r 's  in -  
s tru s tio n s  I ’o s itive ls  labeles! sells ssere visualizes! u s in g  a s trep tav is lin -1  ! R I ’ 
s o n ju g a te  j i k !  D A B  s h r o m o g e n  S e c tio n s  ssere s o u n te rs ta m c s ! ssith  h e ­
m a to x y l in .  s lchssira tes!. ans! m o u n te r !  in  D P X  Im a g e s  ssere c ap tu res ! us ­
in g  a d ig ita l  s a m c ra  i N 4 5 M .  ails! 1 4  So p o s it iv e  cells  ss e re  a n a lv /e s i u s in g  
P h o to s lio p  K a n s lo m ls  seles tesl areas ssere uses! to r  analysis.
In  v itro  osteoclastogenesis assays. B M C ' ssere re m o v e d  fro m  fem u rs  o f  
I >R  4 “’ ans! I >R  P  m ic e  bs s e n tn tu g a tio n  a tte r re m o v a l o t th e  p ro x im a l e iu ! 
B M C  ssere resuspeiislesi 111 si M !  M  s u p p lem e iites l ssith l i r „  I C S ,  2 m M  i -  
g lu ta m in e . ails! a n tib io tis s  i M I . M  lo )  a nd  5 < I O ' cells aslslesl ts) ivo ry  sliscs. 
A tte r  2 h at 4 "  C'. n o n a s lh e ren t s ells ssere re m o s e s i bs transfer o t Ivo rs  sliscs 
to  ness ssells ssith tresh m esiia  s u p p lem e iites l ssith 5 0  n g  m l R A N K L  ails! 
2 5  ng  m l M  C S I ssith  sir s s ith o u t lo  ng  m l I I  1A . A ll m esiia ssere re p le n ­
ishes! a fte r 5 s! I R A P  s ta in in g  ssas pe rto rm es ! as c o rd in g  to  th e  m a n u fa c tu r ­
er's m strus'tisins S i^ m a -A ls ln s  h - a lter ”  s! S ix  tiels!s sit viess sin each shsc 
ssere ssiuntes! to r  I R A P -p o s it is e  m u ltin u s le a te s ! cells I sir h u m a n  ostcsv las- 
tsigenesis assass. p e r ip h e ra l b lsnx! m o n o n u c le a r  s ells ssere uses! as a source  to r  
aslherent cells ails! c u ltu res  ssere m a m ta in e s l tsir 21 s! betsire 1 R A P  s ta in ing .
Statistical analysis. R e as io u ts  csiulsl nsit be  assumes! tsi be n o n n a lly  d is tn b -  
utes! as thes ssere histsilssgical sc sires sir percentages. I heretsire , n o n p a ra m e t-  
nc M  a n n -W  h itn e s  ( tests ssere uses! tsir statistical analysis O n e -s v a y  unpaires! 
a iu l txvsi-svav A N O V A s  ssere used, svhen tes tin g  th e  in flu e n c e  sit thirs i p a ­
ram eters  such as t im e  o r  slose Analyses ssere p e rfo n n e s! o n  CiraphPas! P n z in  
s 4  P -v a lu e s  o t s "  oS ssere nm sislcres! s ig m tic a n t ails! salues sit <0 .01  ssere 
s siiis.sieresl h ig h ly  s ignitis ant.
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